• Abd El-Ghaffar HA, Aladle DA, Farahat SE, Abd El-Hady N. P-Glycoprotein (P-170) expression in acute leukemias. Hematology 11: 35-41 (2006).

• Abdullaev IF, Rudkouskaya A, Schools GP, Kimelberg HK, Mongin AA. Pharmacological comparison of swelling-activated excitatory amino acid release and Cl- currents in rat cultured astrocytes. J. Physiol. 572: 677-689 (2006). *

• Abulrob AG, Gumbleton M. Transport of phosphatidylcholine in MDR3-negative epithelial cell lines via drug-induced MDR1 P-glycoprotein. Biochem. Biophys. Res. Commun. 262: 121-126 (1999). *

• Acalovschi M, Tirziu S, Chiorean E, Krawczyk M, Grunhage F, Lammert F. Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls. Lipids 44: 521-526 (2009).

• Accatino L, Pizarro M, Solis N, Koenig CS, Vollrath V, Chianale J. Modulation of hepatic content and biliary excretion of P-glycoproteins in hepatocellular and obstructive cholestasis in the rat. J. Hepatol. 25: 349-361 (1996). *

• Achard-Joris M, Bourdineaud JP. Heterologous expression of bacterial and human multidrug resistance proteins protect Escherichia coli against mercury and zinc contamination. Biometals 19: 695-704 (2006). *

• Adachi M, Reid G, Schuetz JD. Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv. Drug Deliv. Rev. 54: 1333-1342 (2002). *

• Adachi T, Nakagawa H, Hagiya Y, Yasuoka T, Ishikawa T. Transport-metabolism interplay: LXR-mediated induction of human ABC transporter ABCC2 (cMOAT/MRP2) in HepG2 cells. Mol. Pharm. 6: 1678-1688 (2009). *

• Adachi Y, Kamisako T. Intrahepatic cholestasis. Nippon Rinsho 54: 788-793 (1996).

• Adachi Y, Kamisako T, Okuyama Y, Miya H. Hepatic metabolism and transport of bilirubin and other organic anions. Nippon Rinsho 54: 2276-2290 (1996).

• Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. Anticancer potential of silymarin: from bench to bed side. Anticancer Res. 26: 4457-4498 (2006).

• Agostinelli E, Tempera G, Molinari A, Salvi M, Battaglia V, Toninello A, Arancia G. The physiological role of biogenic amines redox reactions in mitochondria. New perspectives in cancer therapy. Amino Acids 33: 175-187 (2007). *

• Ahmed FE. Molecular markers that predict response to colon cancer therapy. Expert Rev. Mol. Diagn. 5: 353-375 (2005).

• Ahmed S, Vo NT, Thalhammer T, Thalhammer F, Gattringer KB, Jager W. Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. J. Pharm. Pharmacol. 60: 55-62 (2008). *

• Aird RE, Thomson M, Macpherson JS, Thurston DE, Jodrell DI, Guichard SM. ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136. Pharmacogenomics J. 8: 289-296 (2008).

• Aisen AM, Sherman S, Jennings SG, Fogel EL, Li T, Cheng CL, Devereaux BM, McHenry L, Watkins JL, Lehman GA. Comparison of secretin-stimulated magnetic resonance pancreatography and manometry results in patients with suspected sphincter of oddi dysfunction. Acad. Radiol. 15: 601-609 (2008).

• Ak Y, Demirel G, Gulbas Z. MDR1, MRP1 and LRP expression in patients with untreated acute leukaemia: correlation with 99mTc-MIBI bone marrow scintigraphy. Nucl. Med. Commun. 28: 541-546 (2007).

• Akashi M, Tanaka A, Takikawa H. Effect of cyclosporin A on the biliary excretion of cholephilic compounds in rats. Hepatol. Res. 34: 193-198 (2006).

• Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, Gultekin M, Luleci G. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant. Proc. 38: 1290-1292 (2006). *

• Akita H, Suzuki H, Ito K, Kinoshita S, Sato N, Takikawa H, Sugiyama Y. Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim. Biophys. Acta 1511: 7-16 (2001). *

• Akita H, Suzuki H, Sugiyama Y. Sinusoidal efflux of taurocholate correlates with the hepatic expression level of Mrp3. Biochem. Biophys. Res. Commun. 299: 681-687 (2002). *

• Akoume MY, Tuchweber B, Plaa GL, Yousef IM. The role of mdr2 in manganese-bilirubin induced cholestasis in mice. Toxicol. Lett. 148: 41-51 (2004). *

• Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 70: 949-958 (2005). *

• Albrecht C, Elliott JI, Sardini A, Litman T, Stieger B, Meier PJ, Higgins CF. Functional analysis of candidate ABC transporter proteins for sitosterol transport. Biochim. Biophys. Acta 1567: 133-142 (2002). *

• Aleksunes LM, Yeager RL, Klaassen CD. Application of multivariate statistical procedures to identify transcription factors that correlate with MRP2, 3, and 4 mRNA in adult human livers. Xenobiotica 39: 514-522 (2009). *

• Alhanout K, Brunel JM, Raoult D, Rolain JM. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis. J. Antimicrob. Chemother. 64: 810-814 (2009).

• Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 63: 1339-1344 (2003). *

• Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722 (2009). *

• Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 24: 1803-1823 (2007). *

• Alves-Filho JC, Tavares-Murta BM, Barja-Fidalgo C, Benjamim CF, Basile-Filho A, Arraes SM, Cunha FQ. Neutrophil function in severe sepsis. Endocr. Metab. Immune Disord. Drug Targets 6: 151-158 (2006).

• Anapolsky A, Teng S, Dixit S, Piquette-Miller M. The role of pregnane X receptor in 2-acetylaminofluorene-mediated induction of drug transport and metabolizing enzymes in mice. Drug Metab. Dispos. 34: 405-409 (2006). *

• Andersen V, Agerstjerne L, Jensen D, Ostergaard M, Saebo M, Hamfjord J, Kure E, Vogel U. The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study. BMC Med. Genet. 10: 18 (2009). *

• Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in the xenobiotic transporter multidrug resistance 1 (MDR1) gene and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer 9: 407 (2009). *

• Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA, Gwilliam R, Jacob J, Nimmo ER, Drummond H, Lees CW, Onnie CM, Hanson C, Blaszczyk K, Ravindrarajah R, Hunt S, Varma D, Hammond N, Lewis G, Attlesey H, Watkins N, et al. Investigation of Crohn’s disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 136: 523-529.e3 (2009). *

• Andrejko KM, Raj NR, Kim PK, Cereda M, Deutschman CS. IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters. Shock 29: 490-496 (2008). *

• Anglicheau D, Legendre C, Thervet E. Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 78: 311-315 (2004).

• Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Buchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther. 75: 422-433 (2004). *

• Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J, Grissom S, Zeeberg B, Reinhold W, Weinstein J, Pommier Y, Paules RS, Gottesman MM. Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol. Pharmacol. 66: 1397-1405 (2004). *

• Annese V, Latiano A, Rossi L, Bossa F, Damonte G, Dallapiccola B, Serafini S, Pierige F, Andriulli A, Magnani M. The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 10: 27-31 (2006).

• Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J. Gastroenterol. 12: 3636-3644 (2006). *

• Ano H, Matsumoto T, Suetake T, Nagai T, Tamura Y, Takamatsu I, Iwasaki T, Matsuoka H, Sasada S, Tetsumoto S, Tsuyuguchi I, Kusunoki Y, Takashima T. Relationship between the isoniazid-resistant mutation katGS315T and the prevalence of MDR-/XDR-TB in Osaka, Japan. Int. J. Tuberc. Lung Dis. 12: 1300-1305 (2008).

• Ansari SR, Hanna H, Hachem R, Jiang Y, Rolston K, Raad I. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 109: 2615-2622 (2007). *

• Anthoni H, Zucchelli M, Matsson H, Muller-Myhsok B, Fransson I, Schumacher J, Massinen S, Onkamo P, Warnke A, Griesemann H, Hoffmann P, Nopola-Hemmi J, Lyytinen H, Schulte-Korne G, Kere J, Nothen MM, Peyrard-Janvid M. A locus on 2p12 containing the co-regulated MRPL19 and C2ORF3 genes is associated to dyslexia. Hum. Mol. Genet. 16: 667-677 (2007). *

• Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Tima S, Chanarat P, Limtrakul P. Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch. Pharm. Res. 29: 866-873 (2006).

• Aoki K, Nakajima M, Hoshi Y, Saso N, Kato S, Sugiyama Y, Sato H. Effect of aminoguanidine on lipopolysaccharide-induced changes in rat liver transporters and transcription factors. Biol. Pharm. Bull. 31: 412-420 (2008). *

• Aoki K, Saso N, Kato S, Sugiyama Y, Sato H. Nitric oxide and peroxynitrite regulate transporter transcription in rat liver slices. Biol. Pharm. Bull. 31: 1882-1887 (2008). *

• Arab JP, Ramirez C, Munoz P, Pizarro M, Solís N, Riquelme A, Arrese M. Effects of Japanese herbal medicine inchin-ko-to on endotoxin-induced cholestasis in the rat. Ann. Hepatol. 8: 228-233 (2009).

• Aranyi T, Ratajewski M, Bardoczy V, Pulaski L, Bors A, Tordai A, Varadi A. Identification of a DNA methylation-dependent activator sequence in the pseudoxanthoma elasticum gene, ABCC6. J. Biol. Chem. 280: 18643-18550 (2005). *

• Arcus VL, Lott JS, Johnston JM, Baker EN. The potential impact of structural genomics on tuberculosis drug discovery. Drug Discov. Today 11: 28-34 (2006).

• Ardizzone S, Maconi G, Bianchi V, Russo A, Colombo E, Cassinotti A, Penati C, Tenchini ML, Bianchi Porro G. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm. Bowel Dis. 13: 516-523 (2007). *

• Arnedo M, Taffe P, Sahli R, Furrer H, Hirschel B, Elzi L, Weber R, Vernazza P, Bernasconi E, Darioli R, Bergmann S, Beckmann JS, Telenti A, Tarr PE; the Swiss HIV Cohort Study. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet. Genomics 17: 755-764 (2007).

• Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, Zhang M, Siu G, Brewer AW, Viney JL. BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. J. Immunol. 178: 1523-1533 (2007). *

• Arrese M. Cholestasis during pregnancy: rare hepatic diseases unmasked by pregnancy. Ann. Hepatol. 5: 216-218 (2006). *

• Arrese M, Accatino L. Is intrahepatic cholestasis of pregnancy an MDR3-related disease? Gastroenterology 125: 1922-1923 (2003). *

• Asamoto Y, Tazuma S, Ochi H, Chayama K, Suzuki H. Bile-salt hydrophobicity is a key factor regulating rat liver plasma-membrane communication: relation to bilayer structure, fluidity and transporter expression and function. Biochem. J. 359: 605-610 (2001). *

• Asghar A, Gorski JC, Haehner-Daniels B, Hall SD. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab. Dispos. 30: 20-26 (2002). *

• Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist. Updat. 9: 227-246 (2006).

• Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann I, Dijkmans BA, Peters GJ, Jansen G. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem. 278: 6680-6686 (2003). *

• Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD. Interactions between hepatic Mrp4 and Sult2A as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 279: 22250-22257 (2004). *

• Assenat E, Gerbal-Chaloin S, Larrey D, Saric J, Fabre JM, Maurel P, Vilarem MJ, Pascussi JM. Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology 40: 951-960 (2004). *

• Atalay C, Deliloglu Gurhan I, Irkkan C, Gunduz U. Multidrug resistance in locally advanced breast cancer. Tumour Biol. 27: 309-318 (2006).

• Augustine LM, Markelewicz RJ Jr, Boekelheide K, Cherrington NJ. Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. Drug Metab. Dispos. 33: 182-189 (2005). *

• Autschbach F, Giese T, Gassler N, Sido B, Heuschen G, Heuschen U, Zuna I, Schulz P, Weckauf H, Berger I, Otto HF, Meuer SC. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch. 441: 500-513 (2002). *

• Awasthi S, Sharma R, Singhal SS, Zimniak P, Awasthi YC. RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics. Drug Metab. Dispos. 30: 1300-1310 (2002). *

• Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31: 469-497 (2001).

• Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhoseinie SA, Raisjalal GH, Rahsaz M, Pourgholami A, Sagheb F. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. Exp. Clin. Transplant. 4: 416-419 (2006).

• Azzaroli F, Mennone A, Feletti V, Simoni P, Baglivo E, Montagnani M, Rizzo N, Pelusi G, DE Aloysio D, Lodato F, Festi D, Colecchia A, Roda E, Boyer JL, Mazzella G. Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Aliment. Pharmacol. Ther. 26: 1139-1146 (2007). *

• Baars C, Leeb T, von Klopmann T, Tipold A, Potschka H. Allele-specific polymerase chain reaction diagnostic test for the functional MDR1 polymorphism in dogs. Vet. J. 177: 394-397 (2008).

• Bacchetta J, Ranchin B, Brunet AS, Bouvier R, Duquesne A, Edery P, Fabien N, Peretti N. Autoimmune hypoparathyroidism in a 12-year-old girl with McKusick cartilage hair hypoplasia. Pediatr. Nephrol. 24: 2449-2453 (2009).

• Bae SY, Choi SK, Kim KR, Park CS, Lee SK, Roh HK, Shin DW, Pie JE, Woo ZH, Kang JH. Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci. 97: 774-779 (2006). *

• Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Horl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M. Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int. 28: 948-958 (2008). *

• Bai S, Stepkowski SM, Kahan BD, Brunner LJ. Metabolic interaction between cyclosporine and sirolimus. Transplantation 77: 1507-1512 (2004).

• Baier PK, Hempel S, Waldvogel B, Baumgartner U. Zonation of hepatic bile salt transporters. Dig. Dis. Sci. 51: 587-593 (2006). *

• Bain LJ, Feldman RA. Altered expression of sulfotransferases, glucuronosyltransferases and mrp transporters in FVB/mrp1-/- mice. Xenobiotica 33: 1173-1183 (2005). *

• Bakos E, Homolya L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch. 453: 621-641 (2007). *

• Balistreri WF. Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Balkova K, Gbelska Y. ABC transporter proteins in multidrug resistance of microorganisms. Epidemiol. Mikrobiol. Imunol. 56: 129-139 (2007).

• Ballatori N, Fang F, Christian WV, Li N, Hammond CL. Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G179-G186 (2008). *

• Ballatori N, Hammond CL, Cunningham JB, Krance SM, Marchan R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol. Appl. Pharmacol. 204: 238-255 (2005). *

• Ballatori N, Henson JH, Seward DJ, Cai SY, Runnegar M, Fricker G, Miller DS, Boyer JL. Retention of structural and functional polarity in cultured skate hepatocytes undergoing in vitro morphogenesis. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 144: 167-179 (2006). *

• Ballatori N, Rebbeor JF. Roles of MRP2 and oatp1 in hepatocellular export of reduced glutathione. Semin. Liver Dis. 18: 377-387 (1998).

• Ballestero MR, Monte MJ, Briz O, Jimenez F, Gonzalez-San Martin F, Marin JJ. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem. Pharmacol. 72: 729-738 (2006). *

• Ban D, Kudo A, Sui S, Tanaka S, Nakamura N, Ito K, Suematsu M, Arii S. Decreased Mrp2-dependent bile flow in the post-warm ischemic rat liver. J. Surg. Res. 153: 310-316 (2009).

• Banner KH, Cattaneo C, Net JL, Popovic A, Collins D, Gale JD. Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br. J. Pharmacol.143: 590-598 (2004). *

• Barancik M, Bohacova V, Sedlak J, Sulova Z, Breier A. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci. 29: 426-434 (2006). *

• Barash H, R Gross E, Edrei Y, Ella E, Israel A, Cohen I, Corchia N, Ben-Moshe T, Pappo O, Pikarsky E, Goldenberg D, Shiloh Y, Galun E, Abramovitch R. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc. Natl. Acad. Sci. U.S.A. 107: 2207-2212 (2010). *

• Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken M, Jakowski AB, Pruimboom-Brees IM, Cherrington NJ, Manautou JE. Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab. Dispos. 35: 1963-1969 (2007). *

• Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 13: 1424-1429 (2007). *

• Bartels AL, van Berckel BN, Lubberink M, Luurtsema G, Lammertsma AA, Leenders KL. Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat. Disord. 14: 505-508 (2008).

• Barth A, Braun J, Muller D. Influence of verapamil and cyclosporin A on bile acid metabolism and transport in rat liver slices. Exp. Toxicol. Pathol. 58: 31-37 (2006). *

• Bartnicka L, Kurzawski M, Drozdzik A, Plonska-Gosciniak E, Gornik W, Drozdzik M. Effect of ABCB1 (MDR1) 3435C >T and 2677G >A,T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients. Pharmacol. Rep. 59: 323-329 (2007). *

• Bartolini G, Orlandi M, Papi A, Ammar K, Guerra F, Ferreri AM, Rocchi P. A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells. In Vivo 20: 729-733 (2006).

• Basic S, Hajnsek S, Poljakovic Z, Basic M. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 47: 449 (2006). *

• Bassi C, Xavier Dj, Palomino G, Nicolucci P, Soares C, Sakamoto-Hojo E, Donadi E. Efficiency of the DNA repair and polymorphisms of the XRCC1, XRCC3 and XRCC4 DNA repair genes in systemic lupus erythematosus. Lupus 17: 988-995 (2008). *

• Bastone L, Reilly M, Rader DJ, Foulkes AS. MDR and PRP: a comparison of methods for high-order genotype-phenotype associations. Hum. Hered. 58: 82-92 (2004).

• Batrakova EV, Kelly DL, Li S, Li Y, Yang Z, Xiao L, Alakhova DY, Sherman S, Alakhov VY, Kabanov AV. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol. Pharm. 3: 113-123 (2006). *

• Bauer B, Hartz AM, Lucking JR, Yang X, Pollack GM, Miller DS. Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. J. Cereb. Blood Flow Metab. 28: 1222-1234 (2008).

• Beck K, Hayashi K, Dang K, Hayashi M, Boyd CD. Analysis of ABCC6 (MRP6) in normal human tissues. Histochem. Cell. Biol. 123: 517-528 (2005). *

• Becquemont L, Camus M, Kriaa F, Barbu V, Charpentier B, Jaillon P. Low levels of lymphocyte MDR1 gene expression during early renal transplantation in patients treated with tacrolimus. Fundam. Clin. Pharmacol. 14: 225-229 (2000).

• Becquemont L, Glaeser H, Drescher S, Hitzl M, Simon N, Murdter TE, Heinkele G, Hofmann U, Schaefer C, Burk O, Verstuyft C, Eichelbaum M, Fromm MF. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. Clin. Pharmacol. Ther. 79: 449-460 (2006). *

• Beedholm-Ebsen R, van de Wetering K, Hardlei T, Nexo E, Borst P, Moestrup SK. Identification of multidrug resistance protein 1 (MRP1/ABCC1) as a molecular gate for cellular export of cobalamin. Blood Nov 6 [Epub ahead of print] (2009). *

• Beilke LD, Besselsen DG, Cheng Q, Kulkarni S, Slitt AL, Cherrington NJ. Minimal role of hepatic transporters in the hepatoprotection against LCA-induced intrahepatic cholestasis. Toxicol. Sci. 102: 196-204 (2008). *

• Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J. Natl. Cancer Inst. 87: 1593-1602 (1995).

• Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, Chen ZS, Grinberg A, Westphal H, Klein-Szanto A, Lerro A, Kruh GD. Analysis of the in vivo functions of Mrp3. Mol. Pharmacol. 68: 160-168 (2005). *

• Belliard AM, Lacour B, Farinotti R, Leroy C. Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells. J. Pharm. Sci. 93: 1524-1536 (2004). *

• Benlloch M, Ortega A, Ferrer P, Segarra R, Obrador E, Asensi M, Carretero J, Estrela JM. Acceleration of glutathione efflux and inhibition of gamma-glutamyl transpeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. J. Biol. Chem. 280: 6950-6959 (2005). *

• Beretta L, Cappiello F, Moore JH, Barili M, Greene CS, Scorza R. Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. Arthritis Rheum. 59: 974-983 (2008). *

• Beretta L, Cappiello F, Moore JH, Scorza R. Interleukin-1 gene complex single nucleotide polymorphisms in systemic sclerosis: a further step ahead. Hum. Immunol. 69: 187-192 (2008).

• Bergasa NV. The pruritus of cholestasis. J. Hepatol. 43: 1078-1088 (2005). *

• Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *

• Bergen AA, Plomp AS, Gorgels TG, de Jong PT. From gene to disease; pseudoxanthoma elasticum and the ABCC6 gene. Ned. Tijdschr. Geneeskd. 148: 1586-1589 (2004).

• Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H, Swart J, Kool M, van Soest S, Baas F, ten Brink JB, de Jong PT. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat. Genet. 25: 228-231 (2000). *

• Beringer PM, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B, Gill M. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy 28: 883-894 (2008).

• Beringer PM, Slaughter RL. Transporters and their impact on drug disposition. Ann. Pharmacother. 39: 1097-1108 (2005).

• Beuers U. Mechanisms of action of ursodeoxycholic acid in cholestasis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 49-50. October 15-16 (2003). *

• Beuers U. Mechanisms of action of ursodeoxycholic acid for treatment of primary sclerosing cholangitis. Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 12 (2006). *

• Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G, Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 33: 1206-1216 (2001). *

• Beuers U, Denk GU, Soroka CJ, Wimmer R, Rust C, Paumgartner G, Boyer JL. Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets. J. Biol. Chem. 278: 17810-17818 (2003). *

• Beuers U, Hohenester S, Pusl T, Rust C, Wimmer R. Tauroursodeoxycholic acid antagonizes taurolithocholic acid induced cholestasis via a cooperative protein kinase C- and protein kinase A-dependent signaling pathway in the perfused rat liver. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 81 (2006). *

• Beuers U, Hohenester S, Wimmer R, Denk GU, Rust C. Mitogen activated protein kinases and protein kinase C: short-term mediators of the anticholestatic effect of tauroursodeoxycholic acid in bile acid-induced cholestasis? Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 61. June 18-19 (2004). *

• Beukeveld GJ, In 't Veld G, Havinga R, Groen AK, Wolthers BG, Kuipers F. Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. J. Hepatol. 24: 343-352 (1996). *

• Bi YA, Kazolias DC, Duignan DB. Use of cryopreserved human hepatocytes in sandwich-culture to measure hepatobiliary transport. Drug Metab. Dispos. 34: 1658-1665 (2006). *

• Bialecka M, Hnatyszyn G, Bielicka-Cymerman J, Drozdzik M. The effect of MDR1 gene polymorphism in the pathogenesis and the treatment of drug-resistant epilepsy. Neurol. Neurochir. Pol. 39: 476-481 (2005).

• Bilsborough J, Viney JL. Out, out darn toxin: the role of MDR in intestinal homeostasis. Gastroenterology 127: 339-340 (2004). *

• Binder EB, Holsboer F. Pharmacogenomics. Handb. Exp. Pharmacol. 169: 527-546 (2005).

• Bisi A, Gobbi S, Rampa A, Belluti F, Piazzi L, Valenti P, Gyemant N, Molnar J. New potent P-glycoprotein inhibitors carrying a polycyclic scaffold. J. Med. Chem. 49: 3049-3051 (2006). *

• Blaas L, Kornfeld JW, Schramek D, Musteanu M, Zollner G, Gumhold J, van Zijl F, Schneller D, Esterbauer H, Egger G, Mair M, Kenner L, Mikulits W, Eferl R, Moriggl R, Penninger J, Trauner M, Casanova E. Disruption of the growth hormone-signal transducer and activator of transcription 5-insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Bleiber G, May M, Suarez C, Martinez R, Marzolini C, Egger M, Telenti A; Swiss HIV Cohort Study. MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment. J. Infect. Dis. 189: 583-586 (2004). *

• Blokzijl H, van Steenpaal A, Vander Borght S, Bok LI, Libbrecht L, Tamminga M, Geuken M, Roskams TA, Dijkstra G, Moshage H, Jansen PL, Faber KN. Upregulation and cytoprotective role of epithelial multidrug resistance-associated protein 1 in inflammatory bowel disease. J. Biol. Chem. 283: 35630-35637 (2008). *

• Blokzijl H, Vander Borght S, Bok LI, Libbrecht L, Geuken M, van den Heuvel FA, Dijkstra G, Roskams TA, Moshage H, Jansen PL, Faber KN. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm. Bowel Dis. 13: 710-720 (2007). *

• Bock HH, Lammert F. Nuclear xeno-sensors as receptors for cholestatic bile acids: the second line of defense. Hepatology 35: 232-234 (2002). *

• Bode KA, Donner MG, Leier I, Keppler D. Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem. Pharmacol. 64: 151-158 (2002). *

• Bodhini D, Radha V, Dhar M, Narayani N, Mohan V. The rs12255372(G/T) and rs7903146(C/T) polymorphisms of the TCF7L2 gene are associated with type 2 diabetes mellitus in Asian Indians. Metabolism 56: 1174-1178 (2007). *

• Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 278: 23529-23537 (2003). *

• Bohan A, Chen WS, Denson LA, Held MA, Boyer JL. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J. Biol. Chem. 278: 36688-36698 (2003). *

• Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol. 64: 1057-1068 (2008). *

• Bolder U, Jeschke MG, Landmann L, Wolf F, de Sousa C, Schlitt HJ, Przkora R. Heat stress enhances recovery of hepatocyte bile acid and organic anion transporters in endotoxemic rats by multiple mechanisms. Cell Stress Chaperones 11: 89-100 (2006). *

• Bolder U, Trang NV, Hagey LR, Schteingart CD, Ton-Nu HT, Cerre C, Elferink RP, Hofmann AF. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 117: 962-971 (1999). *

• Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, Picard V. MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients. Transplantation 78: 21-25 (2004).

• Bonin S, Pascolo L, Croce LS, Stanta G, Tiribelli C. Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue, and liver diseases. Mol. Med. 8: 318-325 (2002). *

• Borowski E, Bontemps-Gracz MM, Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim. Pol. 52: 609-627 (2005). *

• Borowski LC, Lopes RP, Gonzalez TP, Dummer LA, Chies JA, Silveira IG, Keisermann M, Bauer ME. Is steroid resistance related to multidrug resistance-I (MDR-I) in rheumatoid arthritis? Int. Immunopharmacol. 7: 836-844 (2007).

• Borst P, Balzarini J, Ono N, Reid G, de Vries H, Wielinga P, Wijnholds J, Zelcer N. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res. 62: 1-7 (2004). *

• Borst P, de Wolf C, van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453: 661-673 (2007). *

• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92: 1295-1302 (2000). *

• Borst P, Zelcer N, van de Wetering K, Poolman B. On the putative co-transport of drugs by multidrug resistance proteins. FEBS Lett. 580: 1085-1093 (2006). *

• Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim. Biophys. Acta 1486: 128-144 (2000). *

• Bottema RW, Postma DS, Reijmerink NE, Thijs C, Stelma FF, Smit HA, van Schayck CP, Brunekreef B, Koppelman GH, Kerkhof M. Interaction of T-cell and antigen presenting-cell co-stimulatory genes in childhood IgE. Eur. Respir. J. Jul 2 [Epub ahead of print] (2009).

• Boumendjel A, Baubichon-Cortay H, Trompier D, Perrotton T, Di Pietro A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med. Res. Rev. 25 453-472 (2005). *

• Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 50: 898-903 (2009).

• Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740 (2005). *

• Boyer JL, Denk G, Bohan A, Chen WS, Soroka C, Denson L. Adaptive regulation of bile salt transporters in cholestasis. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 46-47. June 18-19 (2004). *

• Braga F, Ayres-Saraiva D, Gattass CR, Capella MA. Oleanolic acid inhibits the activity of the multidrug resistance protein ABCC1 (MRP1) but not of the ABCB1 (P-glycoprotein): possible use in cancer chemotherapy. Cancer Lett. 248: 147-152 (2007). *

• Brandoni A, Di Giusto G, Franca R, Passamonti S, Torres AM. Expression of kidney and liver bilitranslocase in response to acute biliary obstruction. Nephron. Physiol. 114: p35-p40 (2010).

• Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet.73: 1282-1292 (2003). *

• Branten AJ, Swinkels DW, Klasen IS, Wetzels JF. Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. Nephrol. Dial. Transplant. 19: 2754-2760 (2004). *

• Brassat D, Motsinger AA, Caillier SJ, Erlich HA, Walker K, Steiner LL, Cree BA, Barcellos LF, Pericak-Vance MA, Schmidt S, Gregory S, Hauser SL, Haines JL, Oksenberg JR, Ritchie MD. Multifactor dimensionality reduction reveals gene-gene interactions associated with multiple sclerosis susceptibility in African Americans. Genes Immun. 7: 310-315 (2006). *

• Brcakova E, Fuksa L, Cermanova J, Kolouchova G, Hroch M, Hirsova P, Martinkova J, Staud F, Micuda S. Alteration of methotrexate biliary and renal elimination during extrahepatic and intrahepatic cholestasis in rats. Biol. Pharm. Bull. 32: 1978-1985 (2009). *

• Breen CM, Sykes DB, Baehr C, Fricker G, Miller DS. Fluorescien-methotrexate transport in rat choroid plexus analyzed using confocal microscopy. Am. J. Physiol. Renal Physiol. 287: F562-F569 (2004). *

• Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, Maass G, Tummler B. Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia. Eur. J. Biochem. 206: 137-149 (1992). *

• Bresolin T, de Freitas Rebelo M, Celso Dias Bainy A. Expression of PXR, CYP3A and MDR1 genes in liver of zebrafish. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 140: 403-407 (2005). *

• Breuer W, Slotki IN, Ausiello DA, Cabantchik IZ. Induction of multidrug resistance downregulates the expression of CFTR in colon epithelial cells. Am. J. Physiol. 265: C1711-C1715 (1993).

• Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J. 1: 59-64 (2001). *

• Brites D. Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. Ann. Hepatol. 1: 20-28 (2002). *

• Briz O, Romero MR, Martinez-Becerra P, Macias RI, Perez MJ, Jimenez F, San Martin FG, Marin JJ. OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes? J. Biol. Chem. 281: 30326-30335 (2006). *

• Brooks TA, Kennedy DR, Gruol DJ, Ojima I, Baer MR, Bernacki RJ. Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators. Anticancer Res. 24: 409-415 (2004).

• Brunn A, Hans VJ, Vogelgesang S, Deckert M. Inflammatory myopathy with abundant macrophages and dermatomyositis: two stages of one disorder or two distinct entities? Acta Neuropathol. Jul 10 [Epub ahead of print] (2009).

• Bruns T, Stallmach A. Drug monitoring in inflammatory bowel disease: helpful or dispensable? Dig. Dis. 27: 394-403 (2009).

• Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Rossi AM, Petrini M. MDR1 polymorphism influences the outcome of multiple myeloma patients. Br. J. Haematol. 137: 454-456 (2007). *

• Buda G, Martino A, Maggini V, Orciuolo E, Galimberti S, Gentile M, Morabito F, Antognoni F, Brunori M, Barale R, Rossi AM, Petrini M. MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma. Acta Haematol. 122: 42-45 (2009).

• Burk O, Arnold KA, Geick A, Tegude H, Eichelbaum M. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol. Chem. 386: 503-513 (2005).

• Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, Eichelbaum M. Anti-malarial artemisinin drugs induce CYP and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 67: 1954-1965 (2005). *

• Bush WS, Dudek SM, Ritchie MD. Parallel multifactor dimensionality reduction: a tool for the large scale analysis of gene-gene interactions. Bioinformatics 22: 2173-2174 (2006). *

• Buyse F, Hou YX, Vigano C, Zhao Q, Ruysschaert JM, Chang XB. Substitution of the positive-charged Walker A lysine with a hydrophobic leucine and conformational alterations caused by this mutation in MRP1 impair ATP binding and hydrolysis. Biochem. J. 397: 121-130 (2006). *

• Buyse F, Vandenbranden M, Ruysschaert JM. Mistargeted MRPdeltaF728 mutant is rescued by intracellular GSH. FEBS Lett. 578: 145-151 (2004). *

• Buyse M, Radeva G, Bado A, Farinotti R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem. Pharmacol. 69: 1745-1754 (2005). *

• Cabot MC, Giuliano AE, Han TY, Liu YY. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res. 59: 880-885 (1999). *

• Cai L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic. Biol. Med. 41: 851-861 (2006).

• Cai SY, Boyer JL. FXR: a target for cholestatic syndromes? Expert Opin. Ther. Targets 10: 409-421 (2006).

• Cai SY, Gautam S, Nguyen T, Soroka CJ, Rahner C, Boyer JL. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology 136: 1060-1069.e4 (2009). *

• Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum. Genet. 77: 142-144 (1987).

• Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 83: 559-566 (2008).

• Campa D, Vodicka P, Pardini B, Novotny J, Forsti A, Hemminki K, Barale R, Canzian F. Could polymorphisms in ATP-binding cassette C3/multidrug resistance associated protein 3 (ABCC3/MRP3) modify colorectal cancer risk? Eur. J. Cancer 44: 854-857 (2008). *

• Campion SN, Johnson R, Aleksunes LM, Goedken MJ, van Rooijen N, Scheffer GL, Cherrington NJ, Manautou JE. Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G294-G304 (2008). *

• Cantz T, Nies AT, Brom M, Hofmann AF, Keppler D. MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G522-G531 (2000). *

• Cao L, Owsianik G, Jaspers M, Janssens A, Cuppens H, Cassiman JJ, Nilius B. Functional analysis of CFTR chloride channel activity in cells with elevated MDR1 expression. Biochem. Biophys. Res. Commun. 304: 248-252 (2003). *

• Carlton VE, Pawlikowska L, Bull LN. Molecular basis of intrahepatic cholestasis. Ann. Med. 36: 606-617 (2004).

• Carrella M, Roda E. Evolving concepts in the pathophysiology of biliary lipid secretion. Ital. J. Gastroenterol. Hepatol. 31: 643-648 (1999).

• Carrier I, Urbatsch IL, Senior AE, Gros P. Mutational analysis of conserved aromatic residues in the A-loop of the ABC transporter ABCB1A (mouse Mdr3). FEBS Lett. 581: 301-308 (2007). *

• Cassio D, Macias RI, Grosse B, Marin JJ, Monte MJ. Expression, localization, and inducibility by bile acids of hepatobiliary transporters in the new polarized rat hepatic cell lines, Can 3-1 and Can 10. Cell Tissue Res. 330: 447-460 (2007). *

• Catania VA, Sanchez Pozzi EJ, Luquita MG, Ruiz ML, Villanueva SS, Jones B, Mottino AD. Co-regulation of expression of phase II metabolizing enzymes and multidrug resistance-associated protein 2. Ann. Hepatol. 3: 11-17 (2004). *

• Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin. Chem. Lab. Med. 41: 1345-1350 (2003).

• Cavestro GM, Frulloni L, Cerati E, Ribeiro LA, Corrente V, Sianesi M, Franze A, Di Mario F. Progressive familial intrahepatic cholestasis. Acta Biomed. Ateneo. Parmense. 73: 53-56 (2002).

• Cebecauerova D, Jirasek T, Budisova L, Mandys V, Volf V, Novotna Z, Subhanova I, Hrebicek M, Elleder M, Jirsa M. Dual hereditary jaundice: simultaneous occurrence of mutations causing Gilbert's and Dubin-Johnson syndrome. Gastroenterology 129: 315-320 (2005). *

• Celius T, Garberg P, Lundgren B. Stable suppression of MDR1 gene expression and function by RNAi in Caco-2 cells. Biochem. Biophys. Res. Commun. 324: 365-371 (2004). *

• Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55: 301-305 (2006).

• Centers for Disease Control and Prevention (CDC). Trends in tuberculosis - United States, 2005. MMWR Morb. Mortal. Wkly. Rep. 55: 305-308 (2006).

• Cerf E, Gasper R, Rychnovsky S, Chang XB, Buyse F, Ruysschaert JM. Multidrug resistance protein 1 is not associated to detergent-resistant membranes. Biochem. Biophys. Res. Commun. 355: 1025-1030 (2007). *

• Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P. Valproic acid induces CYP3A4 and MDR1 genes expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos. 35: 1032-1041 (2007). *

• Chanda P, Sucheston L, Zhang A, Brazeau D, Freudenheim JL, Ambrosone C, Ramanathan M. AMBIENCE: a novel approach and efficient algorithm for identifying informative genetic and environment interactions associated with complex phenotypes. Genetics 180: 1191-1210 (2008). *

• Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21: 719-735 (2004). *

• Chandra P, Johnson BM, Zhang P, Pollack GM, Brouwer KL. Modulation of hepatic canalicular or basolateral transport alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver. Drug Metab. Dispos. 33: 1238-1243 (2005). *

• Chang XB. A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev. 26: 15-37 (2007). *

• Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepatology 50: 671- 673 (2009). *

• Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J. Med. Genet. 42: 881-892 (2005). *

• Chen B, Fang J, Zhang W, Jin Z, Yu Z, Cai W. Detection of C1236T, G2677T/A, and C3435T polymorphism of MDR1 by amplification refractory mutation system PCR. J. Clin. Lab. Anal. 23: 110-116 (2009).

• Chen BC, Kuo KK, Chen YH, Liu CH, Tsai LY, Hsu HK, Hsu C. Retinoid X receptor alpha participation in dexamethasone induced rat bile acid coenzyme A-amino acid N-acyltransferase expression in septic liver. Shock 32: 164-171 (2009).

• Chen C, Lin J, Smolarek T, Tremaine L. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab. Dispos. 35: 1725-1729 (2007). *

• Chen DQ, Zeng Y, Zhou J, Yang L, Jiang S, Huang JD, Lu L, Zheng BJ. Association of candidate susceptible loci with chronic infection with hepatitis B virus in a Chinese population. J. Med. Virol. 82: 371-378 (2010). *

• Chen G, Wang S, Bie P, Li X, Dong J. Endogenous bile salts are associated with bile duct injury in the rat liver transplantation model. Transplantation 87: 330-339 (2009).

• Chen HL, Chang PS, Hsu HC, Lee JH, Ni YH, Hsu HY, Jeng YM, Chang MH. Progressive familial intrahepatic cholestasis with high gamma-glutamyltranspeptidase levels in Taiwanese infants: role of MDR3 gene defect? Pediatr. Res. 50: 50-55 (2001). *

• Chen HL, Chen HL, Liu YJ, Feng CH, Wu CY, Shyu MK, Yuan RH, Chang MH. Developmental expression of canalicular transporter genes in human liver. J. Hepatol. 43: 472-477 (2005). *

• Chen HL, Liu YJ, Chen HL, Wu SH, Ni YH, Ho MC, Lai HS, Hsu WM, Tseng HC, Jeng YM, Chang MH. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr. Res. 63: 667-673 (2008). *

• Chen J, Raymond K. Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *

• Chen N, Onisko B, Napoli JL. The nuclear transcription factor RARalpha associates with neuronal RNA granules and suppresses translation. J. Biol. Chem. 283: 20841-20847 (2008). *

• Chen Q, Yang Y, Li L, Zhang JT. The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function. J. Biol. Chem. 281: 31152-31163 (2006). *

• Chen W, Cai SY, Xu S, Denson L, Soroka C, Boyer JL. Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1221-G1227 (2007). *

• Chen XP, Wang Q, Guan J, Huang ZY, Zhang WG, Zhang BX. Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells. World J. Gastroenterol. 12: 3332-3337 (2006). *

• Chen XQ, Wang LL, Shan QW, Tang Q, Lian SJ. Multidrug resistance protein 3 R652G may reduce susceptibility to idiopathic infant cholestasis. World J. Gastroenterol. 15: 5855-5858 (2009). *

• Chen Y, Nie D. Pregnane X receptor and its potential role in drug resistance in cancer treatment. Recent Patents Anticancer Drug Discov. 4: 19-27 (2009).

• Chen Y, Tang Y, Wang MT, Zeng S, Nie D. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res. 67: 10361-10367 (2007). *

• Chen YB, Yan ML, Gong JP, Xia RP, Liu LX, Li N, Lu SC, Zhang JG, Zeng DB, Xie JG, Yang JY, Yan LN. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1. Chin. Med. J. (Engl.) 120: 703-707 (2007).

• Chen YH, Wang JP, Wang H, Sun MF, Wei LZ, Wei W, Xu DX. Lipopolysaccharide treatment downregulates the expression of the pregnane X receptor, cyp3a11 and mdr1a genes in mouse placenta. Toxicology 211: 242-252 (2005). *

• Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD. Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol. Pharmacol. 67: 545-557 (2005). *

• Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62: 3144-3150 (2002). *

• Chen ZT, Wang IJ, Shih YF, Lin LL. The association of haplotype at the lumican gene with high myopia susceptibility in Taiwanese patients. Ophthalmology 116: 1920-1927 (2009).

• Cheng X, Klaassen CD. Regulation of mRNA expression of xenobiotic transporters by the pregnane-X receptor (PXR) in mouse liver, kidney, and intestine. Drug Metab. Dispos. 34: 1863-1867 (2006). *

• Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J. Pharmacol. Exp. Ther. 300: 97-104 (2002). *

• Cherrington NJ, Slitt AL, Li N, Klaassen CD. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab. Dispos. 32: 734-741 (2004). *

• Cherrington NJ, Slitt AL, Maher JM, Zhang XX, Zhang J, Huang W, Wan YJ, Moore DD, Klaassen CD. Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. Drug Metab. Dispos. 31: 1315-1319 (2003). *

• Chianale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, Gonzalez S, Andrade L, Pizarro M, Accatino L. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem. J. 314: 781-786 (1996). *

• Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 40: 539-551 (2004). *

• Chiarello PG, Penaforte FR, Japur CC, Souza CD, Vannucchi H, Troncon LE. Increased folate Intake with no changes in serum homocysteine and decreased levels of C-reactive protein in patients with inflammatory bowel diseases. Dig. Dis. Sci. 54: 627-633 (2009). *

• Chiba M, Itagaki S, Kobayashi M, Hirano T, Iseki K. Down-regulation of intestinal multidrug resistance-associated protein 2 in Long-Evans cinnamon rats. Drug Metab. Pharmacokinet. 22: 450-455 (2007). *

• Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol. Cell Biol. 9: 3808-3820 (1989). *

• Chisaki I, Kobayashi M, Itagaki S, Hirano T, Iseki K. Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver. Biochim. Biophys. Acta 1788: 2396-2403 (2009). *

• Chloupkova M, Pickert A, Lee JY, Souza S, Trinh YT, Connelly SM, Dumont ME, Dean M, Urbatsch IL. Expression of 25 human ABC transporters in the yeast Pichia pastoris and characterization of the purified ABCC3 ATPase activity. Biochemistry 46: 7992-8003 (2007). *

• Cho J. Genetic advances in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 9: 191-200 (2006).

• Cho J. Update on inflammatory bowel disease genetics. Curr. Gastroenterol. Rep. 2: 434-439 (2000).

• Cho JH. Advances in the genetics of inflammatory bowel disease. Curr. Gastroenterol. Rep. 6: 467-473 (2004).

• Cho SK, Sung YK, Park S, Bae SC. Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis. Rheumatol. Int. Aug 25 [Epub ahead of print] (2009). *

• Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr. Relat. Cancer 14: 293-303 (2007).

• Choi JH, Ahn BM, Yi J, Lee JH, Lee JH, Nam SW, Chon CY, Han KH, Ahn SH, Jang IJ, Cho JY, Suh Y, Cho MO, Lee JE, Kim KH, Lee MG. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics 17: 403-415 (2007).

• Choudhuri S, Cherrington NJ, Li N, Klaassen CD. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab. Dispos. 31: 1337-1345 (2003). *

• Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25: 231-259 (2006). *

• Chow EC, Maeng HJ, Liu S, Khan AA, Groothuis GM, Pang KS. 1alpha,25-Dihydroxyvitamin D3 triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharm. Drug Dispos. 30: 457-475 (2009). *

• Chow EC, Sun H, Khan AA, Groothuis GM, Pang KS. Effects of 1alpha,25-dihydroxyvitamin D(3) on transporters and enzymes of the rat intestine and kidney in vivo. Biopharm. Drug. Dispos. 31: 91-108 (2010). *

• Chu X, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human renal transporters hOAT3, OATP4C1, and MDR1 P-glycoprotein. J. Pharmacol. Exp. Ther. 321: 673-683 (2007). *

• Chu X, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, Wang RW, Yabut J, Hartley DP, Evans DC, Evers R. Characterization of mice lacking the multidrug resistance protein Mrp2 (Abcc2). J. Pharmacol. Exp. Ther. 317: 579-589 (2006). *

• Cianfriglia M, Dupuis ML, Molinari A, Verdoliva A, Costi R, Galluzzo CM, Andreotti M, Cara A, Di Santo R, Palmisano L. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology 4: 17 (2007).

• Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Effects of azithromycin on the expression of ATP binding cassette transporters in epithelial cells from the airways of cystic fibrosis patients. J. Chemother. 19: 643-649 (2007).

• Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, Mirossay A. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. Sep 15 [Epub ahead of print] (2009).

• Clarke MW, Burnett JR, Croft KD. Vitamin E in human health and disease. Crit. Rev. Clin. Lab. Sci. 45: 417-450 (2008).

• Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol. Sci. 27: 438-446 (2006). *

• Collett A, Higgs NB, Gironella M, Zeef LA, Hayes A, Salmo E, Haboubi N, Iovanna JL, Carlson GL, Warhurst G. Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in mdr1a(-/-) mice. Inflamm. Bowel Dis. 14: 620-631 (2008). *

• Collett A, Tanianis-Hughes J, Warhurst G. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Biochem. Pharmacol. 68: 783-790 (2004). *

• Colombel JF. IBD: genotypes - phenotypes. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 19 (2005). *

• Colombo C, Okolicsanyi L, Strazzabosco M. Advances in familial and congenital cholestatic diseases. Clinical and diagnostic implications. Dig. Liver Dis. 32: 152-159 (2000).

• Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, Cianfriglia M, Ciervo A, Caraglia M, Budillon A, Meo G, Arancia G, Molinari A. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? J. Invest. Dermatol. 128: 957-971 (2008). *

• Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62: 3387-3394 (2002). *

• Comets E, Verstuyft C, Lavielle M, Jaillon P, Becquemont L, Mentre F. Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. Eur. J. Clin. Pharmacol. 63: 437-449 (2007). *

• Congiu M, Mashford ML, Slavin JL, Desmond PV. Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease. J. Gastroenterol. Hepatol. 24: 1038-1044 (2009). *

• Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SP, Schrenk D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet. 46: 656-663 (2001).

• Conseil G, Deeley RG, Cole SP. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genomics 15: 523-533 (2005).

• Conseil G, Deeley RG, Cole SP. Functional importance of three basic residues clustered at the cytosolic interface of transmembrane helix 15 in the multidrug and organic anion transporter MRP1 (ABCC1). J. Biol. Chem. 281: 43-50 (2006). *

• Constable PA, Lawrenson JG, Dolman DE, Arden GB, Abbott NJ. P-Glycoprotein expression in human retinal pigment epithelium cell lines. Exp. Eye Res. 83: 24-30 (2006). *

• Corich L, Aranda A, Carrassa L, Bellarosa C, Ostrow JD, Tiribelli C. The cytotoxic effect of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells is modulated by the expression level of MRP1 but not MDR1. Biochem. J. 417: 305-312 (2009). *

• Corpechot C, Ping C, Wendum D, Matsuda F, Barbu V, Poupon R. Identification of a novel 974C-->G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. Am. J. Gastroenterol. 101: 2427-2432 (2006). *

• Cortada CM, Gil A, Goncalves S, Sambuelli A, Rubio MC, Carballo MA. P-glycoprotein functional activity in peripheral blood lymphocytes in ulcerative colitis. Medicina (B. Aires) 69: 437-441 (2009).

• Coutinho AM, Sousa I, Martins M, Correia C, Morgadinho T, Bento C, Marques C, Ataide A, Miguel TS, Moore JH, Oliveira G, Vicente AM. Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels. Hum. Genet. 121: 243-256 (2007). *

• Crawford AR, Smith AJ, Hatch VC, Oude Elferink RP, Borst P, Crawford JM. Hepatic secretion of phospholipid vesicles in the mouse critically depends on mdr2 or MDR3 P-glycoprotein expression. Visualization by electron microscopy. J. Clin. Invest. 100: 2562-2567 (1997). *

• Crispim JC, Grespan R, Martelli-Palomino G, Rassi DM, Costa RS, Saber LT, Cunha FQ, Donadi EA. Interleukin-17 and kidney allograft outcome. Transplant. Proc. 41: 1562-1564 (2009). *

• Crocenzi FA, D'Andrea V, Catania VA, Luquita MG, Pellegrino JM, Ochoa JE, Mottino AD, Sanchez Pozzi E. Prevention of Mrp2 activity impairment in ethinylestradiol-induced cholestasis by ursodeoxycholate in the rat. Drug Metab. Dispos. 33: 888-891 (2005). *

• Crocenzi FA, Mottino AD, Cao J, Veggi LM, Pozzi EJ, Vore M, Coleman R, Roma MG. Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G449-G459 (2003). *

• Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, Favre CO, Rodriguez Garay EA, Mottino AD, Coleman R, Roma MG. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets. Hepatology 34: 329-339 (2001). *

• Crocenzi FA, Sanchez Pozzi EJ, Ruiz ML, Zucchetti AE, Roma MG, Mottino AD, Vore M. Ca(2+)-dependent protein kinase C isoforms are critical to estradiol 17beta-D-glucuronide-induced cholestasis in the rat. Hepatology 48: 1885-1895 (2008). *

• Croucher PJ, Mascheretti S, Foelsch UR, Hampe J, Schreiber S. Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterology 125: 1919-1920 (2003). *

• Crouthamel MH, Wu D, Yang Z, Ho RJ. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J. Pharm. Sci. 95: 2767-2777 (2006). *

• Csanaky IL, Aleksunes LM, Tanaka Y, Klaassen CD. Role of hepatic transporters in prevention of bile acid toxicity after partial hepatectomy in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G419-G433 (2009). *

• Cucchiara S, Latiano A, Palmieri O, Canani RB, D'Inca R, Guariso G, Vieni G, De Venuto D, Riegler G, De'Angelis GL, Guagnozzi D, Bascietto C, Miele E, Valvano MR, Bossa F, Annese V; Italian Society of Pediatric Gastroenterology and Nutrition. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44: 171-179 (2007). *

• Cui T, Liu Y, Men X, Xu Z, Wu L, Liu S, Xing A. Bile acid transport correlative protein mRNA expression profile in human placenta with intrahepatic cholestasis of pregnancy. Saudi Med. J. 30: 1406-1410 (2009).

• Cui Y, Cheng X, Miao Weaver Y, Klaassen CD. Tissue distribution, gender-divergent expression, ontogeny and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. Drug Metab. Dispos. 37: 203-210 (2009). *

• Cui Y, Konig J, Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol. 60: 934-943 (2001). *

• Cui YJ, Aleksunes LM, Tanaka Y, Goedken MJ, Klaassen CD. Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol. Sci. 110: 47-60 (2009). *

• D'Agata EM, Cataldo MA, Cauda R, Tacconelli E. The importance of addressing multidrug resistance and not assuming single-drug resistance in case-control studies. Infect. Control Hosp. Epidemiol. 27: 670-674 (2006). *

• Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132: 272-281 (2007). *

• Damiani D, Tiribelli M, Raspadori D, Michelutti A, Gozzetti A, Calistri E, Candoni A, Chiarvesio A, Lenoci M, Russo D, Fanin R. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. Hematol. Oncol. 25: 38-43 (2007).

• Daniel F, Loriot MA, Seksik P, Cosnes J, Gornet JM, Lemann M, Fein F, Vernier-Massouille G, De Vos M, Boureille A, Treton X, Flourie B, Roblin X, Louis E, Zerbib F, Beaune P, Marteau P. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm. Bowel Dis. 13: 19-23 (2007). *

• Dauchy S, Dutheil F, Weaver RJ, Chassoux F, Daumas-Duport C, Couraud PO, Scherrmann JM, De Waziers I, Decleves X. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J. Neurochem. 107: 1518-1528 (2008).

• Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA, Scherrmann JM, De Waziers I, Decleves X. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem. Pharmacol. 77: 897-909 (2009). *

• Davidson DJ, Rolfe M. Mouse models of cystic fibrosis. Trends Genet. 17: S29-S37 (2001). *

• Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J. Rare Dis. 4: 1 (2009). *

• Dawson PA. Molecular pathways for intestinal bile acid transport. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 53. June 18-19 (2004). *

• Dawson PA, Rao A, Craddock AL, Haywood J. Analysis of the molecular mechanisms responsible for intestinal basolateral bile acid transport. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 43 (2006). *

• Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 443: 180-185 (2006). *

• De Iudicibus S, Stocco G, Martelossi S, Drigo I, Norbedo S, Lionetti P, Pozzi E, Barabino A, Decorti G, Bartoli F, Ventura A. Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease. Gut 56: 1319-1320 (2007). *

• de Toledo KA, Pereira FL, Mambole A, Lesavre P, Roque-Barreira MC, Halbwachs-Mecarelli L. The macrophage-derived neutrophil chemotactic factor, MNCF: a lectin with TNF-alpha-like activities on neutrophils. Biochem. Biophys. Res. Commun. 376: 764-769 (2008). *

• de Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, Desrochers M, Burdelski M, Bernard O, Oude Elferink RP, Hadchouel M. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl. Acad. Sci. U.S.A. 95: 282-287 (1998). *

• De Vree JM, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, Oude Elferink RP. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119: 1720-1730 (2000). *

• de Waart DR, Paulusma CC, Kunne C, Oude Elferink RP. Multidrug resistance associated protein 2 mediates transport of prostaglandin E. Liver Int. 26: 362-368 (2006). *

• de Zwart L, Scholten M, Monbaliu JG, Annaert PP, Van Houdt JM, Van den Wyngaert I, De Schaepdrijver LM, Bailey GP, Coogan TP, Coussement WC, Mannens GS. The ontogeny of drug metabolizing enzymes and transporters in the rat. Reprod. Toxicol. 26: 220-230 (2008).

• Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. Dec 29 [Epub ahead of print] (2009).

• Deeley RG, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 580: 1103-1111 (2006). *

• Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86: 849-899 (2006). *

• Degorter MK, Conseil G, Deeley RG, Campbell RL, Cole SP. Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochem. Biophys. Res. Commun. 365: 29-34 (2008). *

• Delaunay JL, Durand-Schneider AM, Delautier D, Rada A, Gautherot J, Jacquemin E, Ait-Slimane T, Maurice M. A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature. Hepatology 49: 1218-1227 (2009). *

• Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, Bernard O, Hadchouel M. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 23: 904-908 (1996). *

• Deng WJ, Yang XQ, Liang YJ, Chen LM, Yan YY, Shuai XT, Fu LW. FG020326-loaded nanoparticle with PEG and PDLLA improved pharmacodynamics of reversing multidrug resistance in vitro and in vivo. Acta Pharmacol. Sin. 28: 913-920 (2007).

• Denk GU, Soroka CJ, Takeyama Y, Chen WS, Schuetz JD, Boyer JL. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J. Hepatol. 40: 585-591 (2004). *

• Denson LA, Auld KL, Schiek DS, McClure MH, Mangelsdorf DJ, Karpen SJ. Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. J. Biol. Chem. 275: 8835-8843 (2000). *

• Denson LA, Bohan A, Held MA, Boyer JL. Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis. Gastroenterology 123: 599-607 (2002). *

• Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 58: 163-170 (2007).

• Diaz GJ. Basolateral and canalicular transport of xenobiotics in the hepatocyte: a review. Cytotechnology 34: 225-235 (2000). *

• Diaz-Carballo D, Freista Hler M, Malak S, Bardenheuer W, Reusch HP. Mucronulatol from Caribbean propolis exerts cytotoxic effects on human tumor cell lines. Int. J. Clin. Pharmacol. Ther. 46: 226-235 (2008).

• Dicato M, Duhem C, Pauly M, Ries F. Multidrug resistance: molecular and clinical aspects. Cytokines Cell Mol. Ther. 3: 91-99 (1997).

• Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. 11: 391-406 (2003).

• Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52: 1788-1795 (2003). *

• Dietrich CG, Geier A, Salein N, Lammert F, Roeb E, Oude Elferink RP, Matern S, Gartung C. Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2. Gastroenterology 126: 1044-1053 (2004). *

• Dietrich CG, Ottenhoff R, de Waart DR, Oude Elferink RP. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 167: 73-81 (2001). *

• Dijkhuis AJ, Klappe K, Kamps W, Sietsma H, Kok JW. Gangliosides do not affect ABC transporter function in human neuroblastoma cells. J. Lipid Res. 47: 1187-1195 (2006). *

• Dilger K, Cascorbi I, Grunhage F, Hohenester S, Sauerbruch T, Beuers U. Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. Liver Int. 26: 285-290 (2006). *

• Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm. Bowel Dis. 10: 578-583 (2004). *

• Dimitrov T, Udo EE, Albaksami O, Al-Shehab S, Kilani A, Shehab M, Al-Nakkas A. Clinical and microbiological investigations of typhoid fever in an infectious disease hospital in Kuwait. J. Med. Microbiol. 56: 538-544 (2007). *

• Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, Weaver J, Nelson-Piercy C, de Swiet M, Warnes G, Elias E, Higgins CF, Johnston DG, McCarthy MI, Williamson C. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum. Mol. Genet. 9: 1209-1217 (2000). *

• Dolis D, Moreau C, Zachowski A, Devaux PF. Aminophospholipid translocase and proteins involved in transmembrane phospholipid traffic. Biophys. Chem. 68: 221-231 (1997).

• Dombrowski F, Stieger B, Beuers U. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab. Invest. 86: 166-174 (2006). *

• Dommels YE, Butts CA, Zhu S, Davy M, Martell S, Hedderley D, Barnett MP, McNabb WC, Roy NC. Characterization of intestinal inflammation and identification of related gene expression changes in mdr1a(-/-) mice. Genes Nutr. 2: 209-223 (2007). *

• Dong J, Yang G, McHaourab HS. Structural basis of energy transduction in the transport cycle of MsbA. Science 308: 1023-1028 (2005). *

• Dong Q, Xu B, Tan Y, Liu Z, Tian L, Zhang B, Lin CK, Kung HF, Sung JJ, He ML. The genetic variability of MDR1 C3435T polymorphisms in four Southern Chinese populations. Biomed. Pharmacother. 63: 658-662 (2009).

• Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 34: 351-359 (2001). *

• Donner MG, Schumacher S, Warskulat U, Heinemann J, Haussinger D. Obstructive cholestasis induces TNF-alpha- and IL-1beta-mediated periportal down-regulation of Bsep and zonal regulation of Ntcp, Oatp1a4 and Oatp1b2. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G1134-G1146 (2007). *

• Donner MG, Warskulat U, Saha N, Haussinger D. Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS. Biol. Chem. 385: 331-339 (2004).

• Doring F, Rimbach G, Lodge JK. In silico search for single nucleotide polymorphisms in genes important in vitamin E homeostasis. IUBMB Life. 56: 615-620 (2004). *

• dos Santos JS, Junior WS, Modena JL, Brunaldi JE, Ceneviva R. Effect of preoperative endoscopic decompression on malignant biliary obstruction and postoperative infection. Hepatogastroenterology 52: 45-47 (2005).

• Douet V, Heller MB, Le Saux O. DNA methylation and Sp1 binding determine the tissue-specific transcriptional activity of the mouse Abcc6 promoter. Biochem. Biophys. Res. Commun. 354: 66-71 (2007). *

• Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358 (2003). *

• Drain S, Catherwood MA, Orr N, Galligan L, Rea IM, Hodkinson C, Drake MB, Kettle PJ, Morris TC, Alexander HD. ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk. Lymphoma 50: 566-570 (2009).

• Dransfeld O, Gehrmann T, Kohrer K, Kircheis G, Holneicher C, Haussinger D, Wettstein M. Oligonucleotide microarray analysis of differential transporter regulation in the regenerating rat liver. Liver Int. 25: 1243-1258 (2005). *

• Drent M, van den Berg R, Haenen GR, van den Berg H, Wouters EF, Bast A. NF-kappaB activation in sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 18: 50-56 (2001).

• Dreuw A, Hermanns HM, Heise R, Joussen S, Rodriguez F, Marquardt Y, Jugert F, Merk HF, Heinrich PC, Baron JM. Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. J. Invest. Dermatol. 124: 28-37 (2005). *

• Drigo I, Piscianz E, Valencic E, De Iudicibus S, Tommasini A, Ventura A, Decorti G. Selective resistance to different glucocorticoids in severe autoimmune disorders. Clin. Immunol. Dec 2 [Epub ahead of print] (2009). *

• Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herczynska M. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol. 62: 933-937 (2006). *

• Drozdzik M, Stefankiewicz J, Kurzawa R, Gornik W, Baczkowski T, Kurzawski M. Association of the MDR1 (ABCB1) gene 3435C>T polymorphism with male infertility. Pharmacol. Rep. 61: 690-696 (2009). *

• Dumoulin FL, Reichel C, Sauerbruch T, Spengler U. Semiquantitation of intrahepatic MDR3 mRNA levels by reverse transcription/competitive polymerase chain reaction. J. Hepatol. 26: 852-856 (1997). *

• Dupuy J, Lespine A, Sutra JF, Alvinerie M. The interaction between moxidectin and MDR transporters in primary cultures of rat hepatocytes. J. Vet. Pharmacol. Ther. 29: 107-111 (2006).

• Duret C, Daujat-Chavanieu M, Pascussi JM, Pichard-Garcia L, Balaguer P, Fabre JM, Vilarem MJ, Maurel P, Gerbal-Chaloin S. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol. Pharmacol. 70: 329-339 (2006). *

• Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68: 598-604 (2000). *

• Dvorak K, Watts GS, Ramsey L, Holubec H, Payne CM, Bernstein C, Jenkins GJ, Sampliner RE, Prasad A, Garewal HS, Bernstein H. Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma. Am. J. Gastroenterol. 104: 302-309 (2009).

• Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J. 2 Suppl. 1: S8 (2003). *

• Efferth T. Adenosine triphosphate-binding cassette transporter genes in ageing and age-related diseases. Ageing Res. Rev. 2: 11-24 (2003).

• Ehret MJ, Levin GM, Narasimhan M, Rathinavelu A. Venlafaxine induces P-glycoprotein in human Caco-2 cells. Hum. Psychopharmacol. 22: 49-53 (2006).

• Ehrhardt M, Lindenmaier H, Burhenne J, Haefeli WE, Weiss J. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem. Pharmacol. 67: 285-292 (2004). *

• Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26: 180-185 (2004).

• Eilers M, Roy U, Mondal D. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp. Biol. Med. (Maywood) 233: 1149-1160 (2008). *

• Eisenbraun MD, Miller RA. mdr1a-encoded P-glycoprotein is not required for peripheral T cell proliferation, cytokine release, or cytotoxic effector function in mice. J. Immunol. 163: 2621-2627 (1999). *

• Ekins S, Erickson JA. A pharmacophore for human pregnane X receptor ligands. Drug Metab. Dispos. 30: 96-99 (2002). *

• Elamiri A, Perwaiz S, Tuchweber B, Yousef IM. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice. Pharmacol. Res. 48: 467-472 (2003). *

• Elferink MG, Olinga P, Draaisma AL, Merema MT, Faber KN, Slooff MJ, Meijer DK, Groothuis GM. LPS-induced down-regulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G1008-G1016 (2004). *

• Elias E, Mills CO. Coordinated defence and the liver. Clin. Med. 7: 180-184 (2007).

• Eloranta JJ, Kullak-Ublick GA. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 433: 397-412 (2005). *

• Eloranta ML, Heiskanen JT, Hiltunen MJ, Mannermaa AJ, Punnonen KR, Heinonen ST. Multidrug resistance 3 gene mutation 1712delT and estrogen receptor alpha gene polymorphisms in Finnish women with obstetric cholestasis. Eur. J. Obstet. Gynecol. Reprod. Biol. 104: 109-112 (2002).

• Eloranta ML, Heiskanen JT, Hiltunen MJ, Mannermaa AJ, Punnonen KR, Heinonen ST. Multidrug resistance 3 gene mutation 1712delT and estrogen receptor alpha gene polymorphisms in Finnish women with obstetric cholestasis. Eur. J. Obstet. Gynecol. Reprod. Biol. 105: 132-135 (2002).

• Engi H, Gyemant N, Lorand T, Levai A, Ocsovszki I, Molnar J. Cinnamylidene ketones as potential modulators of multidrug resistance in mouse lymphoma and human colon cancer cell lines. In Vivo 20: 119-124 (2006).

• Englund G, Jacobson A, Rorsman F, Artursson P, Kindmark A, Ronnblom A. Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm. Bowel Dis. 13: 291-297 (2007). *

• Enjoji M, Yada R, Fujino T, Yoshimoto T, Yada M, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Nakamuta M. The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Hepatol. Int. Jun 16 [Epub ahead of print] (2009). *

• Equi AC, Davies JC, Painter H, Hyde S, Bush A, Geddes DM, Alton EW. Exploring the mechanisms of macrolides in cystic fibrosis. Respir. Med. 100: 687-697 (2006).

• Erdelyi DJ, Kamory E, Zalka A, Semsei AF, Csokay B, Andrikovics H, Tordai A, Borgulya G, Magyarosy E, Galantai I, Fekete G, Falus A, Szalai C, Kovacs GT. The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia. Cell. Immunol. 244: 121-124 (2006). *

• Erickson RP, Bhattacharyya A, Hunter RJ, Heidenreich RA, Cherrington NJ. Liver disease with altered bile acid transport in Niemann-Pick C mice on a high fat, 1% cholesterol diet. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G300-G307 (2005). *

• Erlinger S. Review article: new insights into the mechanisms of hepatic transport and bile secretion. J. Gastroenterol. Hepatol. 11: 575-579 (1996).

• Erlinger S. Mechanisms of hepatic transport and bile secretion. Acta Gastroenterol. Belg. 59: 159-162 (1996).

• Ernst R, Klemm R, Schmitt L, Kuchler K. Yeast ATP-binding cassette transporters: cellular cleaning pumps. Methods Enzymol. 400: 460-484 (2005).

• Espinosa Fernandez MG, Navas Lopez VM, Blasco Alonso J, Sierra Salinas C, Barco Galvez A. Progressive familial intrahepatic cholestasis type 3. An MDR3 defect. An. Pediatr. (Barc.) 69: 182-184 (2008).

• Eum SY, Jeon BY, Min JH, Kim SC, Cho S, Park SK, Cho SN. Tumor necrosis factor-alpha and interleukin-10 in whole blood is associated with disease progression in pulmonary multidrug-resistant tuberculosis patients. Respiration 76: 331-337 (2008).

• Ey B, Eyking A, Gerken G, Podolsky DK, Cario E. TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. J. Biol. Chem. 284: 22332-22343 (2009). *

• Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr. Infect. Dis. J. 28: 123-127 (2009).

• Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int. J. Antimicrob. Agents 33: 503.e1-e13 (2009). *

• Fan J, Liu S, Du Y, Morrison J, Shipman R, Pang KS. Upregulation of transporters and enzymes by the vitamin D receptor (VDR) and ligands [1alpha,25-dihydroxyvitamin D3 and vitamin D analogues in the Caco-2 cell monolayer. J. Pharmacol. Exp. Ther. 330: 389-402 (2009). *

• Fang L, Zhang G, Li C, Zheng X, Zhu L, Xiao JJ, Szakacs G, Nadas J, Chan KK, Wang PG, Sun D. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance. J. Med. Chem. 49: 932-941 (2006). *

• Fantappie O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R. P-Glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res. 67: 4915-4923 (2007). *

• Fardel O, Jigorel E, Le Vee M, Payen L. Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomed. Pharmacother. 59: 104-114 (2005).

• Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen. Pharmacol. 27: 1283-1291 (1996).

• Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V. Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology 167: 37-46 (2001). *

• Farnood A, Naderi N, Moghaddam SJ, Noorinayer B, Firouzi F, Aghazadeh R, Daryani NE, Zali MR. The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis. Int. J. Colorectal Dis. 22: 999-1003 (2007). *

• Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J. Endocrinol. 178: 339-346 (2003). *

• Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PW, Weir DG, Kelleher D. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118: 279-288 (2000). *

• Fecht S, Distl O. Review of prevalence, genetic aspects and adverse effects of the mdr1-1Delta mutation in dogs. Dtsch. Tierarztl. Wochenschr. 115: 212-219 (2008).

• Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, Wang HF. Role of hepatic transporters in the disposition and hepatotoxicity of a Her2 tyrosine kinase inhibitor CP-724,714. Toxicol. Sci. 108: 492-500 (2009). *

• Ferreira PE, Veiga MI, Cavaco I, Martins JP, Andersson B, Mushin S, Ali AS, Bhattarai A, Ribeiro V, Bjorkman A, Gil JP. Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther. Drug Monit. 30: 10-15 (2008).

• Fickert P, Fuchsbichler A, Moustafa T, Halilbasic E, Denk H, Trauner M. Bile acids and liver fibrosis - causative agent and therapeutic tool. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 70-71 (2006). *

• Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R, Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (abcb4) knockout mice. Gastroenterology 127: 261-274 (2004). *

• Fickert P, Stoger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH, Tsybrovskyy O, Jaeschke H, Zatloukal K, Denk H, Trauner M. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am. J. Pathol. 171: 525-536 (2007). *

• Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130: 465-481 (2006). *

• Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121: 170-183 (2001). *

• Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123: 1238-1251 (2002). *

• Fiedler T, Buning C, Reuter W, Pitre G, Gentz E, Schmidt H, Buttner J, Ockenga J, Gerloff T, Meisel C, Lochs H, Roots I, Kopke K, Johne A. Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn's disease. Eur. J. Clin. Pharmacol. 63: 917-925 (2007). *

• Fierer J. MDR-TB and HIV: the perfect storm? Am. J. Trop. Med. Hyg. 75: 1025-1026 (2006).

• Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour B, Sabatino G, Russo G, Castellani D, Willson TM, Pellicciari R, Morelli A. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor (FXR) ligand, in estrogen induced cholestasis. J. Pharmacol. Exp. Ther. 313: 604-612 (2005). *

• Fischer S, Lakatos PL, Group TH, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Szilvasi A, Tulassay Z, Osztovits J, Papp J, Demeter P, Schwab R, Tordai A, Andrikovics H. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgery in Hungarian patients with inflammatory bowel diseases. Scand. J. Gastroenterol. 42: 726-733 (2007). *

• Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J. Mol. Med. 80: 271-281 (2002). *

• Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Montagnani M, Marchesoni D, Variola A, Rosa Rizzotto E, Braghin C, Mazzella G. Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. Dig. Liver Dis. 40: 366-370 (2008).

• Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Variola A, Tommasi AM, Marchesoni D, Braghin C, Mazzella G. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment. Pharmacol. Ther. 23: 1649-1653 (2006). *

• Fodor A, Harel C, Fodor L, Armoni M, Salmon P, Trono D, Karnieli E. Adult rat liver cells transdifferentiated with lentiviral IPF1 vectors reverse diabetes in mice: an ex vivo gene therapy approach. Diabetologia 50: 121-130 (2007). *

• Foell D, Wittkowski H, Ren Z, Turton J, Pang G, Daebritz J, Ehrchen J, Heidemann J, Borody T, Roth J, Clancy R. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J. Pathol. 216: 183-192 (2008). *

• Foss-Freitas MC, Foss NT, Donadi EA, Foss MC. In vitro TNF-alpha and IL-6 production by adherent peripheral blood mononuclear cells obtained from type 1 and type 2 diabetic patients evaluated according to the metabolic control. Ann. N. Y. Acad. Sci. 1079: 177-180 (2006). *

• Foss-Freitas MC, Foss NT, Rassi DM, Donadi EA, Foss MC. Evaluation of cytokine production from peripheral blood mononuclear cells of type 1 diabetic patients. Ann. N. Y. Acad. Sci. 1150: 290-296 (2008). *

• Fouassier L, Beaussier M, Schiffer E, Rey C, Barbu V, Mergey M, Wendum D, Callard P, Scoazec JY, Lasnier E, Stieger B, Lienhart A, Housset C. Hypoxia-induced changes in the expression of rat hepatobiliary transporter genes. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G25-G35 (2007). *

• Fouassier L, Kinnman N, Lefevre G, Lasnier E, Rey C, Poupon R, Oude Elferink RP, Housset C. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. 37: 184-191 (2002). *

• Franca AV, Valerio HM, Trevisan M, Escanhoela C, Seva-Pereira T, Zucoloto S, Martinelli A, Soares EC. Fine needle aspiration biopsy for improving the diagnostic accuracy of cut needle biopsy of focal liver lesions. Acta Cytol. 47: 332-336 (2003).

• Franchimont D. Mechanisms of steroid refractory disease. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 72-73. May 7-8 (2004). *

• Fraser A, Paul M, Attamna A, Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst. Rev. 2: CD005435 (2006). *

• Fredericks S, Jorga A, Macphee IA, Reboux S, Shiferaw E, Moreton M, Carter ND, Holt DW, Johnston A. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin. Transplant. 21: 252-257 (2007). *

• Fredericks S, Moreton M, Reboux S, Carter ND, Goldberg L, Holt DW, Macphee IA. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 82: 705-708 (2006).

• Frelet A, Klein M. Insight in eukaryotic ABC transporter function by mutation analysis. FEBS Lett. 580: 1064-1084 (2006). *

• Frijters CM, Ottenhoff R, Van Wijland MJ, Van Nieuwkerk C, Groen AK, Oude Elferink RP. Influence of bile salts on hepatic mdr2 P-glycoprotein expression. Adv. Enzyme Regul. 36: 351-363 (1996). *

• Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25: 423-429 (2004). *

• Fromm MF. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 181-182: 299-303 (2002). *

• Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 54: 1295-1310 (2002). *

• Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am. J. Pathol. 157: 1575-1580 (2000). *

• Frota ML Jr, Klamt F, Dal-Pizzol F, Schiengold M, Moreira JC. Retinol-induced mdr1 and mdr3 modulation in cultured rat Sertoli cells is attenuated by free radical scavengers. Redox Rep. 9: 161-165 (2004).

• Fu D, van Dam EM, Brymora A, Duggin IG, Robinson PJ, Roufogalis BD. The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein. Biochim. Biophys. Acta 1773: 1062-1072 (2007). *

• Fuchs M, Stange EF. Cholesterol and cholestasis: a lesson from the Mdr2 (-/-) mouse. J. Hepatol. 34: 339-341 (2001). *

• Fujiyama N, Shitara Y, Ito K, Masubuchi Y, Horie T. Down-regulation of hepatic transporters for BSP in rats with indomethacin-induced intestinal injury. Biol. Pharm. Bull. 30: 556-561 (2007). *

• Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, Ogura Y, Oike F, Takada Y, Egawa H, Uemoto S, Inui K. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin. Pharmacol. Ther. 80: 331-345 (2006). *

• Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet. Genomics 18: 413-423 (2008).

• Fukuen S, Fukuda T, Matsuda H, Sumida A, Yamamoto I, Inaba T, Azuma J. Identification of the novel splicing variants for the hPXR in human livers. Biochem. Biophys. Res. Commun. 298: 433-438 (2002). *

• Fukushima-Uesaka H, Saito Y, Tohkin M, Maekawa K, Hasegawa R, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Kajio H, Kuzuya N, Yasuda K, Sawada J. Genetic variations and haplotype structures of the ABC transporter gene ABCC1 in a Japanese population. Drug Metab. Pharmacokinet. 22: 48-60 (2007). *

• Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta 1794: 860-871 (2009). *

• Funk C. The role of hepatic transporters in drug elimination. Expert Opin. Drug Metab. Toxicol. 4: 363-379 (2008).

• Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59: 627-635 (2001). *

• Furukawa T, Akiyama S. Mechanisms of substrate transport by ABC transporter, MRP1/ABCC1. Seikagaku 78: 110-121 (2006).

• Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Umemura K, Ishizaki T, Hishida A. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment. Pharmacol. Ther. 26: 693-703 (2007). *

• Gai XD, Li GL, Huang JZ, Xue HJ, Wang D. Reversal of multidrug resistance of human hepatocellular carcinoma cells by wild-type p53 gene and related mechanisms. Ai Zheng 25: 954-959 (2006).

• Galimberti S, Guerrini F, Palumbo GA, Consoli U, Fazzi R, Morabito F, Santini V, Petrini M. Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk. Res. 28: 367-372 (2004).

• Gallego O, Belyaeva OV, Porte S, Ruiz FX, Stetsenko AV, Shabrova EV, Kostereva NV, Farres J, Pares X, Kedishvili NY. Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases, and aldo-keto reductases with retinoids. Biochem. J. 399: 101-109 (2006). *

• Galski H, Sivan H, Lazarovici P, Nagler A. In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies. Leuk. Res. 30: 1151-1158 (2006).

• Gannon MK 2nd, Holt JJ, Bennett SM, Wetzel BR, Loo TW, Bartlett MC, Clarke DM, Sawada GA, Higgins JW, Tombline G, Raub TJ, Detty MR. Rhodamine inhibitors of P-glycoprotein: an amide/thioamide "switch" for ATPase activity. J. Med. Chem. 52: 3328-3341 (2009). *

• Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol. Appl. Pharmacol. 133: 269-276 (1995). *

• Gao B, St Pierre MV, Stieger B, Meier PJ. Differential expression of bile salt and organic anion transporters in developing rat liver. J. Hepatol. 41: 201-208 (2004). *

• Gatlik-Landwojtowicz E, Aanismaa P, Seelig A. Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 45: 3020-3032 (2006). *

• Gatmaitan ZC, Nies AT, Arias IM. Regulation and translocation of ATP-dependent apical membrane proteins in rat liver. Am. J. Physiol. 272: G1041-G1049 (1997).

• Gavrilova O, Geyer J, Petzinger E. In vivo relevance of Mrp2-mediated biliary excretion of the Amanita mushroom toxin demethylphalloin. Biochim. Biophys. Acta 1768: 2070-2077 (2007). *

• Gawronska-Szklarz B, Wrzesniewska J, Starzynska T, Pawlik A, Safranow K, Ferenc K, Drozdzik M. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur. J. Clin. Pharmacol. 61: 375-379 (2005). *

• Gazouli M, Zacharatos P, Gorgoulis V, Mantzaris G, Papalambros E, Ikonomopoulos J. The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. Gastroenterology 126: 367-369 (2004). *

• Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276: 14581-14587 (2001). *

• Geier A, Dietrich CG, Grote T, Beuers U, Prufer T, Fraunberger P, Matern S, Gartung C, Gerbes AL, Bilzer M. Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J. Hepatol. 43: 1021-1030 (2005). *

• Geier A, Dietrich CG, Lammert F, Orth T, Mayet WJ, Matern S, Gartung C. Regulation of organic anion transporters in a new rat model of acute and chronic cholangitis resembling human primary sclerosing cholangitis. J. Hepatol. 36: 718-724 (2002). *

• Geier A, Dietrich CG, Voigt S, Ananthanarayanan M, Lammert F, Schmitz A, Trauner M, Wasmuth HE, Boraschi D, Balasubramaniyan N, Suchy FJ, Matern S, Gartung C. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G831-G841 (2005). *

• Geier A, Dietrich CG, Voigt S, Kim SK, Gerloff T, Kullak-Ublick GA, Lorenzen J, Matern S, Gartung C. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38: 345-354 (2003). *

• Geier A, Kim SK, Gerloff T, Dietrich CG, Lammert F, Karpen SJ, Stieger B, Meier PJ, Matern S, Gartung C. Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride. J. Hepatol. 37: 198-205 (2002). *

• Geier A, Mertens PR, Gerloff T, Dietrich CG, En-Nia A, Kullak-Ublick GA, Karpen SJ, Matern S, Gartung C. Constitutive rat multidrug-resistance protein 2 gene transcription is down-regulated by Y-box protein 1. Biochem. Biophys. Res. Commun. 309: 612-618 (2003). *

• Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 1773: 283-308 (2007). *

• Gendrot C, Bacq Y, Brechot MC, Lansac J, Andres C. A second heterozygous MDR3 nonsense mutation associated with intrahepatic cholestasis of pregnancy. J. Med. Genet. 40: e32 (2003). *

• Gennuso F, Fernetti C, Tirolo C, Testa N, L'Episcopo F, Caniglia S, Morale MC, Ostrow JD, Pascolo L, Tiribelli C, Marchetti B. Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc. Natl. Acad. Sci. U.S.A. 101: 2470-2475 (2004). *

• Gentzsch M, Choudhury A, Chang XB, Pagano RE, Riordan JR. Misassembled mutant DeltaF508 CFTR in the distal secretory pathway alters cellular lipid trafficking. J. Cell. Sci. 120: 447-455 (2007). *

• Gerk PM, Li W, Megaraj V, Vore M. Human multidrug resistance protein 2 (MRP2/ABCC2) transports the therapeutic bile salt tauroursodeoxycholate. J. Pharmacol. Exp. Ther. 320: 893-899 (2007). *

• Gerloff T, Geier A, Stieger B, Hagenbuch B, Meier PJ, Matern S, Gartung C. Differential expression of basolateral and canalicular organic anion transporters during regeneration of rat liver. Gastroenterology 117: 1408-1415 (1999). *

• Germain DP, Perdu J, Remones V, Jeunemaitre X. Homozygosity for the R1268Q mutation in MRP6, the pseudoxanthoma elasticum gene, is not disease-causing. Biochem. Biophys. Res. Commun. 274: 297-301 (2000). *

• Germann UA, Chambers TC. Molecular analysis of the multidrug transporter, P-glycoprotein. Cytotechnology 27: 31-60 (1998). *

• Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations. Ther. Drug Monit. 27: 819-821 (2005).

• Geuken E, Visser D, Kuipers F, Blokzijl H, Leuvenink HG, de Jong KP, Peeters PM, Jansen PL, Slooff MJ, Gouw AS, Porte RJ. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J. Hepatol. 41: 1017-1025 (2004). *

• Geuken E, Visser DS, Leuvenink HG, de Jong KP, Peeters PM, Slooff MJ, Kuipers F, Porte RJ. Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients. Hepatology 42: 1166-1174 (2005). *

• Geyer J, Doring B, Godoy JR, Leidolf R, Moritz A, Petzinger E. Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. J. Vet. Pharmacol. Ther. 28: 545-551 (2005). *

• Gheduzzi D, Guidetti R, Anzivino C, Tarugi P, Di Leo E, Quaglino D, Ronchetti IP. ABCC6 mutations in Italian families affected by pseudoxanthoma elasticum (PXE). Hum. Mutat. 24: 438-439 (2004). *

• Ghibellini G, Leslie EM, Pollack GM, Brouwer KL. Use of Tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm. Res. 25: 1851-1860 (2008). *

• Ghose R, Guo T, Haque N. Regulation of gene expression of hepatic drug metabolizing enzymes and transporters by the Toll-like receptor 2 ligand, lipoteichoic acid. Arch. Biochem. Biophys. 481: 123-130 (2009). *

• Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, Antonopoulou A, Tsaganos T, Kanellakopoulou K, Giamarellou H. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int. J. Antimicrob. Agents 27: 476-481 (2006). *

• Gibson PR. Increased gut permeability in Crohn's disease: is TNF the link? Gut 53: 1724-1725 (2004). *

• Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C, Warzok R, Engel G, Weitschies W, Cascorbi I, Kroemer HK, Siegmund W. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin. Pharmacol. Ther. 75: 213-222 (2004). *

• Gillet JP, Efferth T, Steinbach D, Hamels J, de Longueville F, Bertholet V, Remacle J. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res. 64: 8987-8993 (2004). *

• Girardin F. Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin. Neurosci. 8: 311-321 (2006).

• Glas J, Torok HP, Schiemann U, Folwaczny C. MDR1 gene polymorphism in ulcerative colitis. Gastroenterology 126: 367 (2004). *

• Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug Deliv. 1: 27-42 (2004). *

• Gollapudi S, Kim C, Gupta S. P-glycoprotein (encoded by multidrug resistance genes) is not required for interleukin-2 secretion in mice and humans. Genes Immun. 1: 371-379 (2000). *

• Gong R, Liu Z, Li L. Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors. Arthritis Rheum. 56: 1608-1617 (2007). *

• Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E. Liver diseases related to MDR3 (ABCB4) gene deficiency. Front. Biosci. 14: 4242-4256 (2009).

• Gonzalez MA, Alvarez Mdel L, Pisani GB, Bernal CA, Roma MG, Carrillo MC. Involvement of oxidative stress in the impairment in biliary secretory function induced by intraperitoneal administration of aluminum to rats. Biol. Trace Elem. Res. 116: 329-348 (2007).

• Gonzalez MA, Roma MG, Bernal CA, Alvarez Mde L, Carrillo MC. Biliary secretory function in rats chronically intoxicated with aluminum. Toxicol. Sci. 79: 189-195 (2004). *

• Gorelik J, Patel P, Ng'andwe C, Vodyanoy I, Diakonov I, Lab M, Korchev Y, Williamson C. Genes encoding bile acid, phospholipid and anion transporters are expressed in a human fetal cardiomyocyte culture. BJOG 113: 552-558 (2006). *

• Goto K, Sugiyama K, Sugiura T, Ando T, Mizutani F, Terabe K, Ban K, Togari H. Bile salt export pump gene mutations in two Japanese patients with progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 36: 647-650 (2003). *

• Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, Inui K. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14: 471-478 (2004).

• Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, Tsuda H, Tenjin Y, Kikuchi Y. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol. Rep. 15: 1265-1271 (2006). *

• Gouvea EF, Branco RC, Monteiro RC, Halpern M, Ribeiro-Filho J, Silveira VG, Tavares GC, Rodrigues MS, Coelho HS, Basto ST, Santoro-Lopes G. Outcome of infections caused by multiple drug-resistant bacteria in liver transplant recipients. Transplant. Proc. 36: 958-960 (2004). *

• Gradhand U, Lang T, Schaeffeler E, Glaeser H, Tegude H, Klein K, Fritz P, Jedlitschky G, Kroemer HK, Bachmakov I, Anwald B, Kerb R, Zanger UM, Eichelbaum M, Schwab M, Fromm MF. Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J. 8: 42-52 (2008). *

• Gradhand U, Tegude H, Burk O, Eichelbaum M, Fromm MF, Konig J. Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene. Life Sci. 80: 1490-1494 (2007). *

• Gradilone SA, Tietz PS, Splinter PL, Marinelli RA, LaRusso NF. Expression and subcellular localization of aquaporin water channels in the polarized hepatocyte cell line, WIF-B. BMC Physiol. 5: 13 (2005). *

• Granzotto M, Drigo I, Candussio L, Rosati A, Bartoli F, Giraldi T, Decorti G. Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. Cancer Lett. 205: 107-115 (2004). *

• Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. Mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res. 12: 854-859 (2006). *

• Greger DL, Gropp F, Morel C, Sauter S, Blum JW. Nuclear receptor and target gene mRNA abundance in duodenum and colon of dogs with chronic enteropathies. Domest. Anim. Endocrinol. 31: 327-329 (2006). *

• Groen AK, Oude Elferink RP, Tager JM. Control analysis of biliary lipid secretion. J. Theor. Biol. 182: 427-436 (1996). *

• Groen AK, Van Wijland MJ, Frederiks WM, Smit JJ, Schinkel AH, Oude Elferink RP. Regulation of protein secretion into bile: studies in mice with a disrupted mdr2 p-glycoprotein gene. Gastroenterology 109: 1997-2006 (1995). *

• Gu L, Tsark WM, Brown DA, Blanchard S, Synold TW, Kane SE. A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. Proc. Natl. Acad. Sci. U.S.A. 106: 5394-5399 (2009). *

• Gu W, Zhang YN, Li B, Han J, Cheng BB, Ling CQ. Establishment of a multidrug-resistant cell line BEL-7402/5-FU of human hepatocellular carcinoma and its biological characteristics. Zhong Xi Yi Jie He Xue Bao 4: 265-270 (2006).

• Guardigli M, Marangi M, Casanova S, Grigioni WF, Roda E, Roda A. Chemiluminescence quantitative immunohistochemical determination of MRP2 in liver biopsies. J. Histochem. Cytochem. 53: 1451-1457 (2005). *

• Guminski AD, Balleine RL, Chiew YE, Webster LR, Tapner M, Farrell GC, Harnett PR, Defazio A. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol. Oncol. 100: 239-246 (2006).

• Gummadi SN, Kumar KS. The mystery of phospholipid flip-flop in biogenic membranes. Cell. Mol. Biol. Lett. 10: 101-121 (2005). *

• Gumus-Akay G, Rustemoglu A, Karadag A, Sunguroglu A. Genotype and allele frequencies of MDR1 gene C1236T polymorphism in a Turkish population. Genet. Mol. Res. 7: 1193-1199 (2008).

• Guo C, Ding J, Yao L, Sun L, Lin T, Song Y, Sun L, Fan D. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int. J. Cancer 116: 155-160 (2005). *

• Guo C, Jin X. Chemoprotection effect of multidrug resistance 1 (MDR1) gene transfer to hematopoietic progenitor cells and engrafted in mice with cancer allows intensified chemotherapy. Cancer Invest. 24: 659-668 (2006).

• Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Kliewer SA, Gonzalez FJ, Sinal CJ. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278: 45062-45071 (2003). *

• Gupta A, Mugundu G, Desai PB, Thummel KE, Unadkat JD. Intestinal human colon adenocarcinoma cell line, LS180, is an excellent model to study PXR- but not CAR-mediated CYP3A4 and MDR1 induction: studies with anti-HIV protease Inhibitors. Drug Metab. Dispos. 36: 1172-1180 (2008). *

• Gupta D, Venkatesh M, Wang H, Kim S, Sinz M, Goldberg GL, Whitney K, Longley C, Mani S. Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin. Cancer Res. 14: 5332-5340 (2008). *

• Gupta S, Todd Stravitz R, Pandak WM, Muller M, Reno Vlahcevic Z, Hylemon PB. Regulation of multidrug resistance 2 P-glycoprotein expression by bile salts in rats and in primary cultures of rat hepatocytes. Hepatology 32: 341-347 (2000). *

• Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem. Pharmacol. 70: 605-609 (2005). *

• Gutmann H, Hruz P, Zimmermann C, Straumann A, Terracciano L, Hammann F, Lehmann F, Beglinger C, Drewe J. Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls. Digestion 78: 154-162 (2008). *

• Gyamfi MA, Wan YJ. Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis. J. Biol. Chem. 284: 9321-9330 (2009). *

• Hagenauer B, Maier-Salamon A, Thalhammer T, Zollner P, Senderowicz A, Jager W. Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. Oncol. Rep. 11: 1069-1075 (2004).

• Hagenbuch N, Reichel C, Stieger B, Cattori V, Fattinger KE, Landmann L, Meier PJ, Kullak-Ublick GA. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. J. Hepatol. 34: 881-887 (2001). *

• Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. 5: 21-53 (2004).

• Haimeur A, Conseil G, Deeley RG, Cole SP. Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). Mol. Pharmacol. 65: 1375-1385 (2004). *

• Halilbasic E, Fickert P, Foirotto R , Marschall HU, Moustafa T, Fuchsbichler A, Gumhold J, Silbert D, Langner C, Maitra U, Denk H , Strazzabosco M, Trauner M. Side-chain-modification critically determines the physiologic and therapeutic properties of 24-nor-ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice and isolated bile duct units. Falk Symposium 165: XX International Bile Acid Meeting. Bile Acid Biology and Therapeutic Actions. June 13-14, 2008, Amsterdam, Netherlands, p. 55 (2008). *

• Halilbasic E, Fickert P, Fuchbichler A , Langner C, Gumhold J, Silbert D, Maitra U, Zatloukal K, Denk H, Trauner M. Taurine-conjugation critically determines the therapeutic effectiveness of 24-nor-ursodeoxycholic acid (norUDCA) in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. J. Hepatol. 46: S51 (2007). *

• Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 49: 1972-1981 (2009). *

• Han Y, Sugiyama Y. Expression and regulation of breast cancer resistance protein and multidrug resistance associated protein 2 in BALB/c mice. Biol. Pharm. Bull. 29: 1032-1035 (2006). *

• Hanauer SB. Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 26-31 (2004). *

• Hannivoort RA, Dunning S, Vander Borght S, Schroyen B, Woudenberg J, Oakley F, Buist-Homan M, van den Heuvel FA, Geuken M, Geerts A, Roskams T, Faber KN, Moshage H. Multidrug resistance-associated proteins are crucial for the viability of activated rat hepatic stellate cells. Hepatology 48: 624-634 (2008). *

• Hao Z, Li X, Qiao T, Du R, Hong L, Fan D. CIAPIN1 confers multidrug resistance by upregulating the expression of MDR-1 and MRP-1 in gastric cancer cells. Cancer Biol. Ther. 5: 261-266 (2006). *

• Hao Z, Li X, Qiao T, Du R, Zhang G, Fan D. Subcellular localization of CIAPIN1. J. Histochem. Cytochem. 54: 1437-1444 (2006). *

• Harding SV, Adegoke OA, Fraser KG, Marliss EB, Chevalier S, Kimball SR, Jefferson LS, Wykes LJ. Maintaining adequate nutrition, not probiotic administration, prevents growth stunting and maintains skeletal muscle protein synthesis rates in a piglet model of colitis. Pediatr. Res. Nov 25 [Epub ahead of print] (2009).

• Harmsen S, Meijerman I, Beijnen JH, Schellens JH. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat. Rev. 33: 369-380 (2007). *

• Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, Schellens JH. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother. Pharmacol. Dec 30 [Epub ahead of print] (2009). *

• Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. 303: 273-281 (2002). *

• Hartmann G, Kim H, Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int. Immunopharmacol. 1: 189-199 (2001).

• Hasan Z, Tanveer M, Kanji A, Hasan Q, Ghebremichael S, Hasan R. Spoligotyping of Mycobacterium tuberculosis isolates from Pakistan reveals predominance of Central Asian strain 1 and Beijing isolates. J. Clin. Microbiol. 44: 1763-1768 (2006). *

• Hasegawa T, Bai J, Zhang S, Wang J, Matsubara J, Kawakami J, Tomida A, Tsuruo T, Hirose K, Sakai J, Kikuchi M, Abe M, Ando M. Structure-activity relationships of some taxoids as multidrug resistance modulator. Bioorg. Med. Chem. Lett. 17: 1122-1126 (2007).

• Hasegawa Y, Kishimoto S, Takahashi H, Inotsume N, Takeuchi Y, Fukushima S. Altered expression of MRP2, MRP3 and UGT2B1 in the liver affects the disposition of morphine and its glucuronide conjugate in a rat model of cholestasis. J. Pharm. Pharmacol. 61: 1205-1210 (2009).

• Hasko G, Deitch EA, Nemeth ZH, Kuhel DG, Szabo C. Inhibitors of ATP-binding cassette transporters suppress interleukin-12 p40 production and major histocompatibility complex II up-regulation in macrophages. J. Pharmacol. Exp. Ther. 301: 103-110 (2002). *

• Haslam IS, Jones K, Coleman T, Simmons NL. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochem. Pharmacol. 76: 850-861 (2008). *

• Haslam IS, Jones K, Coleman T, Simmons NL. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Br. J. Pharmacol. 154: 246-255 (2008). *

• Hattori H, Suminoe A, Wada M, Koga Y, Kohno K, Okamura J, Hara T, Matsuzaki A. Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk. Res. 31: 1633-1640 (2007).

• Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14: 147-154 (2004).

• Hayashi H, Takada T, Suzuki H, Onuki R, Hofmann AF, Sugiyama Y. Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep. Biochim. Biophys. Acta 1738: 54-62 (2005). *

• Hayashi M, Tomita M. Mechanistic analysis for drug permeation through intestinal membrane. Drug. Metab. Pharmacokinet. 22: 67-77 (2007). *

• Hayeshi R, Chinyanga F, Chengedza S, Mukanganyama S. Inhibition of human glutathione transferases by multidrug resistance chemomodulators in vitro. J. Enzyme Inhib. Med. Chem. 21: 581-587 (2006).

• Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology (Bethesda) 20: 125-133 (2005). *

• Heemskerk S, van Koppen A, van den Broek L, Poelen GJ, Wouterse AC, Dijkman HB, Russel FG, Masereeuw R. Nitric oxide differentially regulates renal ATP-binding cassette transporters during endotoxemia. Pflugers Arch. 454: 321-334 (2007). *

• Heffeter P, Pongratz M, Steiner E, Chiba P, Jakupec MA, Elbling L, Marian B, Korner W, Sevelda F, Micksche M, Keppler BK, Berger W. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A). J. Pharmacol. Exp. Ther. 312: 281-289 (2005). *

• Hegedus T, Sessler T, Scott R, Thelin W, Bakos E, Varadi A, Szabo K, Homolya L, Milgram SL, Sarkadi B. C-terminal phosphorylation of MRP2 modulates its interaction with PDZ proteins. Biochem. Biophys. Res. Commun. 302: 454-461 (2003). *

• Heidema GA, Boer JM, Nagelkerke N, Mariman EC, van der A DL, Feskens EJ. The challenge for genetic epidemiologists: how to analyze large numbers of SNPs in relation to complex diseases. BMC Genet. 7: 23 (2006). *

• Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, Schreiber S, Rutgeerts P, Vermeire S. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin. Gastroenterol. Hepatol. 7: 972-980.e2 (2009).

• Hendig D, Schulz V, Eichgrun J, Szliska C, Gotting C, Kleesiek K. New ABCC6 gene mutations in German pseudoxanthoma elasticum patients. J. Mol. Med. 83: 140-147 (2005). *

• Hendrikse NH, Kuipers F, Meijer C, Havinga R, Bijleveld CM, Van Der Graaf WT, Vaalburg W, De Vries EG. In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. Cancer Chemother. Pharmacol. 54: 131-138 (2004). *

• Heresbach D, Gicquel-Douabin V, Birebent B, D'halluin PN, Heresbach-Le Berre N, Dreano S, Siproudhis L, Dabadie A, Gosselin M, Mosser J, Semana G, Bretagne JF, Yaouanq J. NOD2/CARD15 gene polymorphisms in Crohn's disease: a genotype-phenotype analysis. Eur. J. Gastroenterol. Hepatol. 16: 55-62 (2004).

• Hesselink DA, Van Gelder T, Van Schaik RH, Balk AH, Van der Heiden IP, Van Dam T, Van der Werf M, Weimar W, Mathot RA. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. 76: 545-556 (2004). *

• Hierro L, Jara P. Childhood cholestasis and bile transporters. Gastroenterol. Hepatol. 28: 388-395 (2005).

• Hirai T, Fukui Y, Motojima K. PPARalpha agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine. Biol. Pharm. Bull. 30: 2185-2190 (2007). *

• Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. Bile salt export pump (BSEP/ABCB11) can transport a non-bile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 314: 876-882 (2005). *

• Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 68: 800-807 (2005). *

• Hirano T, Onda K, Toma T, Miyaoka M, Moriyasu F, Oka K. MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration. J. Clin. Pharmacol. 44: 481-486 (2004). *

• Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J. Biol. Chem. 275: 2905-2910 (2000). *

• Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, Watanabe K, Watanabe S, Uese K, Kanegane H, Origasa H, Ichida F, Roth J, Miyawaki T, Saji T. Infliximab reduce the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr. Res. 65: 696-701 (2009).

• Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I, Ohtsubo K, Sugiyama Y. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm. Res. 21: 742-748 (2004). *

• Hirouchi M, Suzuki H, Sugiyama Y. Treatment of hyperbilirubinemia in Eisai hyperbilirubinemic rat by transfecting human MRP2/ABCC2 gene. Pharm. Res. 22: 661-666 (2005). *

• Hisaeda K, Inokuchi A, Nakamura T, Iwamoto Y, Kohno K, Kuwano M, Uchiumi T. Interleukin-1 represses MRP2 gene expression through inactivation of interferon regulatory factor 3 in HepG2 cells. Hepatology 39: 1574-1582 (2004). *

• Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr. Cancer Drug Targets 6: 295-311 (2006).

• Ho GT, Gaya DR, Satsangi J. Multidrug resistance (MDR1) gene in inflammatory bowel disease: a key player? Inflamm. Bowel Dis. 11: 1013-1019 (2005). *

• Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52: 759-766 (2003). *

• Ho GT, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, Arnott ID, Satsangi J. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128: 288-296 (2005). *

• Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. The ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum. Mol. Genet. 15: 797-805 (2006). *

• Ho MM, Hogge DE, Ling V. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp. Hematol. 36: 433-442 (2008). *

• Hoblinger A, Grunhage F, Sauerbruch T, Lammert F. Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion 80: 36-39 (2009).

• Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm. Res. 21: 1686-1691 (2004). *

• Hoekstra H, Porte RJ, Tian Y, Jochum W, Stieger B, Moritz W, Slooff MJ, Graf R, Clavien PA. Bile salt toxicity aggravates cold ischemic injury of bile ducts after liver transplantation in Mdr2+/- mice. Hepatology 43: 1022-1031 (2006). *

• Hoffmann U, Kroemer HK. The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab. Rev. 36: 669-701 (2004). *

• Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Hepatobiliary disposition of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J. Pharmacol. Exp. Ther. 311: 1203-1210 (2004). *

• Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97: 3473-3478 (2000). *

• Hofmann AF. Biliary secretion and excretion in health and disease: current concepts. Ann. Hepatol. 6: 15-27 (2007). *

• Holland IB, Blight MA. ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J. Mol. Biol. 293: 381-399 (1999). *

• Holland KA, Holland IB. Adventures with ABC-proteins: highly conserved ATP-dependent transporters. Acta Microbiol. Immunol. Hung. 52: 309-322 (2005).

• Holland ML, Allen JD, Arnold JC. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur. J. Pharmacol. 591: 128-131 (2008). *

• Holland ML, Panetta JA, Hoskins JM, Bebawy M, Roufogalis BD, Allen JD, Arnold JC. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem. Pharmacol. 71: 1146-1154 (2006). *

• Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann. Pharmacother. 40: 1939-1945 (2006).

• Homolya L, Varadi A, Sarkadi B. Multidrug resistance-associated proteins: export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 17: 103-114 (2003).

• Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br. J. Pharmacol. 143: 856-864 (2004). *

• Hong L, Wang J, Han Y, Zhao Y, Gao J, Wang J, Han Y, Zhang X, Yan L, Zhou X, Qiao T, Chen Z, Fan D. Reversal of multidrug resistance of vincristine-resistant gastric adenocarcinoma cells through up-regulation of DARPP-32. Cell Biol. Int. 31: 1010-1015 (2007). *

• Hoof T, Demmer A, Hadam MR, Riordan JR, Tummler B. Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1. J. Biol. Chem. 269: 20575-20583 (1994). *

• Hooijberg JH, Jansen G, Assaraf YG, Kathmann I, Pieters R, Laan AC, Veerman AJ, Kaspers GJ, Peters GJ. Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem. Pharmacol. 67: 1541-1548 (2004). *

• Hooijberg JH, Peters GJ, Assaraf YG, Kathmann I, Priest DG, Bunni MA, Veerman AJ, Scheffer GL, Kaspers GJ, Jansen G. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem. Pharmacol. 65: 765-771 (2003). *

• Hooiveld GJ, Heegsma J, van Montfoort JE, Jansen PL, Meijer DK, Muller M. Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins. Br. J. Pharmacol. 135: 1685-1694 (2002). *

• Hooiveld GJ, Vos TA, Scheffer GL, Van Goor H, Koning H, Bloks V, Loot AE, Meijer DK, Jansen PL, Kuipers F, Muller M. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 117: 678-687 (1999). *

• Horikawa M, Kato Y, Tyson CA, Sugiyama Y. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab. Pharmacokinet. 18: 16-22 (2004). *

• Hosohata K, Masuda S, Yonezawa A, Katsura T, Oike F, Ogura Y, Takada Y, Egawa H, Uemoto S, Inui KI. MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm. Res. 26: 1590-1595 (2009). *

• Hosoya K, Tomi M, Takayama M, Komokata Y, Nakai D, Tokui T, Nishimura K, Ueda M, Obinata M, Hori S, Ohtsuki S, Amidon GL, Terasaki T. Transporter mRNA expression in a conditionally immortalized rat small intestine epithelial cell line (TR-SIE). Drug Metab. Pharmacokinet. 19: 264-269 (2004). *

• Hsieh CH, Liang KH, Hung YJ, Huang LC, Pei D, Liao YT, Kuo SW, Bey MS, Chen JL, Chen EY. Analysis of epistasis for diabetic nephropathy among type 2 diabetic patients. Hum. Mol. Genet. 15: 2701-2708 (2006). *

• Hu X, Plomp A, Wijnholds J, Ten Brink J, van Soest S, van den Born LI, Leys A, Peek R, de Jong PT, Bergen AA. ABCC6/MRP6 mutations: further insight into the molecular pathology of pseudoxanthoma elasticum. Eur. J. Hum. Genet. 11: 215-224 (2003). *

• Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA. Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Surv. Ophthalmol. 48: 424-438 (2003). *

• Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J, Redinbo MR, Teotico DG, Locker J, Kalpana GV, Mani S. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26: 258-268 (2007). *

• Huang L, Smit JW, Meijer DK, Vore M. Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology 32: 66-72 (2000). *

• Huang L, Vore M. Multidrug resistance P-glycoprotein 2 is essential for the biliary excretion of indocyanine green. Drug Metab. Dispos. 29: 634-637 (2001). *

• Huang L, Wang Y, Grimm SW. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistant protein. Drug Metab. Dispos. 34: 738-742 (2006). *

• Huang L, Zhao A, Lew JL, Zhang T, Hrywna Y, Thompson JR, de Pedro N, Royo I, Blevins RA, Pelaez F, Wright SD, Cui J. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 278: 51085-51090 (2003). *

• Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 26: 183-201 (2007). *

• Huebner C, Browning BL, Petermann I, Yeo Han D, Philpott M, Barclay M, Gearry R, McCulloch A, Demmers P, Ferguson LR. Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflamm. Bowel Dis. 15: 1784-1793 (2009). *

• Huebner C, Petermann I, Browning BL, Shelling AN, Ferguson LR. Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol. Biomarkers Prev. 16: 1185-1192 (2007). *

• Huebner C, Petermann I, Lam WJ, Shelling AN, Ferguson LR. Characterization of single-nucleotide polymorphisms relevant to inflammatory bowel disease in commonly used gastrointestinal cell lines. Inflamm. Bowel Dis. 16: 282-295 (2010).

• Huff LM, Lee JS, Robey RW, Fojo T. Characterization of gene rearrangements leading to activation of MDR- 1. J. Biol. Chem. 281: 36501-36509 (2006). *

• Hugnet C, Bentjen SA, Mealey KL. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from France. J. Vet. Pharmacol. Ther. 27: 227-229 (2004). *

• Huh HJ, Park CJ, Jang S, Seo EJ, Chi HS, Lee JH, Lee KH, Seo JJ, Moon HN, Ghim T. Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J. Korean Med. Sci. 21: 253-258 (2006). *

• Hulzebos CV, Voshol PJ, Wolters H, Kruit JK, Ottenhof R, Groen AK, Stellaard F, Verkade HJ, Kuipers F. Bile duct proliferation associated with bile salt-induced hypercholeresis in Mdr2 P-glycoprotein-deficient mice. Liver Int. 25: 604-612 (2005). *

• Hur EH, Lee JH, Lee MJ, Choi SJ, Lee JH, Kang MJ, Seol M, Jang YE, Lee HJ, Kang IS, Shim SK, Ryu SG, Kang YA, Lee YS, Park CJ, Chi HS, Lee KH. C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia. Leuk. Res. 32: 1601-1604 (2008).

• Hutchins H. Omega-3 fatty acids: recommendations for therapeutics and prevention. MedGenMed. 7: 18 (2005). *

• Huwyler J, Wright MB, Gutmann H, Drewe J. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr. Drug Metab. 7: 119-126 (2006).

• Hyogo H, Tazuma S, Nishioka T, Ochi H, Yamaguchi A, Numata Y, Kanno K, Sakomoto M, Asamoto Y, Tsuboi K, Nakai K, Yasumiba S, Sunami Y, Kajiyama G. Phospholipid alterations in hepatocyte membranes and transporter protein changes in cholestatic rat model. Dig. Dis. Sci. 46: 2089-2097 (2001). *

• Ieiri I, Suzuki H, Kimura M, Takane H, Nishizato Y, Irie S, Urae A, Kawabata K, Higuchi S, Otsubo K, Sugiyama Y. Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. Hepatol. Res. 30: 91-95 (2004).

• Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet. 43: 553-576 (2004).

• Ifergan I, Assaraf YG. Chapter 4. Molecular mechanisms of adaptation to folate deficiency. Vitam. Horm. 79: 99-143 (2008).

• Ifergan I, Jansen G, Assaraf YG. The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation: RFC as a double-edged sword in folate homeostasis. J. Biol. Chem. 283: 20687-20695 (2008). *

• Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression: a role for BCRP in cellular folate homeostasis. J. Biol. Chem. 279: 25527-25534 (2004). *

• Igolnikov AC, Green RM. Mice heterozygous for the Mdr2 gene demonstrate decreased PEMT activity and diminished steatohepatitis on the MCD diet. J. Hepatol. 44: 586-592 (2006). *

• Iizasa H, Genda N, Kitano T, Tomita M, Nishihara K, Hayashi M, Nakamura K, Kobayashi S, Nakashima E. Altered expression and function of P-glycoprotein in dextran sodium sulfate-induced colitis in mice. J. Pharm. Sci. 92: 569-576 (2003). *

• Ikebuchi Y, Takada T, Ito K, Yoshikado T, Anzai N, Kanai Y, Suzuki H. Receptor for activated C-kinase 1 regulates the cellular localization and function of ABCB4. Hepatol. Res. 39: 1091-1107 (2009). *

• Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A. Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J. Biol. Chem. 277: 16860-16867 (2002). *

• Inokuchi A, Hinoshita E, Iwamoto Y, Kohno K, Kuwano M, Uchiumi T. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. J. Biol. Chem. 276: 46822-46829 (2001). *

• Inoue S, Nakase H, Matsuura M, Mikami S, Ueno S, Uza N, Chiba T. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin. Exp. Immunol. 156: 172-182 (2009). *

• Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab. Pharmacokinet. 19: 1-14 (2004). *

• Ishikawa T, Onishi Y, Hirano H, Oosumi K, Nagakura M, Tarui S. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol. Pharm. Bull. 27: 939-948 (2004). *

• Israeli D, Ziaei S, Gonin P, Garcia L. A proposal for the physiological significance of mdr1 and Bcrp1/Abcg2 gene expression in normal tissue regeneration and after cancer therapy. J. Theor. Biol. 232: 41-45 (2005). *

• Itagaki S, Chiba M, Kobayashi M, Hirano T, Iseki K. Contribution of multidrug resistance-associated protein 2 to secretory intestinal transport of organic anions. Biol. Pharm. Bull. 31: 146-148 (2008). *

• Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Hirano T, Iseki K. Comparison of the disposition behavior of organic anions in an animal model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal Long-Evans Agouti rats. Drug Metab. Pharmacokinet. 19: 150-154 (2004). *

• Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Iseki K. Mechanism of active secretion of phenolsulfonphthalein in the liver via Mrp2 (abcc2), an organic anion transporter. Drug Metab. Pharmacokinet. 18: 238-244 (2004). *

• Itani T, Kobayashi Y, Kuroda M, Ma N, Mifuji R, Urawa N, Tanaka Y, Kaito M, Adachi Y. Transfecting the multidrug resistance protein 2 gene improves transcellular organic anion transport. Int. J. Mol. Med. 16: 821-825 (2005). *

• Ito K, Hoekstra D, van Ijzendoorn SC. Cholesterol but not association with detergent resistant membranes is necessary for the transport function of MRP2/ABCC2. FEBS Lett. 582: 4153-4157 (2008). *

• Ito K, Koresawa T, Nakano K, Horie T. Mrp2 is involved in benzylpenicillin-induced choleresis. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G42-G49 (2004). *

• Ito K, Olsen SL, Qiu W, Deeley RG, Cole SP. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J. Biol. Chem. 276: 15616-15624 (2001). *

• Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 22: 1559-1577 (2005). *

• Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11: 175-184 (2001).

• Iwaki K, Sakaeda T, Kakumoto M, Nakamura T, Komoto C, Okamura N, Nishiguchi K, Shiraki T, Horinouchi M, Okumura K. Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein. J. Pharm. Pharmacol. 58: 1617-1622 (2006).

• Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, Maeda T, Onishi S. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol. Res. 16: 12-18 (1999).

• Izar MC. Hypolipidemic treatment under special conditions: posttransplant and/or immunosupressive therapy. Arq. Bras. Cardiol. 85 Suppl. 4: 50-57 (2005).

• Jacquemin E. Progressive familial intrahepatic cholestasis and hereditary anomalies of hepatocellular metabolism of bile acids. Arch. Pediatr. 5: 45-53 (1998).

• Jacquemin E. Progressive familial intrahepatic cholestasis. Genetic basis and treatment. Clin. Liver Dis. 4: 753-763 (2000).

• Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin. Liver Dis. 21: 551-562 (2001). *

• Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 353: 210-211 (1999).

• Jacquemin E, De Vree JM, Cresteil D, Sokal EM, Sturm E, Dumont M, Scheffer GL, Paul M, Burdelski M, Bosma PJ, Bernard O, Hadchouel M, Oude Elferink RP. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 120: 1448-1458 (2001). *

• Jahnel J, Fickert P, Langner C, Hogenauer C, Silbert D, Gumhold J, Fuchsbichler A, Trauner M. Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. Liver Int. 29: 1316-1325 (2009). *

• Jain S, Laphookhieo S, Shi Z, Fu LW, Akiyama SI, Chen ZS, Youssef DT, Soest RW, Sayed KA. Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids. J. Nat. Prod. 70: 928-931 (2007). *

• Jamroziak K, Balcerczak E, Cebula B, Kowalczyk M, Panczyk M, Janus A, Smolewski P, Mirowski M, Robak T. Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol. Rep. 57: 882-888 (2005). *

• Jamroziak K, Balcerczak E, Smolewski P, Robey RW, Cebula B, Panczyk M, Kowalczyk M, Szmigielska-Kaplon A, Mirowski M, Bates SE, Robak T. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol. Rep. 58: 720-728 (2006). *

• Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, Robak T. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. 72: 314-321 (2004). *

• Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 9: 91-105 (2004).

• Jansen G, Scheper RJ, Dijkmans BA. Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. Scand. J. Rheumatol. 32: 325-336 (2003).

• Jansen PL. The pathophysiology of cholestasis with special reference to primary biliary cirrhosis. Baillieres Best Pract. Res. Clin. Gastroenterol. 14: 571-583 (2000).

• Jansen PL. Genetics of cholestasis. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 37-40 (2006). *

• Jansen PL, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJ, Koning JH, De Jager-Krikken A, Kuipers F, Stellaard F, Bijleveld CM, Gouw A, Van Goor H, Thompson RJ, Muller M. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117: 1370-1379 (1999). *

• Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 23: 315-322 (2003). *

• Jedlitschky G, Tirschmann K, Lubenow LE, Nieuwenhuis HK, Akkerman JW, Greinacher A, Kroemer HK. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 104: 3603-3610 (2004). *

• Jekerle V, Klinkhammer W, Reilly RM, Piquette-Miller M, Wiese M. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. Cancer Chemother. Pharmacol. 59: 61-69 (2007). *

• Jensen LE, Wall AM, Cook M, Hoess K, Thorn CF, Whitehead AS, Mitchell LE. A common ABCC2 promoter polymorphism is not a determinant of the risk of spina bifida. Birth Defects Res. Part A. Clin. Mol. Teratol. 70: 396-399 (2004). *

• Ji B, Ito K, Sekine S, Tajima A, Horie T. Ethacrynic-acid-induced glutathione depletion and oxidative stress in normal and Mrp2-deficient rat liver. Free Radic. Biol. Med. 37: 1718-1729 (2004).

• Jiang H, Chen K, He J, Pan F, Li J, Chen J, Chen W, Liang H. Association of pregnane X receptor with multidrug resistance-related protein 3 and its role in human colon cancer chemoresistance. J. Gastrointest. Surg. 13: 1831-1838 (2009). *

• Jiang MD, Peng ZP, Li SL, Wang ZG, Ran HT, Huo SH, Yin XL. Reversion of multidrug resistance of hepatocellular carcinoma by antisense oligonucleotides and ultrasonic microbubble intensifier transfection combined with ultrasound irradiation. Zhonghua Gan Zang Bing Za Zhi 14: 341-345 (2006).

• Jiang ZP, Xu P, Liu RR, Li HD, Wang GP, Zhao XL, Chen FP. Correlation between MDR1 methylation status in the promoter region and MDR1 genetic polymorphism in 194 healthy Chinese Han subjects. Pharmacogenomics 9: 1801-1808 (2008).

• Jiao Z, Liang HQ, Ding JJ, Li ZD, Shi XJ, Zhong MK. Effect of MDR1 polymorphic expression on oral disposition of cyclosporine A. Yao Xue Xue Bao 39: 971-974 (2004).

• Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Dispos. 34: 1756-1763 (2006). *

• Jin J, Sun H, Wei H, Liu G. The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis. Invest. New Drugs 25: 95-105 (2007). *

• Johansen IS. Rapid diagnoses of mycobacterial diseases, and their implication on clinical management. Dan. Med. Bull. 53: 28-45 (2006).

• Johnson AD, Zhang Y, Papp AC, Pinsonneault JK, Lim JE, Saffen D, Dai Z, Wang D, Sadee W. Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet. Genomics 18: 781-791 (2008).

• Johnson BM, Zhang P, Schuetz JD, Brouwer KL. Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab. Dispos. 34: 556-562 (2006). *

• Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC. The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res. 61: 1469-1476 (2001). *

• Johnson DR, Habeebu SS, Klaassen CD. Increase in bile flow and biliary excretion of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is mediated by multidrug resistance protein 2. Toxicol. Sci. 66: 16-26 (2002). *

• Jorgensen L, Van Beek J, Lund S, Schousboe A, Badolo L. Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes. Eur. J. Pharm. Sci. 30: 181-189 (2007). *

• Jou YS, Lee CS, Chang YH, Hsiao CF, Chen CF, Chao CC, Wu LS, Yeh SH, Chen DS, Chen PJ. Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma. Cancer Res. 64: 3030-3036 (2004). *

• Juchems MS, Fleiter TR, Pauls S, Schmidt SA, Brambs HJ, Aschoff AJ. CT colonography: comparison of a colon dissection display versus 3D endoluminal view for the detection of polyps. Eur. Radiol. 16: 68-72 (2006).

• Juyal G, Midha V, Amre D, Sood A, Seidman E, Thelma BK. Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. Pharmacogenet. Genomics 19: 77-85 (2009).

• Kagawa T, Watanabe N, Sato M, Nakano A, Nishizaki Y, Hosoi K, Takashimizu S, Uchiyama J, Kimura M, Matsuzaki S. Differential expression of multidrug resistance (mdr) and canalicular multispecific organic anion transporter (cMOAT) genes following extrahepatic biliary obstruction in rats. Biochem. Mol. Biol. Int. 44: 443-452 (1998).

• Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am. J. Cardiol. 93: 1046-1050 (2004). *

• Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab. Dispos. 32: 20-27 (2004). *

• Kameyama N, Arisawa S, Ueyama J, Kagota S, Shinozuka K, Hattori A, Tatsumi Y, Hayashi H, Takagi K, Wakusawa S. Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes. Biochim. Biophys. Acta 1782: 355-360 (2008). *

• Kamisako T, Gabazza EC, Ishihara T, Adachi Y. Molecular aspects of organic compound transport across the plasma membrane of hepatocytes. J. Gastroenterol. Hepatol. 14: 405-412 (1999). *

• Kamisako T, Kobayashi Y, Takeuchi K, Ishihara T, Higuchi K, Tanaka Y, Gabazza EC, Adachi Y. Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J. Gastroenterol. 35: 659-664 (2000). *

• Kamisako T, Ogawa H. Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat. J. Gastroenterol. Hepatol. 19: 879-883 (2004). *

• Kamisako T, Ogawa H. Alteration of the expression of adenosine triphosphate-binding cassette transporters associated with bile acid and cholesterol transport in the rat liver and intestine during cholestasis. J. Gastroenterol. Hepatol. 20: 1429-1434 (2005). *

• Kamisako T, Ogawa H, Yamamoto K. Effect of cholesterol, cholic acid and cholestyramine administration on the intestinal mRNA expressions related to cholesterol and bile acid metabolism in the rat. J. Gastroenterol. Hepatol. 22: 1832-1837 (2007). *

• Kang H, Fisher MH, Xu D, Miyamoto YJ, Marchand A, Van Aerschot A, Herdewijn P, Juliano RL. Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides. Nucleic Acids Res. 32: 4411-4419 (2004). *

• Kang HA, Cho HY, Lee YB. The effect of MDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects. Arch. Pharm. Res. 30: 96-101 (2007).

• Kang HJ, Song IS, Lee SS, Yoo MA, Shin JG. Effects of dietary salt on the expression of drug transporters, cytochrome P4503a, and nuclear receptors in rats. Xenobiotica 38: 147-155 (2008). *

• Kang YJ. Metallothionein redox cycle and function. Exp. Biol. Med. (Maywood) 231: 1459-1467 (2006). *

• Kankesan J, Vanama R, Yusuf A, Thiessen JJ, Ling V, Rao PM, Rajalakshmi S, Sarma DS. Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats. Carcinogenesis 25: 425-230 (2004). *

• Kanno K, Tazuma S, Niida S, Chayama K. Unique reciprocal changes of hepatocellular membrane transporter expression and fluidity in rats with selective biliary obstruction. Hepatol. Res. 26: 157-163 (2003).

• Kano M, Shoda J, Sumazaki R, Oda K, Nimura Y, Tanaka N. Mutations identified in the human multidrug resistance P-glycoprotein 3 (ABCB4) gene in patients with primary hepatolithiasis. Hepatol. Res. 29: 160-166 (2004).

• Kaplowitz N. Hepatology highlights. Hepatology 39: 271-272 (2004). *

• Karlsen TH, Boberg KM, Schrumpf E. Role of polymorphisms in genes involved in bile acid detoxification pathways in primary sclerosing cholangitis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 87 (2006). *

• Karlsen TH, Hampe J, Wiencke K, Schrumpf E, Thorsby E, Lie BA, Broome U, Schreiber S, Boberg KM. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am. J. Gastroenterol. 102: 115-121 (2007). *

• Kars MD, Iseri OD, Gunduz U, Ural AU, Arpaci F, Molnar J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res. 26: 4559-4568 (2006).

• Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277: 2908-2915 (2002). *

• Kastelic M, Koprivsek J, Plesnicar BK, Serretti A, Mandelli L, Locatelli I, Grabnar I, Dolzan V. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry Jan 7 [Epub ahead of print] (2010).

• Kaszubiak A, Kupstat A, Muller U, Hausmann R, Holm PS, Lage H. Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1. Biochem. Biophys. Res. Commun. 357: 295-301 (2007). *

• Kato R, Nishide M, Kozu C, Iwamoto A, Urashima K, Suzuki K, Ijiri Y, Hayashi T, Tanaka K. Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur. J. Clin. Pharmacol. Oct 13 [Epub ahead of print] (2009).

• Kato S, Ito K, Kato Y, Wakayama T, Kubo Y, Iseki S, Tsuji A. Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate. Pharm. Res. 26: 1467-1476 (2009). *

• Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab. Dispos. 36: 1088-1096 (2008). *

• Katona E, Aslanidis C, Remenyik E, Csikos M, Karpati S, Paragh G, Schmitz G. Identification of a novel deletion in the ABCC6 gene leading to pseudoxanthoma elasticum. J. Dermatol. Sci. 40: 115-121 (2005).

• Katzenellenbogen M, Pappo O, Barash H, Klopstock N, Mizrahi L, Olam D, Jacob-Hirsch J, Amariglio N, Rechavi G, Mitchell LA, Kohen R, Domany E, Galun E, Goldenberg D. Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Res. 66: 4001-4010 (2006). *

• Kauffmann HM, Keppler D, Gant TW, Schrenk D. Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch. Toxicol. 72: 763-768 (1998). *

• Kauffmann HM, Pfannschmidt S, Zoller H, Benz A, Vorderstemann B, Webster JI, Schrenk D. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology 171: 137-146 (2002). *

• Kawabata Y, Kamada E, Furuta S, Takei M, Kurimoto T, Okudaira K, Nishigaki R. ATP-dependent transport of a novel thromboxane A2 receptor antagonist, [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) and its xenobiotic taurine conjugate (Z-335-Tau) by rat bile canalicular membrane vesicles. Pharm. Res. 21: 467-475 (2004). *

• Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, Sasatomi K, Kimura R, Ueno T, Sawada N, Mori M, Sata M. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology 31: 1285-1295 (2000). *

• Kawase A, Tsunokuni Y, Iwaki M. Effects of alterations in CAR on bilirubin detoxification in mouse collagen-induced arthritis. Drug Metab. Dispos. 35: 256-261 (2007). *

• Kawase A, Yoshida I, Tsunokuni Y, Iwaki M. Decreased PXR and CAR inhibit transporter and CYP mRNA levels in the liver and intestine of mice with collagen-induced arthritis. Xenobiotica 37: 366-374 (2007). *

• Kedmi M, Maayan S, Cohen SB, Hauzi M, Rund D. MDR1 and CYP3A4 polymorphisms are associated with HIV seropositivity in Israeli patients but do not influence the course of HIV disease. AIDS Patient Care STDS 21: 653-658 (2007).

• Keitel V, Burdelski M, Warskulat U, Kuhlkamp T, Keppler D, Haussinger D, Kubitz R. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 41: 1160-1172 (2005). *

• Keitel V, Vogt C, Haussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 131: 624-629 (2006). *

• Kelleher D, Farrell R, McManus R. Pharmacogenetics of inflammatory bowel disease. Novartis Found. Symp. 263: 41-53 (2004).

• Keppler D. Uptake and efflux transporters for conjugates in human hepatocytes. Methods Enzymol. 400: 531-542 (2005).

• Keppler D, Konig J. Hepatic secretion of conjugated drugs and endogenous substances. Semin. Liver Dis. 20: 265-272 (2000).

• Keppler D, Konig J. Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J. 11: 509-516 (1997). *

• Keppler D, Konig J, Buchler M. The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv. Enzyme Regul. 37: 321-333 (1997). *

• Keppler D, Leier I, Jedlitschky G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol. Chem. 378: 787-791 (1997).

• Keppler D, Leier I, Jedlitschky G, Mayer R, Buchler M. The function of the multidrug resistance proteins (MRP and cMRP) in drug conjugate transport and hepatobiliary excretion. Adv. Enzyme Regul. 36: 17-29 (1996). *

• Keppler D, Rius M. The concept of basolateral efflux pumps of the hepatocyte. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 30-31 (2006). *

• Keppler D, Rius M, Nies AT. Bile salt efflux mediated by multidrug resistance protein MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 38. June 18-19 (2004). *

• Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 234: 4-33 (2006). *

• Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2: 51-64 (2001).

• Kern A, Szentpetery Z, Liliom K, Bakos E, Sarkadi B, Varadi A. Nucleotides and transported substrates modulate different steps of the ATPase catalytic cycle of MRP1 multidrug transporter. Biochem. J. 380: 549-560 (2004). *

• Kikuchi S, Hata M, Fukumoto K, Yamane Y, Matsui T, Tamura A, Yonemura S, Yamagishi H, Keppler D, Tsukita S, Tsukita S. Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes. Nat. Genet. 31: 320-325 (2002). *

• Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR, Lee KB. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int. J. Cancer 118: 2195-2201 (2005). *

• Kim DW, Kim M, Lee SK, Kang R, Lee SY. Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 15: 344-347 (2006).

• Kim HJ, Chung DH, Kim MJ, Jang JH, Kim YW, Han SK, Shim YS, Yim JJ. Decreased phosphorylation of STAT-1, STAT-4 and cytokine release in MDR-TB patients with primary resistance. Int. J. Tuberc. Lung Dis. 12: 1071-1076 (2008).

• Kim HJ, Hwang SY, Kim JH, Park HJ, Lee SG, Lee SW, Joo JC, Kim YK. Association between genetic polymorphism of multidrug resistance 1 gene and sasang constitutions. Evid. Based Complement. Alternat. Med. 6 Suppl. 1: 73-80 (2009).

• Kim JC, Kim SY, Roh SA, Cho DH, Kim DD, Kim JH, Kim YS. Gene expression profiling: canonical molecular changes and clinicopathological features in sporadic colorectal cancers. World J. Gastroenterol. 14: 6662-6672 (2008). *

• Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Invest. 33 Suppl. 2: 1-5 (2003).

• Kim SG, Jeon CH, Suh HS, Choe JY, Shin IH. P-glycoprotein expression in extracellular matrix formation of chondrogenic differentiation of human adult stem cells. Cell Biol. Int. 31: 1042-1048 (2007). *

• Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm. Res. 21: 1284-1293 (2004). *

• Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528 (2007). *

• Kimura Y, Morita SY, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 98: 1303-1310 (2007). *

• Kimura Y, Selmi C, Leung PS, Mao TK, Schauer J, Watnik M, Kuriyama S, Nishioka M, Ansari AA, Coppel RL, Invernizzi P, Podda M, Gershwin ME. Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. Hepatology 41: 55-63 (2005). *

• Kinuya S, Bai J, Shiba K, Yokoyama K, Mori H, Fukuoka M, Watanabe N, Shuke N, Michigishi T, Tonami N. 99mTc-sestamibi to monitor treatment with antisense oligodeoxynucleotide complementary to MRP mRNA in human breast cancer cells. Ann. Nucl. Med. 20: 29-34 (2006).

• Kipp H, Arias IM. Intracellular trafficking and regulation of canalicular ATP-binding cassette transporters. Semin. Liver Dis. 20: 339-351 (2000).

• Kipp H, Arias IM. Newly synthesized canalicular ABC transporters are directly targeted from the Golgi to the hepatocyte apical domain in rat liver. J. Biol. Chem. 275: 15917-15925 (2000). *

• Kitada H, Miyata M, Nakamura T, Tozawa A, Honma W, Shimada M, Nagata K, Sinal CJ, Guo GL, Gonzalez FJ, Yamazoe Y. Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. J. Biol. Chem. 278: 17838-17844 (2003). *

• Kitagawa S. Inhibitory effects of polyphenols on P-glycoprotein-mediated transport. Biol. Pharm. Bull. 29: 1-6 (2006). *

• Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos. 36: 2014-2023 (2008). *

• Kitamura Y, Kusuhara H, Sugiyama Y. Basolateral efflux mediated by multidrug resistance-associated protein 3 (Mrp3/Abcc3) facilitates intestinal absorption of folates in mouse. Pharm. Res. Feb 11 [Epub ahead of print] (2010). *

• Kitanaka S, Sato U, Igarashi T. Regulation of human insulin, IGF-I, and multidrug resistance protein 2 promoter activity by hepatocyte nuclear factor (HNF)-1beta and HNF-1alpha and the abnormality of HNF-1beta mutants. J. Endocrinol. 192: 141-147 (2007). *

• Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24: 239-247 (2007). *

• Kivisto KT, Zukunft J, Hofmann U, Niemi M, Rekersbrink S, Schneider S, Luippold G, Schwab M, Eichelbaum M, Fromm MF. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn. Schmiedebergs. Arch. Pharmacol. 370: 124-130 (2004). *

• Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab. 6: 309-328 (2005).

• Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim. Biophys. Acta 1461: 237-262 (1999). *

• Klein M, Geisler M, Suh SJ, Kolukisaoglu HU, Azevedo L, Plaza S, Curtis MD, Richter A, Weder B, Schulz B, Martinoia E. Disruption of AtMRP4, a guard cell plasma membrane ABCC-type ABC transporter, leads to deregulation of stomatal opening and increased drought susceptibility. Plant J. 39: 219-236 (2004). *

• Klingenberg M. Transport viewed as a catalytic process. Biochimie 89: 1042-1048 (2007).

• Kneuer C, Honscha W, Gabel G, Honscha KU. Adaptive response to increased bile acids: induction of MDR1 gene expression and P-glycoprotein activity in renal epithelial cells. Pflugers Arch. 454: 587-594 (2007). *

• Kobayashi K, Ito K, Takada T, Sugiyama Y, Suzuki H. Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3. Pharmacogenet. Genomics 18: 823-833 (2008).

• Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by Mrp2 in rats. J. Pharmacol. Exp. Ther. 309: 1029-1035 (2004). *

• Kocher O, Comella N, Gilchrist A, Pal R, Tognazzi K, Brown LF, Knoll JH. PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein. Lab. Invest. 79: 1161-1170 (1999).

• Kock K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA, Kroemer HK. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin. Pharmacokinet. 46: 449-470 (2007).

• Koehn J, Fountoulakis M, Krapfenbauer K. Multiple drug resistance associated with function of ABC-transporters in diabetes mellitus: molecular mechanism and clinical relevance. Infect. Disord. Drug Targets 8: 109-118 (2008).

• Kojima C, Qu W, Waalkes MP, Himeno S, Sakurai T. Chronic exposure to methylated arsenicals stimulates arsenic excretion pathways and induces arsenic tolerance in rat liver cells. Toxicol. Sci. 91: 70-81 (2006). *

• Kojima H, Nies AT, Konig J, Hagmann W, Spring H, Uemura M, Fukui H, Keppler D. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J. Hepatol. 39: 693-702 (2003). *

• Kojima H, Sakurai S, Uemura M, Kitamura K, Kanno H, Nakai Y, Fukui H. Disturbed colocalization of multidrug resistance protein 2 and radixin in human cholestatic liver diseases. J. Gastroenterol. Hepatol. 23: e120-e128 (2008). *

• Kojima H, Sakurai S, Yoshiji H, Uemura M, Yoshikawa M, Fukui H. The role of radixin in altered localization of canalicular conjugate export pump Mrp2 in cholestatic rat liver. Hepatol. Res. 38: 202-210 (2008). *

• Kok T, Bloks VW, Wolters H, Havinga R, Jansen PL, Staels B, Kuipers F. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem. J. 369: 539-547 (2003). *

• Kok T, Wolters H, Bloks VW, Havinga R, Jansen PL, Staels B, Kuipers F. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology 124: 160-171 (2003). *

• Komar AA. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 8: 1075-1080 (2007).

• Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, Yano H, Suzuki T, Matsuda M, Fujii H, Desmet VJ, Kojiro M, Roskams T. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 47: 1544-1556 (2008). *

• Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129: 894-901 (2005). *

• Kong FM, Sui CY, Li YJ, Guo KJ, Guo RX. Hepatobiliary membrane transporters involving in the formation of cholesterol calculus. Hepatobiliary Pancreat. Dis. Int. 5: 286-289 (2006). *

• Konig J, Hartel M, Nies AT, Martignoni ME, Guo J, Buchler MW, Friess H, Keppler D. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer 115: 359-367 (2005). *

• Konig J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29: 1156-1163 (1999). *

• Kooij G, Backer R, Koning JJ, Reijerkerk A, van Horssen J, van der Pol SM, Drexhage J, Schinkel A, Dijkstra CD, den Haan JM, Geijtenbeek TB, de Vries HE. P-Glycoprotein acts as an immunomodulator during neuroinflammation. PLoS One 4: e8212 (2009). *

• Koopen NR, Wolters H, Havinga R, Vonk RJ, Jansen PL, Muller M, Kuipers F. Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol-induced cholestasis in the rat. Hepatology 27: 537-545 (1998). *

• Koopen NR, Wolters H, Voshol P, Stieger B, Vonk RJ, Meier PJ, Kuipers F, Hagenbuch B. Decreased Na+-dependent taurocholate uptake and low expression of the sinusoidal Na+-taurocholate cotransporting protein (Ntcp) in livers of mdr2 P-glycoprotein-deficient mice. J. Hepatol. 30: 14-21 (1999). *

• Kosters A, White DD, Sun H, Thevananther S, Karpen SJ. Redundant roles for cJun-N-terminal kinase 1 and 2 in interleukin-1beta-mediated reduction and modification of murine hepatic nuclear retinoid X receptor alpha. J. Hepatol. 51: 898-908 (2009).

• Kotrych K, Domanski L, Gornik W, Drozdzik M. MDR1 gene polymorphism in allogeenic kidney transplant patients with tremor. Pharmacol. Rep. 57: 241-245 (2005). *

• Kotrych K, Sulikowski T, Domanski L, Bialecka M, Drozdzik M. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population. Pharmacol. Rep. 59: 199-205 (2007). *

• Kowalski P, Surowiak P, Lage H. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol. Ther. 11: 508-522 (2005).

• Koyama T, Nakamura T, Komoto C, Sakaeda T, Taniguchi M, Okamura N, Tamura T, Aoyama N, Kamigaki T, Kuroda Y, Kasuga M, Kadoyama K, Okumura K. MDR1 T-129C polymorphism can be predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese. Biol. Pharm. Bull. 29: 1449-1453 (2006). *

• Kris-Etherton PM, Grieger JA, Etherton TD. Dietary reference intakes for DHA and EPA. Prostaglandins Leukot. Essent. Fatty Acids 81: 99-104 (2009). *

• Krishnamurthy P, Schuetz JD. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 46: 381-410 (2006). *

• Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheok M, Nakauchi H, Marzolini C, Kim RB, Poonkuzhali B, Schuetz E, Evans W, Relling M, Schuetz JD. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 68: 4983-4989 (2008). *

• Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG; Pharmacogenetics of Membrane Transporters Investigators. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13: 481-494 (2003).

• Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 453: 675-684 (2007). *

• Kruit JK, Plosch T, Havinga R, Boverhof R, Groot PH, Groen AK, Kuipers F. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 128: 147-156 (2005). *

• Krupoves A, Seidman EG, Mack D, Israel D, Morgan K, Lambrette P, Costea I, Deslandres C, Grimard G, Law L, Levy E, Amre DK. Associations between ABCB1/MDR1 gene polymorphisms and Crohn's disease: a gene-wide study in a pediatric population. Inflamm. Bowel Dis. 15: 900-908 (2009). *

• Kubitz R, D'urso D, Keppler D, Haussinger D. Osmodependent dynamic localization of the multidrug resistance protein 2 in the rat hepatocyte canalicular membrane. Gastroenterology 113: 1438-1442 (1997). *

• Kubitz R, Keitel V, Burdelski M, Haussinger D. Regulation of hepatobiliary transporters in chronic cholestasis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 33-35 (2006). *

• Kubo K, Sekine S, Saito M. Induction of multidrug resistance-associated protein MRP3 in the liver of rats fed with docosahexaenoic acid. Biosci. Biotechnol. Biochem. 70: 1672-1680 (2006). *

• Kubo K, Sekine S, Saito M. Compensatory expression of MRP3 in the livers of MRP2-deficient EHBRs is promoted by DHA intake. Biosci. Biotechnol. Biochem. 73: 2432-2438 (2009). *

• Kudo A, Kashiwagi S, Kajimura M, Yoshimura Y, Uchida K, Arii S, Suematsu M. Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver. Hepatology 39: 1099-1109 (2004). *

• Kullak-Ublick GA. Regulation of bile salt transporter genes by nuclear receptors. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 43. June 18-19 (2004). *

• Kullak-Ublick GA, Baretton GB, Oswald M, Renner EL, Paumgartner G, Beuers U. Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol. Res. 23: 78-82 (2002).

• Kullak-Ublick GA, Becker MB. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab. Rev. 35: 305-317 (2003).

• Kullak-Ublick GA, Beuers U, Paumgartner G. Hepatobiliary transport. J. Hepatol. 32: S3-S18 (2000).

• Kullak-Ublick GA, Meier PJ. Mechanisms of cholestasis. Clin. Liver Dis. 4: 357-385 (2000).

• Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ. Hepatic transport of bile salts. Semin. Liver Dis. 20: 273-292 (2000). *

• Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126: 322-342 (2004). *

• Kumagi T, Alswat K, Hirschfield GM, Heathcote J. New insights into autoimmune liver diseases. Hepatol. Res. 38: 745-761 (2008). *

• Kumkate S, Chunchob S, Janvilisri T. Expression of ATP-binding cassette multidrug transporters in the giant liver fluke Fasciola gigantica and their possible involvement in the transport of bile salts and anthelmintics. Mol. Cell. Biochem. 317: 77-84 (2008). *

• Kunishio K, Okada M, Matsumoto Y, Nagao S, Nishiyama Y. Technetium-99m sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression in pituitary adenoma. J. Med. Invest. 53: 285-291 (2006). *

• Kurose K, Koyano S, Ikeda S, Tohkin M, Hasegawa R, Sawada J. 5' Diversity of human hepatic PXR (NR1I2) transcripts and identification of the major transcription initiation site. Mol. Cell. Biochem. 273: 79-85 (2005). *

• Kurose K, Saeki M, Tohkin M, Hasegawa R. Thyroid hormone receptor mediates human MDR1 gene expression: identification of the response region essential for gene expression. Arch. Biochem. Biophys. 474: 82-90 (2008). *

• Kurzawski M, Bartnicka L, Florczak M, Gornik W, Drozdzik M. Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol. Rep. 59: 107-111 (2007). *

• Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet. Genomics 18: 861-868 (2008).

• Labialle S, Dayan G, Gayet L, Rigal D, Gambrelle J, Baggetto LG. New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein. Nucleic Acids Res. 32: 3864-3876 (2004). *

• Lage H. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr. Drug Targets 7: 813-821 (2006).

• Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int. J. Antimicrob. Agents 22: 188-199 (2003). *

• Lal S, Stempak JM, Law C, Elkadri AA, Steinhart AH, Silverberg MS. Association between the C3435T polymorphism of the MDR1 gene and Crohn's disease. Inflamm. Bowel Dis. 12: 1006-1007 (2006). *

• Lalloo AK, Luo FR, Guo A, Paranjpe P, Lee SH, Vyas V, Rubin E, Sinko PJ. Membrane transport of camptothecin is facilitated by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2). BMC Med. 2: 16 (2004). *

• Lam P, Wang R, Ling V. Bile acid transport in sister of P-glycoprotein (ABCB11) knockout mice. Biochemistry 44: 12598-12605 (2005). *

• Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab. Dispos. 36: 169-181 (2008). *

• Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther. 79: 325-338 (2006). *

• Lamireau T, Bouchard G, Yousef IM, Clouzeau-Girard H, Rosenbaum J, Desmouliere A, Tuchweber B. Dietary lecithin protects against cholestatic liver disease in cholic acid-fed Abcb4- deficient mice. Pediatr. Res. 61: 185-190 (2007). *

• Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey MC. Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology 39: 117-128 (2004). *

• Lampen A, Ebert B, Stumkat L, Jacob J, Seidel A. Induction of gene expression of xenobiotic metabolism enzymes and ABC-transport proteins by PAH and a reconstituted PAH mixture in human Caco-2 cells. Biochim. Biophys. Acta 1681: 38-46 (2004). *

• Lancon A, Hanet N, Jannin B, Delmas D, Heydel JM, Lizard G, Chagnon MC, Artur Y, Latruffe N. Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab. Dispos. 35: 699-703 (2007). *

• Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, Pauli-Magnus C. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics 17: 47-60 (2007).

• Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, Keil A, Mornhinweg E, Stieger B, Kullak-Ublick G, Kerb R. Genetic variability, haplotype structures, and ethnical diversity of hepatic transporters MDR3 (ABCB4) and BSEP (ABCB11). Drug Metab. Dispos. 34: 1582-1599 (2006). *

• Langheim S, Yu L, von Bergmann K, Lutjohann D, Xu F, Hobbs HH, Cohen JC. ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile. J. Lipid Res. 46: 1732-1738 (2005). *

• Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, Schmitz G. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127: 26-40 (2004). *

• Lappalainen M, Halme L, Turunen U, Saavalainen P, Einarsdottir E, Farkkila M, Kontula K, Paavola-Sakki P. Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. Inflamm. Bowel Dis. 14: 1118-1124 (2008). *

• Larsen UL, Olesen HL, Nyvold GC, Eriksen J, Jakobsen P, Ostergaard M, Autrup H, Andersen V. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand. J. Clin. Lab. Invest. 67: 123-134 (2007). *

• Lasagna N, Fantappie O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res. 66: 2673-2682 (2006). *

• Launay-Vacher V, Izzedine H, Karie S, Hulot JS, Baumelou A, Deray G. Renal tubular drug transporters. Nephron. Physiol. 103: p97-p106 (2006).

• Lazaridis KN, LaRusso NF. Bile formation: do not ignore the role of plasma membrane-cytoskeleton linking proteins. Hepatology 37: 218-220 (2003). *

• Lazarowski A, Caltana L, Merelli A, Rubio MD, Ramos AJ, Brusco A. Neuronal MDR-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? J. Neurol. Sci. 258: 84-92 (2007). *

• Le Goff W, Settle M, Greene DJ, Morton RE, Smith JD. Reevaluation of the role of the multidrug resistant P-glycoprotein in cellular cholesterol homeostasis. J. Lipid Res. 47: 51-58 (2006). *

• Le Saux O, Beck K, Sachsinger C, Treiber C, Goring HH, Curry K, Johnson EW, Bercovitch L, Marais AS, Terry SF, Viljoen DL, Boyd CD. Evidence for a founder effect for pseudoxanthoma elasticum in the Afrikaner population of South Africa. Hum. Genet. 111: 331-338 (2002). *

• Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the pro-inflammatory cytokine interleukin-1beta. Drug Metab. Dispos. 36: 217-222 (2008). *

• Le Vee M, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the pro-inflammatory cytokines TNF-alpha or IL-6. Drug Metab. Dispos. 37: 685-693 (2009). *

• Leal-Ugarte E, Gutierrez-Angulo M, Macías-Gomez NM, Peralta-Leal V, Duran-Gonzalez J, De La Luz Ayala-Madrigal M, Partida-Perez M, Barros-Nunez P, Ruiz-Diaz D, Moreno-Ortiz JM, Peregrina-Sandoval J, Meza-Espinoza JP. MDR1 C3435T polymorphism in Mexican children with acute lymphoblastic leukemia and in healthy individuals. Hum. Biol. 80: 449-455 (2009).

• Lecoeur S, Videmann B, Mazallon M. Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein. Toxicol. Lett. 161: 200-209 (2006). *

• Lecureur V, Courtois A, Payen L, Verhnet L, Guillouzo A, Fardel O. Expression and regulation of hepatic drug and bile acid transporters. Toxicology 153: 203-219 (2000). *

• Lee BI, Choi KY, Lee KM, Chung WC, Kim BW, Choi H, Cho SH, Kang HJ, Lee JS, Kim MS, Chae HS, Chun IS. Is C3435T polymorphism of MDR1 related to inflammatory bowel disease or colorectal cancer in Korean? Korean J. Gastroenterol. 47: 22-29 (2006).

• Lee CG, Tang K, Cheung YB, Wong LP, Tan C, Shen H, Zhao Y, Pavanni R, Lee EJ, Wong MC, Chong SS, Tan EK. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J. Med. Genet. 41: e60 (2004). *

• Lee JH, Chen HL, Chen HL, Ni YH, Hsu HY, Chang MH. Neonatal Dubin-Johnson syndrome: long-term follow-up and MRP2 mutations study. Pediatr. Res. 59: 584-589 (2006). *

• Lee S. Gallstones: how do we translate an old story into future therapy? Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 2-3 (2004). *

• Lee SY, Chung Y, Elston RC, Kim Y, Park T. Log-linear model based multifactor dimensionality reduction method to detect gene-gene interactions. Bioinformatics 23: 2589-2595 (2007). *

• Lee YM, Cui Y, Konig J, Risch A, Jager B, Drings P, Bartsch H, Keppler D, Nies AT. Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 14: 213-223 (2004).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).

• Leite DF, Echevarria-Lima J, Calixto JB, Rumjanek VM. Multidrug resistance related protein (ABCC1) and its role on nitrite production by the murine macrophage cell line RAW 264.7. Biochem. Pharmacol. 73: 665-674 (2007). *

• Leite DF, Echevarria-Lima J, Salgado LT, Capella MA, Calixto JB, Rumjanek VM. In vivo and in vitro modulation of MDR molecules in murine thymocytes. Int. Immunopharmacol. 6: 204-215 (2006).

• Lencioni KC, Seamons A, Treuting PM, Maggio-Price L, Brabb T. Murine norovirus: an intercurrent variable in a mouse model of bacteria-induced inflammatory bowel disease. Comp. Med. 58: 522-533 (2008). *

• Lengyel G, Veres Z, Tugyi R, Vereczkey L, Molnár T, Glavinas H, Krajcsi P, Jemnitz K. Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes. Hepatol. Res. 38: 300-309 (2008). *

• Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167: 3-23 (2001). *

• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204: 216-237 (2005). *

• Leslie EM, Haimeur A, Waalkes MP. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J. Biol. Chem. 279: 32700-32708 (2004). *

• Letschert K, Komatsu M, Hummel-Eisenbeiss J, Keppler D. Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2 (MRP2). J. Pharmacol. Exp. Ther. 313: 549-556 (2005). *

• Leung TF, Chan IH, Wong GW, Li CY, Tang NL, Yung E, Lam CW. Association between candidate genes and lung function growth in Chinese asthmatic children. Clin. Exp. Allergy 37: 1480-1486 (2007). *

• Lewis K, Moy TI, Ausubel FM, Casadei G, Bremner JB, Ball AR, Samosorn S. Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial. ACS Chem. Biol. 1: 594-600 (2006). *

• Li C, Krishnamurthy PC, Penmatsa H, Marrs KL, Wang XQ, Zaccolo M, Jalink K, Li M, Nelson DJ, Schuetz JD, Naren AP. Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell 131: 940-951 (2007). *

• Li D, Gui R, Li J, Huang Z, Nie X. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant. Proc. 38: 2850-2852 (2006). *

• Li D, Lu W, Zhu JY, Gao J, Lou YQ, Zhang GL. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J. Clin. Pharm. Ther. 32: 505-515 (2007). *

• Li D, Zhang GL, Lou YQ, Li Q, Wang X, Bu XY. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J. Clin. Pharm. Ther. 32: 89-95 (2007).

• Li G, Chen X, Wang Q, Xu Z, Zhang W, Ye L. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J. Huazhong Univ. Sci. Technolog. Med. Sci. 27: 173-175 (2007).

• Li G, Dong S, Qu J, Sun Z, Huang Z, Ye L, Liang H, Ai X, Zhang W, Chen X. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma. Liver Int. Sep 23 [Epub ahead of print] (2009). *

• Li GX, Pei QL, Gao Y, Liu KM, Nie JS, Han G, Qiu YL, Zhang WP. Protective effects of hepatocellular canalicular conjugate export pump (Mrp2) on sodium arsenite-induced hepatic dysfunction in rats. Exp. Toxicol. Pathol. 58: 447-453 (2007). *

• Li L, Pan Q, Sun M, Lu Q, Hu X. Dibenzocyclooctadiene lignans - a class of novel inhibitors of multidrug resistance-associated protein 1. Life Sci. 80: 741-748 (2007). *

• Li L, Stanton JD, Tolson AH, Luo Y, Wang H. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm. Res. 26: 872-882 (2009). *

• Li L, Xu J, Min T, Huang W. Up-regulation of P-glycoprotein expression by catalase via JNK activation in HepG2 cells. Redox Rep. 11: 173-178 (2006).

• Li LC, Mun YF. Partial characterization of genes encoding the ATP-binding cassette proteins of Cryptosporidium parvum. Trop. Biomed. 22: 115-122 (2005).

• Li N, Bi YA, Duignan DB, Lai Y. Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol. Pharm. 6: 1180-1189 (2009). *

• Li Y, Wang Y, Sun J, Li Y, Yang L. Distribution of the functional MDR1 C3435T polymorphism in the Han population of China. Swiss Med. Wkly. 136: 377-382 (2006). *

• Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 3: 321-331 (2006). *

• Li Z, Agellon LB, Vance DE. Phosphatidylcholine homeostasis and liver failure. J. Biol. Chem. 280: 37798-37802 (2005). *

• Liang X, Gao Y, Lam TK, Li Q, Falk C, Yang XR, Goldstein AM, Goldin LR. Identifying rheumatoid arthritis susceptibility genes using high-dimensional methods. BMC Proc. 3 Suppl. 7: S79 (2009). *

• Liang XJ, Aszalos A. Multidrug transporters as drug targets. Curr. Drug Targets 7: 911-921 (2006).

• Lickteig AJ, Slitt AL, Arkan MC, Karin M, Cherrington NJ. Differential regulation of hepatic transporters in the absence of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and nuclear factor-kappaB in two models of cholestasis. Drug Metab. Dispos. 35: 402-409 (2007). *

• Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell. Biochem. 296: 85-95 (2007). *

• Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J. Chemother. 17: 86-95 (2005).

• Limtrakul P, Siwanon S, Yodkeeree S, Duangrat C. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells. Phytomedicine 14: 381-389 (2007). *

• Lin Y, Yasuda K, Assem M, Cline C, Barber J, Li CW, Kholodovych V, Ai N, Chen JD, Welsh WJ, Ekins S, Schuetz E. The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab. Dispos. 37: 1295-1304 (2009). *

• Linn SC, Giaccone G. MDR1/P-glycoprotein expression in colorectal cancer. Eur. J. Cancer 31A: 1291-1294 (1995).

• Linsdell P, Hanrahan JW. Substrates of multidrug resistance-associated proteins block the cystic fibrosis transmembrane conductance regulator chloride channel. Br. J. Pharmacol. 126: 1471-1477 (1999). *

• Lisak RP, Benjamins JA, Bealmear B, Nedelkoska L, Studzinski D, Retland E, Yao B, Land S. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell cultures. J. Neuroinflammation 6: 4 (2009).

• Liscovitch M, Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 1-7 (2002). *

• Liscovitch M, Lavie Y. Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem. Sci. 25: 530-534 (2000). *

• Liu HT, Sabirov RZ, Okada Y. Oxygen-glucose deprivation induces ATP release via maxi-anion channels in astrocytes. Purinergic Signal. 4: 147-154 (2008).

• Liu HT, Toychiev AH, Takahashi N, Sabirov RZ, Okada Y. Maxi-anion channel as a candidate pathway for osmosensitive ATP release from mouse astrocytes in primary culture. Cell Res. 18: 558-565 (2008). *

• Liu JJ, Glickman JN, Masyuk AI, LaRusso NF. Cholangiocyte bile salt transporters in cholesterol gallstone-susceptible and resistant inbred mouse strains. J. Gastroenterol. Hepatol. 23: 1596-1602 (2008). *

• Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, Pang KS. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J. Pharmacol. Exp. Ther. 318: 395-402 (2006). *

• Liu X, LeCluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, Meier PJ, Brouwer KL. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am. J. Physiol. 277: G12-G21 (1999). *

• Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 112: 1678-1687 (2003). *

• Liu Y, Ji W, Yin Y, Fan L, Zhang J, Yun H, Wang N, Li Q, Wei Z, Ouyang D, Zhou HH. The effects of splicing variant of PXR PAR-2 on CYP3A4 and MDR1 mRNA expressions. Clin. Chim. Acta 403: 142-144 (2009). *

• Liu Y, Liu H, Han B, Zhang JT. Identification of 14-3-3{sigma} as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res. 66: 3248-3255 (2006). *

• Liu Y, Zhang H, Zhou K, Chen L, Xu Z, Zhong Y, Liu H, Li R, Shugart YY, Wei Q, Jin L, Huang F, Lu D, Zhou L. Tagging SNPs in nonhomologous end-joining pathway genes and risk of glioma. Carcinogenesis 28: 1906-1913 (2007). *

• Loeuillet C, Weale M, Deutsch S, Rotger M, Soranzo N, Wyniger J, Lettre G, Dupre Y, Thuillard D, Beckmann JS, Antonarakis SE, Goldstein DB, Telenti A. Promoter polymorphisms and allelic imbalance in ABCB1 expression. Pharmacogenet. Genomics 17: 951-959 (2007).

• Lokhande TN, Viswanathan CL, Joshi A, Juvekar A. Design, synthesis and evaluation of naphthalene-2-carboxamides as reversal agents in MDR cancer. Bioorg. Med. Chem. 14: 6022-6026 (2006). *

• Lombardo L, Pellitteri R, Balazy M, Cardile V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr. Neurovasc. Res. 5: 82-92 (2008).

• Lomri N, Fitz JG, Scharschmidt BF. Hepatocellular transport: role of ATP-binding cassette proteins. Semin. Liver Dis. 16: 201-210 (1996).

• Lopez-Alvarez MR, Moya-Quiles MR, Minguela A, Gil J, Miras M, Campillo JA, Díaz-Alderete MA, Garcia-Alonso AM, Sanchez-Bueno F, Vicario JL, Muro M, Alvarez-Lopez MR. HLA-C matching and liver transplants: donor-recipient genotypes influence early outcome and CD8+KIR2D+ T-cells recuperation. Transplantation 88: S54-S61 (2009).

• Lopez-Sanchez LM, Corrales FJ, Barcos M, Espejo I, Munoz-Castaneda JR, Rodriguez-Ariza A. Inhibition of nitric oxide synthesis during induced cholestasis ameliorates hepatocellular injury by facilitating S-nitrosothiol homeostasis. Lab. Invest. Oct 5 [Epub ahead of print] (2009). *

• Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, Elston RC, Li MD. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am. J. Hum. Genet. 80: 1125-1137 (2007). *

• Lourenco JJ, Maia RC, Scheiner MA, Vasconcelos FC, Moreira MA. Genomic variation at the MDR1 promoter and P-glycoprotein expression and activity in AML patients. Leuk. Res. 32: 976-979 (2008).

• Lucena JF, Herrero JI, Quiroga J, Sangro B, Garcia-Foncillas J, Zabalegui N, Sola J, Herraiz M, Medina JF, Prieto J. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 124: 1037-1042 (2003). *

• Ludwig AH, Kupryjanczyk J. Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy? Clin. Cancer Res. 12: 6204 (2006). *

• Lugering N, Kucharzik T, Stoll R, Domschke W. Current concept of the role of monocytes/macrophages in inflammatory bowel disease - balance of proinflammatory and immunosuppressive mediators. Ital. J. Gastroenterol. Hepatol. 30: 338-344 (1998).

• Lugering N, Kucharzik T, Stoll R, Domschke W. A system of nonspecific defense in chronic inflammatory bowel diseases - pathophysiologic and therapeutic aspects. Z. Gastroenterol. 36: 173-187 (1998).

• Luo G, Garner CE, Xiong H, Hu H, Richards LE, Brouwer KL, Duan J, Decicco CP, Maduskuie T, Shen H, Lee FW, Gan LS. Effect of DPC 333, a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter based drug-drug interaction case study. Drug Metab. Dispos. 35: 835-840 (2007). *

• Luo S, Kansara VS, Zhu X, Mandava NK, Pal D, Mitra AK. Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery. Mol. Pharm. 3: 329-339 (2006). *

• Lv H, He Z, Liu X, Yuan J, Yu Y, Chen Z. Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs. J. Cell. Biochem. 102: 75-81 (2007). *

• Macdonald N, Gledhill A. Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans. Arch. Toxicol. 81: 553-563 (2007). *

• Machida I, Inagaki Y, Suzuki S, Hayashi H, Wakusawa S. Mutation analysis of the multidrug resistance protein 2 (MRP2) gene in a Japanese patient with Dubin-Johnson syndrome. Hepatol. Res. 30: 86-90 (2004).

• Macias RI, Jimenez S, Serrano MA, Monte MJ, Marin JJ. Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sci. 79: 1014-1019 (2006). *

• Macias RI, Serrano MA, Monte MJ, Jimenez S, Hernandez B, Marin JJ. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis. J. Pharmacol. Exp. Ther. 312: 751-758 (2005). *

• Madejczyk MS, Aremu DA, Simmons-Willis TA, Clarkson TW, Ballatori N. Accelerated urinary excretion of methylmercury following administration of its antidote N-acetylcysteine requires Mrp2/Abcc2, the apical multidrug resistance-associated protein. J. Pharmacol. Exp. Ther. 322: 378-384 (2007). *

• Madgula VL, Avula B, L NR, Khan IA, Khan SI. Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability. Planta Med. 73: 330-335 (2007).

• Madoulet C, Perrin L, Tosi PF, Albert P. Anti-tumor immunotherapy against multidrug resistance. Ann. Pharm. Fr. 64: 87-96 (2006).

• Maggini V, Buda G, Martino A, Presciuttini S, Galimberti S, Orciuolo E, Barale R, Petrini M, Rossi AM. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet. Genomics 18: 383-389 (2008).

• Maggio-Price L, Bielefeldt-Ohmann H, Treuting P, Iritani BM, Zeng W, Nicks A, Tsang M, Shows D, Morrissey P, Viney JL. Dual infection with Helicobacter bilis and Helicobacter hepaticus in P-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia. Am. J. Pathol. 166: 1793-1806 (2005). *

• Maggio-Price L, Shows D, Waggie K, Burich A, Zeng W, Escobar S, Morrissey P, Viney JL. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am. J. Pathol. 160: 739-751 (2002). *

• Maggs JR, Chapman RW. Sclerosing cholangitis. Curr. Opin. Gastroenterol. 23: 310-316 (2007).

• Mahadevan D. Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies? Leuk. Res. 30: 1077-1078 (2006).

• Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 104: 1940-1951 (2004). *

• Mahady GB. Medicinal plants for the prevention and treatment of bacterial infections. Curr. Pharm. Des. 11: 2405-2427 (2005).

• Mahagita C, Tanphichai K, Suksamrarn A, Ballatori N, Piyachaturawat P. 4-Hydroxyacetophenone-induced choleresis in rats is mediated by the Mrp2-dependent biliary secretion of its glucuronide conjugate. Pharm. Res. 23: 2603-2610 (2006). *

• Maher J, Aleksunes L, Dieter M, Tanaka Y, Peters J, Manautou J, Klaassen C. Nrf2 and PPARalpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol. Sci. 106: 319-328 (2008). *

• Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. Induction of the Mrp family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos. 33: 956-962 (2005). *

• Maher JM, Cheng X, Tanaka Y, Scheffer GL, Klaassen CD. Hormonal regulation of renal multidrug resistance-associated proteins 3 and 4 (Mrp3 and Mrp4) in mice. Biochem. Pharmacol. 71: 1470-1478 (2006). *

• Maher JM, Cherrington NJ, Slitt AL, Klaassen CD. Tissue distribution and induction of the rat multidrug resistance-associated proteins 5 and 6. Life Sci. 78: 2219-2225 (2006). *

• Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, Klaassen CD. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem. Pharmacol. 72: 512-522 (2006). *

• Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G, Budde K, Roots I. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br. J. Clin. Pharmacol. 58: 548-553 (2004). *

• Maier A, Zimmermann C, Beglinger C, Drewe J, Gutmann H. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br. J. Pharmacol. 150: 361-368 (2007). *

• Maisonnette F, Abita T, Barriere E, Pichon N, Vincensini JF, Descottes B. The MDR3 gene mutation: a rare cause of progressive familial intrahepatic cholestasis (PFIC). Ann. Chir. 130: 581-583 (2005).

• Maitz S, Wimmer R, Rust C, Denk GU, Invernizzi P, Ferdinandusse S, Wanders RJ, Fuchsbichler A, Fickert P, Trauner M, Hofmann AF, Beuers U. Role of side chain amidation for the anticholestatic action of norUDCA in rat liver. Falk Symposium 165: XX International Bile Acid Meeting. Bile Acid Biology and Therapeutic Actions. June 13-14, 2008, Amsterdam, Netherlands, p. 56 (2008). *

• Makowski P, Pikula S. Participation of the multispecific organic anion transporter in hepatobiliary excretion of glutathione S-conjugates, drugs and other xenobiotics. Pol. J. Pharmacol. 49: 387-394 (1997).

• Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, Augustijns P. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 35: 1055-1066 (2005). *

• Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Oude Elferink RP. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42: 1091-1098 (2005). *

• Mann DA, Oakley F. NF-kappaB: a signal for cancer. J. Hepatol. 42: 610-611 (2005).

• Mano Y, Usui T, Kamimura H. Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats. Eur. J. Drug Metab. Pharmacokinet. 31: 117-121 (2006).

• Mano Y, Usui T, Kamimura H. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm. Drug Dispos. 28: 13-18 (2006). *

• Manuguerra M, Matullo G, Veglia F, Autrup H, Dunning AM, Garte S, Gormally E, Malaveille C, Guarrera S, Polidoro S, Saletta F, Peluso M, Airoldi L, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulos D, et al. Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. Carcinogenesis 28: 414-422 (2007). *

• Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 7: E118-E133 (2005).

• Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12: 927-941 (2007). *

• Mariani SM. Genes and autoimmune diseases - a complex inheritance. MedGenMed. 6: 18 (2004). *

• Marin JJ, Macias RI, Briz O, Perez MJ, Serrano MA. Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Ann. Hepatol. 4: 70-76 (2005).

• Markova S, Nakamura T, Sakaeda T, Makimoto H, Uchiyama H, Okamura N, Okumura K. Genotype-dependent down-regulation of gene expression and function of MDR1 in human peripheral blood mononuclear cells under acute inflammation. Drug Metab. Pharmacokinet. 21: 194-200 (2006). *

• Maroo S, Farrell RJ. From SNPs to haplotypes: unraveling the role of MDR1 in IBD. Inflamm. Bowel Dis. 12: 74-76 (2006). *

• Marra F, Cox VC, FitzGerald JM, Moadebi S, Elwood RK. Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant. Int. J. Tuberc. Lung Dis. 8: 905-909 (2004).

• Marschall HU, Wagner M, Bodin K, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Sjovall J, Trauner M. Fxr -/- mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J. Lipid Res. 47: 582-592 (2006). *

• Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129: 476-485 (2005). *

• Marschall HU, Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Diczfalusy U, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Comprehensive study of the effects of rifampicin and ursodeoxycholic acid on genes and proteins involved in regulation, transport and detoxification of biliary compounds in gallstone patients. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 47. June 18-19 (2004). *

• Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem. J. 391: 549-560 (2005). *

• Martinez A, Marquez A, Mendoza JL, Taxonera C, Fernandez-Arquero M, Diaz-Rubio M, de la Concha EG, Urcelay E. Role of the PXR gene locus in inflammatory bowel diseases. Inflamm. Bowel Dis. 13: 1484-1487 (2007). *

• Marumo T, Fukusato T, Takikawa H. Biliary excretion of bile acids and organic anions in rats with dichloroethylene-induced bile canalicular injury. J. Gastroenterol. 39: 981-987 (2004). *

• Maruyama K, Harada S, Yokoyama A, Naruse S, Hirota M, Nishimori I, Otsuki M. Association analysis among polymorphisms of the various genes and chronic alcoholic pancreatitis. J. Gastroenterol. Hepatol. 23 Suppl. 1: S69-S72 (2008). *

• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75: 13-33 (2004). *

• Massart C, Poirier C, Fergelot P, Fardel O, Gibassier J. Effect of sodium butyrate on doxorubicin resistance and expression of multidrug resistance genes in thyroid carcinoma cells. Anticancer Drugs 16: 255-261 (2005).

• Masunaga Y, Noto T, Suzuki K, Takahashi K, Shimizu Y, Morokata T. Expression profiles of cytokines and chemokines in murine MDR1a-/- colitis. Inflamm. Res. 56: 439-446 (2007). *

• Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anti-cancer agents in endometrial cancer cells. Mol. Pharmacol. 72: 1045-1053 (2007). *

• Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T, Hiramatsu Y. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol. Endocrinol. 19: 1170-1180 (2005). *

• Materna V, Lage H. Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient. J. Hum. Genet. 48: 484-486 (2003). *

• Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3: e466 (2006). *

• Matsumoto T, Miyazaki H, Nakahashi Y, Hirohara J, Seki T, Inoue K, Okazaki K. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol. Res. 30: 125-136 (2004).

• Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, Sugiyama Y. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol. Pharmacol. 73: 1474-1483 (2008). *

• Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. Identification of the hepatic efflux transporters of organic anions using double transfected MDCKII cells expressing human OATP1B1/MRP2, OATP1B1/MDR1 and OATP1B1/BCRP. J. Pharmacol. Exp. Ther. 314: 1059-1067 (2005). *

• Matthews C, Catherwood MA, Larkin AM, Clynes M, Morris TC, Alexander HD. MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk. Lymphoma 47: 2308-2313 (2006).

• Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 145: 1237-1245 (1994). *

• Mayur YC, Jagadeesh S, Thimmaiah KN. Targeting calmodulin in reversing multi drug resistance in cancer cells. Mini. Rev. Med. Chem. 6: 1383-1389 (2006).

• Mbongo-Kama E, Harnois F, Mennecier D, Leclercq E, Burnat P, Ceppa F. MDR3 mutations associated with intrahepatic and gallbladder cholesterol cholelithiasis: an update. Ann. Hepatol. 6: 143-149 (2007). *

• McBride BF, Yang T, Roden DM. Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J. 9: 194-201 (2009).

• McCarthy TC, Li X, Sinal CJ. Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein-3 gene expression by bile acids. J. Biol. Chem. 280: 23232-23242 (2005). *

• McClain MT, Rapp EC, Harley JB, James JA. Infectious mononucleosis patients temporarily recognize a unique, cross-reactive epitope of Epstein-Barr virus nuclear antigen-1. J. Med. Virol. 70: 253-257 (2003). *

• McCole DF, Rogler G, Varki N, Barrett KE. Epidermal growth factor partially restores colonic ion transport responses in mouse models of chronic colitis. Gastroenterology 129: 591-608 (2005). *

• McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol. Ther. 113: 429-441 (2007). *

• Mealey KL. Therapeutic implications of the MDR-1 gene. J. Vet. Pharmacol. Ther. 27: 257-264 (2004). *

• Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11: 727-733 (2001).

• Mealey KL, Bentjen SA, Waiting DK. Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of collies from the northwestern United States. Am. J. Vet. Res. 63: 479-481 (2002).

• Mealey KL, Northrup NC, Bentjen SA. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J. Am. Vet. Med. Assoc. 223: 1453-1455, 1434 (2003).

• Mechetner E. Detection of the MDR1 P-glycoprotein expression and function. Methods Mol. Biol. 378: 175-193 (2007).

• Mei H, Ma D, Ashley-Koch A, Martin ER. Extension of multifactor dimensionality reduction for identifying multilocus effects in the GAW14 simulated data. BMC Genet. 6 Suppl. 1: S145 (2005). *

• Mei L, Li X, Yang K, Cui J, Fang B, Guo X, Rotter JI. Evaluating gene x gene and gene x smoking interaction in rheumatoid arthritis using candidate genes in GAW15. BMC Proc. 1 Suppl. 1: S17 (2007). *

• Mei Q, Richards K, Strong-Basalyga K, Fauty SE, Taylor A, Yamazaki M, Prueksaritanont T, Lin JH, Hochman J. Using real-time quantitative TaqMan RT-PCR to evaluate the role of dexamethasone in gene regulation of rat P-glycoproteins mdr1a/1b and cytochrome P450 3A1/2. J. Pharm. Sci. 93: 2488-2496 (2004). *

• Meier PJ, Stieger B. Bile salt transporters. Annu. Rev. Physiol. 64: 635-661 (2002). *

• Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, Stieger B. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44: 62-74 (2006). *

• Meier-Abt PJ. Transport and metabolic functions. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 21-22. October 20 - 21 (2003). *

• Meissner K, Jedlitschky G, Meyer Zu Schwabedissen H, Dazert P, Eckel L, Vogelgesang S, Warzok RW, Bohm M, Lehmann C, Wendt M, Cascorbi I, Kroemer HK. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 14: 381-385 (2004).

• Meissner K, Kessler W, Meyer Zu Schwabedissen HE, Schuster K, Saalfeld K, Grube M, Buck A, Jedlitschky G, Maier S, Traeger T, Mostertz J, Homuth G, Heidecke CD, Lehmann C, Kroemer HK. Sepsis affects cardiac expression of multidrug resistance protein 5 (MRP5, ABCC5), an ABC-type cGMP export pump. Shock 28: 564-569 (2007). *

• Meloni I, Rubegni P, De Aloe G, Bruttini M, Pianigiani E, Cusano R, Seri M, Mondillo S, Federico A, Bardelli AM, Andreassi L, Fimiani M, Renieri A. Pseudoxanthoma elasticum: point mutations in the ABCC6 gene and a large deletion including also ABCC1 and MYH11. Hum. Mutat. 18: 85 (2001). *

• Mendez-Sanchez N, King-Martínez AC, Ramos MH, Pichardo-Bahena R, Uribe M. The Amerindian's genes in the Mexican population are associated with development of gallstone disease. Am. J. Gastroenterol. 99: 2166-2170 (2004). *

• Mendoza JL, Urcelay E, Lana R, Martin MC, Lopez N, Guijarro LG, Mayol JA, Taxonera C, de la Concha EG, Pena AS, Diaz-Rubio M. MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease. Inflamm. Bowel Dis. 13: 585-590 (2007). *

• Meng Y, Ma Q, Yu Y, Farrell J, Farrer LA, Wilcox MA. Multifactor-dimensionality reduction versus family-based association tests in detecting susceptibility loci in discordant sib-pair studies. BMC Genet. 6 Suppl. 1: S146 (2005). *

• Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, Hagey L, Schuetz JD, Boyer JL. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 43: 1013-1021 (2006). *

• Menon R, Velez DR, Simhan H, Ryckman K, Jiang L, Thorsen P, Vogel I, Jacobsson B, Merialdi M, Williams SM, Fortunato SJ. Multilocus interactions at maternal tumor necrosis factor-alpha, tumor necrosis factor receptors, interleukin-6 and interleukin-6 receptor genes predict spontaneous preterm labor in European-American women. Am. J. Obstet. Gynecol. 194: 1616-1624 (2006). *

• Merino V, Jimenez-Torres NV, Merino-Sanjuan M. Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. Curr. Drug Deliv. 1: 203-212 (2004).

• Meuwis MA, Fillet M, Geurts P, de Seny D, Lutteri L, Chapelle JP, Bours V, Wehenkel L, Belaiche J, Malaise M, Louis E, Merville MP. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem. Pharmacol. 73: 1422-1433 (2007). *

• Meyer zu Schwabedissen HE, Dreisbach A, Hammer E, Fusch C, Hecker M, Volker U, Kroemer HK. Direct mass spectrometric identification of ABCB1 (P-glycoprotein/MDR1) from the apical membrane fraction of human placenta using fourier transform ion cyclotron mass spectrometry. Pharmacogenet. Genomics 16: 385-389 (2006).

• Michalak K, Wesolowska O, Motohashi N, Molnar J, Hendrich AB. Interactions of phenothiazines with lipid bilayer and their role in multidrug resistance reversal. Curr. Drug Targets 7: 1095-1105 (2006).

• Michl P, Pauls S, Gress TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 20: 227-251 (2006).

• Micuda S, Fuksa L, Brcakova E, Osterreicher J, Cermanova J, Cibicek N, Mokry J, Staud F, Martinkova J. Zonation of multidrug resistance-associated protein 2 in rat liver after induction with dexamethasone. J. Gastroenterol. Hepatol. 23: e225-e230 (2008). *

• Mieli-Vergani G, Vergani D. Approach to a child with chronic liver disease. J. Gastroenterol. Hepatol. 19: S377-S378 (2004). *

• Mignogna C, Staibano S, Altieri V, De Rosa G, Pannone G, Santoro A, Zamparese R, D'Armiento M, Rocchetti R, Mezza E, Nasti M, Strazzullo V, Montanaro V, Mascolo M, Bufo P. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer 6: 293 (2006). *

• Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 32: 1439-1444 (2008).

• Mikami M, Takikawa H. Effect of genipin on the biliary excretion of cholephilic compounds in rats. Hepatol. Res. 38: 614-621 (2008). *

• Mikamo E, Harada S, Nishikawa J, Nishihara T. Endocrine disruptors induce cytochrome P450 by affecting transcriptional regulation via pregnane X receptor. Toxicol. Appl. Pharmacol. 193: 66-72 (2003). *

• Miki Y, Suzuki T, Tazawa C, Blumberg B, Sasano H. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol. Cell. Endocrinol. 231: 75-85 (2005).

• Milkiewicz P, Chilton AP, Hubscher SG, Elias E. Antidepressant induced cholestasis: hepatocellular redistribution of multidrug resistant protein (MRP2). Gut 52: 300-303 (2003). *

• Milkiewicz P, Gallagher R, Chambers J, Eggington E, Weaver J, Elias E. Obstetric cholestasis with elevated gamma glutamyl transpeptidase: incidence, presentation and treatment. J. Gastroenterol. Hepatol. 18: 1283-1286 (2003). *

• Miller B, Patel VA, Sorokin A. Cyclooxygenase-2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P-glycoprotein). J. Am. Soc. Nephrol. 17: 977-985 (2006). *

• Miller DS, Shaw JR, Stanton CR, Barnaby R, Karlson KH, Hamilton JW, Stanton BA. MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus): MRP2 and acquired tolerance. Toxicol. Sci. 97: 103-110 (2007). *

• Miller KL, Kelsey KT, Wiencke JK, Moghadassi M, Miike R, Liu M, Wrensch M. The C3435T polymorphism of MDR1 and susceptibility to adult glioma. Neuroepidemiology 25: 85-90 (2005).

• Minich T, Riemer J, Schulz JB, Wielinga P, Wijnholds J, Dringen R. The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. J. Neurochem. 97: 373-384 (2006).

• Miranda S, Vollrath V, Wielandt AM, Loyola G, Bronfman M, Chianale J. Overexpression of mdr2 gene by peroxisome proliferators in the mouse liver. J. Hepatol. 26: 1331-1339 (1997). *

• Mitchell AM, Tom M, Mortimer RH. Thyroid hormone export from cells: contribution of P-glycoprotein. J. Endocrinol. 185: 93-98 (2005). *

• Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63: 1161-1169 (2007).

• Mizutani T, Hattori A. New horizon of MDR1 (P-glycoprotein) study. Drug Metab. Rev. 37: 489-510 (2005). *

• Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y, Kawai Y, Nakahira K, Shinkai S, Takahashi K. Genuine functions of P-glycoprotein (ABCB1). Curr. Drug Metab. 9: 167-174 (2008).

• Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, Manautou J. Induction of hepatic transporters Mrp3 and Mrp4 by clofibrate is regulated by PPARalpha. J. Pharmacol. Exp. Ther. 317: 537-545 (2006). *

• Mohammadzadeh A, Farnia P, Ghazvini K, Behdani M, Rashed T, Ghanaat J. Rapid and low-cost colorimetric method using 2,3,5-triphenyltetrazolium chloride for detection of multidrug-resistant Mycobacterium tuberculosis. J. Med. Microbiol. 55: 1657-1659 (2006). *

• Monte MJ, Fernandez-Tagarro M, Macias RI, Jimenez F, Gonzalez-San Martin F, Marin JJ. Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. Clin. Sci. (Lond.) 109: 199-207 (2005). *

• Moore JH, Gilbert JC, Tsai CT, Chiang FT, Holden T, Barney N, White BC. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J. Theor. Biol. 241: 252-261 (2006). *

• Mor-Cohen R, Zivelin A, Rosenberg N, Goldberg I, Seligsohn U. A novel ancestral splicing mutation in the multidrug resistance protein 2 gene causes Dubin-Johnson syndrome in Ashkenazi Jewish patients. Hepatol. Res. 31: 104-111 (2005).

• Mor-Cohen R, Zivelin A, Rosenberg N, Shani M, Muallem S, Seligsohn U. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J. Biol. Chem. 276: 36923-36930 (2001). *

• Morita SY, Kobayashi A, Takanezawa Y, Kioka N, Handa T, Arai H, Matsuo M, Ueda K. Bile salt-dependent efflux of cellular phospholipids mediated by ATP binding cassette protein B4. Hepatology 46: 188-199 (2007). *

• Moriwaki T, Yasui H, Yamamoto A. Pharmacokinetic analysis of ramatroban using a recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference in Sprague-Dawley and Eisai hyperbilirubinemic rats. Pharm. Res. 21: 1055-1064 (2004). *

• Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 25: 1356-1359 (2002). *

• Morozevich GE, Kozlova NI, Preobrazhenskaya ME, Ushakova NA, Eltsov IA, Shtil AA, Berman AE. The role of beta1 integrin subfamily in anchorage-dependent apoptosis of breast carcinoma cells differing in multidrug resistance. Biochemistry (Mosc.) 71: 489-495 (2006). *

• Morris DO, Mauldin EA, O'Shea K, Shofer FS, Rankin SC. Clinical, microbiological, and molecular characterization of methicillin-resistant Staphylococcus aureus infections of cats. Am. J. Vet. Res. 67: 1421-1425 (2006). *

• Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci. 78: 2116-2130 (2006). *

• Moseley RH. Liver and biliary tract disorders. Curr. Opin. Gastroenterol. 23: 217-220 (2007).

• Mosyagin I, Runge U, Schroeder HW, Dazert E, Vogelgesang S, Siegmund W, Warzok RW, Cascorbi I. Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 49: 1555-1561 (2008).

• Mota P, Diogo N, Pina J. Multi-drug resistant tuberculosis in a respiratory infectious diseases unit - results from five years. Rev. Port. Pneumol. 11: S44-S45 (2005).

• Motohashi N, Kawase M, Satoh K, Sakagami H. Cytotoxic potential of phenothiazines. Curr. Drug Targets 7: 1055-1066 (2006).

• Motsinger AA, Ritchie MD. Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum. Genomics 2: 318-328 (2006).

• Mottino AD, Cao J, Veggi LM, Crocenzi F, Roma MG, Vore M. Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis. Hepatology 35: 1409-1419 (2002). *

• Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J. Gastroenterol. 14: 7068-7074 (2008). *

• Mottino AD, Hoffman T, Crocenzi FA, Sanchez Pozzi EJ, Roma MG, Vore M. Disruption of function and localization of tight-junctional structures and Mrp2 in sustained estradiol-17beta-D-glucuronide-induced cholestasis. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G391-G402 (2007). *

• Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, De Meyer M, Malaise J, Eddour DC, Lison D, Squifflet JP, Haufroid V. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80: 977-984 (2005).

• Mrowczynska L, Bobrowska-Hagerstrand M, Wrobel A, Soderstrom T, Hagerstrand H. Inhibition of MRP1-mediated efflux in human erythrocytes by mono-anionic bile salts. Anticancer Res. 25: 3173-3178 (2005).

• Mrozikiewicz PM, Seremak-Mrozikiewicz A, Semczuk A, Landt O, Breborowicz GH, Drews K. The significance of C3435T point mutation of the MDR1 gene in endometrial cancer. Int. J. Gynecol. Cancer 17: 728-731 (2007).

• Mu Y, Zhang J, Zhang S, Zhou HH, Toma D, Ren S, Huang L, Yaramus M, Baum A, Venkataramanan R, Xie W. Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate PXR and increase warfarin clearance in rats. J. Pharmacol. Exp. Ther. 316: 1369-1377 (2006). *

• Muhlfeld A, Kubitz R, Dransfeld O, Haussinger D, Wettstein M. Taurine supplementation induces multidrug resistance protein 2 and bile salt export pump expression in rats and prevents endotoxin-induced cholestasis. Arch. Biochem. Biophys. 413: 32-40 (2003). *

• Mulas MF, Demuro G, Mulas C, Putzolu M, Cavallini G, Donati A, Bergamini E, Dessi S. Dietary restriction counteracts age-related changes in cholesterol metabolism in the rat. Mech. Ageing Dev. 126: 648-654 (2005).

• Muller M, de Vries EG, Jansen PL. Role of multidrug resistance protein (MRP) in glutathione S-conjugate transport in mammalian cells. J. Hepatol. 24 Suppl. 1: 100-108 (1996).

• Muller M, Jansen PL. Molecular aspects of hepatobiliary transport. Am. J. Physiol. 272: G1285-G1303 (1997).

• Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, de Vries EG, Jansen PL. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. U.S.A. 91: 13033-13037 (1994). *

• Muller M, Roelofsen H, Jansen PL. Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein. Semin. Liver Dis. 16: 211-220 (1996).

• Muller O, Schalla C, Scheibner J, Stange EF, Fuchs M. Expression of liver plasma membrane transporters in gallstone-susceptible and gallstone-resistant mice. Biochem. J. 361: 673-679 (2002). *

• Muller P, Asher N, Heled M, Cohen SB, Risch A, Rund D. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk. Res. 32: 919-929 (2008).

• Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin. Drug Metab. Toxicol. 4: 923-939 (2008).

• Murakami Y, Higashi Y, Matsunaga N, Koyanagi S, Ohdo S. Circadian clock-controlled intestinal expression of the multidrug-resistance gene Mdr1a in mice. Gastroenterology 135: 1636-1644.e3 (2008). *

• Muramatsu T, Johnson DR, Finch RA, Johnson LK, Leffert JJ, Lin ZP, Pizzorno G, Sartorelli AC. Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice. Oncol. Res. 14: 331-343 (2004).

• Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin. Pharmacol. Ther. 80: 509-521 (2006). *

• Nagaoka R, Iwasaki T, Rokutanda N, Takeshita A, Koibuchi Y, Horiguchi J, Shimokawa N, Iino Y, Morishita Y, Koibuchi N. Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells. Endocrine 30: 261-268 (2006).

• Nakamuta M, Fujino T, Yada R, Yasutake K, Yoshimoto T, Harada N, Yada M, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nishinakagawa T, Machida K, Matsunaga K, Nakashima M, Kotoh K, Enjoji M. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. Int. J. Clin. Pharmacol. Ther. 48: 22-28 (2010).

• Nakken KE, Labori KJ, Rodningen OK, Nakken S, Berge KE, Eiklid K, Raeder MG. ABCB4 sequence variations in young adults with cholesterol gallstone disease. Liver Int. 29: 743-747 (2009). *

• Nannelli A, Rossignolo F, Tolando R, Rossato P, Pellegatti M, Longo V, Giovanni Gervasi P. Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol. Cell. Biochem. Oct 22 [Epub ahead of print] (2009). *

• Naramoto H, Uematsu T, Uchihashi T, Doto R, Matsuura T, Usui Y, Uematsu S, Li X, Takahashi M, Yamaoka M, Furusawa K. Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int. J. Oncol. 30: 393-401 (2007). *

• Narang VS, Fraga C, Kumar N, Shen J, Throm S, Stewart CF, Waters CM. Dexamethasone increases expression and activity of multi-drug resistance transporters at the rat blood-brain barrier. Am. J. Physiol. Cell Physiol. 295: C440-C450 (2008). *

• Neff MW, Robertson KR, Wong AK, Safra N, Broman KW, Slatkin M, Mealey KL, Pedersen NC. Breed distribution and history of canine mdr1-1-delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc. Natl. Acad. Sci. U.S.A. 101: 11725-11730 (2004). *

• Negoro K, Yamano Y, Fushimi K, Saito K, Nakatani K, Shiiba M, Yokoe H, Bukawa H, Uzawa K, Wada T, Tanzawa H, Fujita S. Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. Int. J. Oncol. 30: 1325-1332 (2007). *

• Nemeth J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, Breuhahn K, Gebhardt C, Schirmacher P, Hahn M, Ben-Neriah Y, Pikarsky E, Angel P, Hess J. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 50: 1251-1262 (2009).

• Neudeck BL, Loeb JM, Faith NG, Czuprynski CJ. Intestinal P glycoprotein acts as a natural defense mechanism against Listeria monocytogenes. Infect. Immun. 72: 3849-3854 (2004). *

• Newton DJ, Wang RW, Evans DC. Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR(-) and EHBR rats. Life Sci. 77: 1106-1115 (2005). *

• Nezasa K, Tian X, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KL. Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metab. Dispos. 34: 718-723 (2006). *

• Nickoloff BJ, Ben-Neriah Y, Pikarsky E. Inflammation and cancer: is the link as simple as we think? J. Invest. Dermatol. 124: x-xiv (2005). *

• Nicolis E, Pasetto M, Cigana C, Pradal U, Assael BM, Melotti P. The GCC repeat length in the 5'UTR of MRP1 gene is polymorphic: a functional characterization of its relevance for cystic fibrosis. BMC Med. Genet. 7: 7 (2006). *

• Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivisto KT. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14: 429-440 (2004).

• Nieri P, Romiti N, Adinolfi B, Chicca A, Massarelli I, Chieli E. Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells. Br. J. Pharmacol. 148: 682-687 (2006). *

• Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 453: 643-659 (2007). *

• Nikougoftar M, Farhadi M, Pourfathollah AA. P-glycoprotein quantitation in acute leukemia. Iran J. Allergy Asthma Immunol. 2: 57-60 (2003).

• Nisa AU, Ahmad Z. Dubin-Johnson syndrome. J. Coll. Physicians Surg. Pak. 18: 188-189 (2008).

• Nishimura M, Koeda A, Suzuki E, Kawano Y, Nakayama M, Satoh T, Narimatsu S, Naito S. Regulation of mRNA expression of MDR1, MRP1, MRP2 and MRP3 by prototypical microsomal enzyme inducers in primary cultures of human and rat hepatocytes. Drug Metab. Pharmacokinet. 21: 297-307 (2006). *

• Nishio N, Katsura T, Ashida K, Okuda M, Inui K. Modulation of P-glycoprotein expression in hyperthyroid rat tissues. Drug Metab. Dispos. 33: 1584-1587 (2005). *

• Nishioka T, Hyogo H, Numata Y, Yamaguchi A, Kobuke T, Komichi D, Nonaka M, Inoue M, Nabeshima Y, Ogi M, Iwamoto K, Ishitobi T, Ajima T, Chayama K, Tazuma S. A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion. J. Atheroscler. Thromb. 12: 211-217 (2005). *

• Nishiya T, Kataoka H, Mori K, Goto M, Sugawara T, Furuhama K. Tienilic acid enhances hyperbilirubinemia in Eisai hyperbilirubinuria rats through hepatic multidrug resistance-associated protein 3 and heme oxygenase-1 induction. Toxicol. Sci. 91: 651-659 (2006). *

• No authors listed. Mdr-1 c3435t polymorphism influences tacrolimus concentration/dose requirement in liver transplant recipients. Transplantation 82 (1 Suppl. 2): 714 (2006).

• No authors listed. Mdr-1 haplotypes have only a minor influence on tacrolimus dose requirement in renal transplant recipients. Transplantation 82 (1 Suppl. 2): 490 (2006).

• Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 7: 861-879 (2006).

• Noguchi E, Yokouchi Y, Zhang J, Shibuya K, Shibuya A, Bannai M, Tokunaga K, Doi H, Tamari M, Shimizu M, Shirakawa T, Shibasaki M, Ichikawa K, Arinami T. Positional identification of an asthma susceptibility gene on human chromosome 5q33. Am. J. Respir. Crit. Care Med. 172: 183-188 (2005). *

• Noji Y, Inazu A, Higashikata T, Nohara A, Kawashiri MA, Yu W, Todo Y, Nozue T, Uno Y, Hifumi S, Mabuchi H. Identification of two novel missense mutations (p.R1221C and p.R1357W) in the ABCC6 (MRP6) gene in a Japanese patient with pseudoxanthoma elasticum (PXE). Intern. Med. 43: 1171-1176 (2004). *

• Nones K, Dommels YE, Martell S, Butts C, McNabb WC, Park ZA, Zhu S, Hedderley D, Barnett MP, Roy NC. The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a-/-) mice, a model of inflammatory bowel diseases. Br. J. Nutr. 101: 169-181 (2009). *

• Notenboom S, Wouterse AC, Peters B, Kuik LH, Heemskerk S, Russel FG, Masereeuw R. Increased apical insertion of the multidrug resistance protein 2 (MRP2/ABCC2) in renal proximal tubules following gentamicin exposure. J. Pharmacol. Exp. Ther. 318: 1194-1202 (2006). *

• Nseir S, Di Pompeo C, Cavestri B, Jozefowicz E, Nyunga M, Soubrier S, Roussel-Delvallez M, Saulnier F, Mathieu D, Durocher A. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit. Care Med. 34: 2959-2966 (2006).

• Nwankwo JO. Significant transcriptional down-regulation of the human MDR1 gene by beta-naphthoflavone: a proposed hypothesis linking potent CYP gene induction to MDR1 inhibition. Med. Hypotheses 68: 661-669 (2007).

• O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J, Kennedy S. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res. 27: 2115-2120 (2007).

• O'Leary JG, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 23: 232-236 (2007).

• Oerlemans R, van der Heijden J, Vink J, Dijkmans BA, Kaspers GJ, Lems WF, Scheffer GL, Ifergan I, Scheper RJ, Cloos J, Assaraf YG, Jansen G. Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum. 54: 557-568 (2006). *

• Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, Sugiyama Y. Characterization of inducible nature of MRP3 in rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G438-G446 (2000). *

• Oh JH, Dong MS, Choi MG, Yoo HW, Lee SB, Park YI, Chung IS. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin. J. Gastroenterol. Hepatol. 24: 294-298 (2009). *

• Ohishi Y, Nakamura M, Iio N, Higa S, Inayoshi M, Aiba Y, Komori A, Omagari K, Ishibashi H, Tsukamoto K. Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology 48: 853-862 (2008). *

• Oka M, Fukuda M, Soda H. Anticancer drugs and ABC transporters. Gan To Kagaku Ryoho 32: 585-592 (2005).

• Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, Ohtsuki M, Goto N, Sugimoto H, Utsunomiya H, Oda K, Warabi E, Ishii T, Yamamoto M. Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. Biochem. Biophys. Res. Commun. 389: 431-436 (2009). *

• Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, Ohtsuki M, Goto N, Takeda K, Utsunomiya H, Oda K, Warabi E, Ishii T, Osaka K, Hyodo I, Yamamoto M. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification and antioxidative stress systems in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G735-G747 (2008). *

• Okahara S, Arimura Y, Yabana T, Kobayashi K, Gotoh A, Motoya S, Imamura A, Endo T, Imai K. Inflammatory gene signature in ulcerative colitis with cDNA macroarray analysis. Aliment. Pharmacol. Ther. 21: 1091-1097 (2005). *

• Okazaki T, Wang MH, Rawsthorne P, Sargent M, Datta LW, Shugart YY, Bernstein CN, Brant SR. Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions. Inflamm. Bowel Dis. 14: 1528-1541 (2008). *

• Okumura H, Katoh M, Minami K, Nakajima M, Yokoi T. Change of drug excretory pathway by CCl(4)-induced liver dysfunction in rat. Biochem. Pharmacol. 74: 488-495 (2007). *

• Olinga P, Elferink MG, Draaisma AL, Merema MT, Castell JV, Perez G, Groothuis GM. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur. J. Pharm. Sci. 33: 380-389 (2008). *

• Oliveira AL, de Souza M, Carvalho-Dias VM, Ruiz MA, Silla L, Tanaka PY, Simoes BP, Trabasso P, Seber A, Lotfi CJ, Zanichelli MA, Araujo VR, Godoy C, Maiolino A, Urakawa P, Cunha CA, de Souza CA, Pasquini R, Nucci M. Epidemiology of bacteremia and factors associated with multi-drug-resistant Gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 39: 775-781 (2007).

• Oliynyk I, Varelogianni G, Schalling M, Asplund MS, Roomans GM, Johannesson M. Azithromycin increases chloride efflux from cystic fibrosis airway epithelial cells. Exp. Lung Res. 35: 210-221 (2009).

• Ollivier H, Pichavant-Rafini K, Puill-Stephan E, Calves P, Nonnotte L, Nonnotte G. Effects of hyposmotic stress on ATP release in isolated turbot (Scophthalmus maximus) hepatocytes. Biol. Cell 98: 427-437 (2006). *

• Onnie CM, Fisher SA, Pattni R, Sanderson J, Forbes A, Lewis CM, Mathew CG. Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study. Inflamm. Bowel Dis. 12: 263-271 (2006). *

• Oostenbrug LE, Dijkstra G, Nolte IM, Van Dullemen HM, Oosterom E, Faber KN, De Jong DJ, Van Der Linde K, Te Meerman GJ, Van Der Steege G, Kleibueker JH, Jansen PL. Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease. Scand. J. Gastroenterol. 41: 1174-1182 (2006). *

• Ortiz D, Arias IM. MDR3 mutations: a glimpse into pandora's box and the future of canalicular pathophysiology. Gastroenterology 120: 1549-1552 (2001). *

• Ortiz DF, Li S, Iyer R, Zhang X, Novikoff P, Arias IM. MRP3, a new ATP-binding cassette protein localized to the canalicular domain of the hepatocyte. Am. J. Physiol. 276: G1493-G1500 (1999). *

• Ortiz DF, Moseley J, Calderon G, Swift AL, Li S, Arias IM. Identification of HAX-1 as a protein that binds bile salt export protein and regulates its abundance in the apical membrane of Madin-Darby canine kidney cells. J. Biol. Chem. 279: 32761-32770 (2004). *

• Ortiz DF, St Pierre MV, Abdulmessih A, Arias IM. A yeast ATP-binding cassette-type protein mediating ATP-dependent bile acid transport. J. Biol. Chem. 272: 15358-15365 (1997). *

• Oselin K, Gerloff T, Mrozikiewicz PM, Pahkla R, Roots I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam. Clin. Pharmacol. 17: 463-469 (2003). *

• Oshima H, Kon J, Ooe H, Hirata K, Mitaka T. Functional expression of organic anion transporters in hepatic organoids reconstructed by rat small hepatocytes. J. Cell. Biochem. 104: 68-81 (2008). *

• Ostergaard M, Ernst A, Labouriau R, Dagiliene E, Krarup HB, Christensen M, Thorsgaard N, Jacobsen BA, Tage-Jensen U, Overvad K, Autrup H, Andersen V. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population. Scand. J. Gastroenterol. 44: 65-73 (2009). *

• Ostrovsky O, Nagler A, Korostishevsky M, Gazit E, Galski H. Genotype and allele frequencies of C3435T polymorphism of the MDR1 gene in various Jewish populations of Israel. Ther. Drug Monit. 26: 679-684 (2004).

• Osuga T, Sakaeda T, Nakamura T, Yamada T, Koyama T, Tamura T, Aoyama N, Okamura N, Kasuga M, Okumura K. MDR1 C3435T polymorphism is predictive of later onset of ulcerative colitis in Japanese. Biol. Pharm. Bull. 29: 324-329 (2006). *

• Oswald M, Kullak-Ublick GA, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 21: 247-253 (2001). *

• Oude Elferink RP, Groen AK. The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. J. Hepatol. 23: 617-625 (1995). *

• Oude Elferink RP, Groen AK. The mechanism of biliary lipid secretion and its defects. Gastroenterol. Clin. North Am. 28: 59-74, vi (1999).

• Oude Elferink RP, Groen AK. Genetic defects in hepatobiliary transport. Biochim. Biophys. Acta 1586: 129-145 (2002). *

• Oude Elferink RP, Ottenhoff R, Fricker G, Seward DJ, Ballatori N, Boyer J. Lack of biliary lipid excretion in the little skate, Raja erinacea, indicates the absence of functional Mdr2, Abcg5, and Abcg8 transporters. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G762-G768 (2004). *

• Oude Elferink RP, Ottenhoff R, van Wijland M, Frijters CM, van Nieuwkerk C, Groen AK. Uncoupling of biliary phospholipid and cholesterol secretion in mice with reduced expression of mdr2 P-glycoprotein. J. Lipid Res. 37: 1065-1075 (1996). *

• Oude Elferink RP, Ottenhoff R, van Wijland M, Smit JJ, Schinkel AH, Groen AK. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J. Clin. Invest. 95: 31-38 (1995). *

• Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch. 453: 601-610 (2007). *

• Oude Elferink RP, Tytgat GN, Groen AK. Hepatic canalicular membrane 1: the role of mdr2 P-glycoprotein in hepatobiliary lipid transport. FASEB J. 11: 19-28 (1997). *

• Owen A, Chandler B, Back DJ, Khoo SH. Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir. Ther. 9: 819-821 (2004).

• Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br. J. Clin. Pharmacol. 59: 365-370 (2005). *

• Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. 19: 83-95 (2004). *

• Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 78: 2131-2145 (2006). *

• Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 78: 49-55 (2009).

• Panczyk M, Salagacka A, Mirowski M. MDR1 (ABCB1) gene encoding glycoprotein P (P-gp), a member of ABC transporter superfamily: consequences for therapy and progression of neoplastic diseases. Postepy. Biochem. 53: 361-373 (2007).

• Pankratz N. A two-stage classification approach identifies seven susceptibility genes for a simulated complex disease. BMC Proc. 1 Suppl. 1: S30 (2007). *

• Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 161: 5733-5744 (1998). *

• Pares X, Farres J, Kedishvili N, Duester G. Medium-chain and short-chain dehydrogenases/reductases in retinoid metabolism. Cell. Mol. Life Sci. 65: 3936-3949 (2008). *

• Pascussi JM, Dvorak Z, Gerbal-Chaloin S, Assenat E, Maurel P, Vilarem MJ. Pathophysiological factors affecting CAR gene expression. Drug Metab. Rev. 35: 255-268 (2003).

• Pascussi JM, Vilarem MJ. Molecular mechanisms linking xenobiotic metabolism and inflammation. Med. Sci. (Paris) 24: 301-305 (2008).

• Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am. J. Ther. 11: 262-277 (2004).

• Patel NJ, Zamek-Gliszczynski MJ, Zhang P, Han YH, Jansen PL, Meier PJ, Stieger B, Brouwer KL. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol. Pharmacol. 64: 154-159 (2003). *

• Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 135: 660-670 (2008). *

• Paul KB, Hedge JM, Devito MJ, Crofton KM. Short-term exposure to triclosan decreases thyroxine in vivo via upregulation of hepatic catabolism in young Long-Evans rats. Toxicol. Sci. 113: 367-379 (2010). *

• Paule B, Castagne V, Picard V, Saffroy R, Adam R, Guettier C, Farinotti R, Bonhomme-Faivre L. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med. Oncol. Oct 28 [Epub ahead of print] (2009). *

• Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, Beuers U, Meier PJ. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 39: 779-791 (2004). *

• Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm. Res. 21: 904-913 (2004). *

• Pauli-Magnus C, Kroetz DL. MDR1 reference sequence and reference function. Clin. Pharmacol. Ther. 72: 100-101 (2002).

• Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, Zimmermann R, Kenngott S, Beuers U, Reichel C, Kerb R, Penger A, Meier PJ, Kullak-Ublick GA. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 14: 91-102 (2004).

• Pauli-Magnus C, Murdter T, Godel A, Mettang T, Eichelbaum M, Klotz U, Fromm MF. P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn. Schmiedebergs. Arch. Pharmacol. 363: 337-343 (2001). *

• Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn. Schmiedebergs. Arch. Pharmacol. 364: 551-557 (2001). *

• Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J. Pharmacol. Exp. Ther. 293: 376-382 (2000). *

• Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, Oude Elferink RP. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271: 1126-1128 (1996). *

• Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36: 525-531 (2002). *

• Paumi CM, Chuk M, Snider J, Stagljar I, Michaelis S. ABC transporters in Saccharomyces cerevisiae and their interactors: new technology advances the biology of the ABCC (MRP) subfamily. Microbiol. Mol. Biol. Rev. 73: 577-593 (2009). *

• Paus TC, Schneider G, Van De Vondel P, Sauerbruch T, Reichel C. Diagnosis and therapy of intrahepatic cholestasis of pregnancy. Z. Gastroenterol. 42: 623-628 (2004).

• Pavek P, Cerveny L, Svecova L, Brysch M, Libra A, Vrzal R, Nachtigal P, Staud F, Ulrichova J, Fendrich Z, Dvorak Z. Examination of glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines. Placenta 28: 1004-1011 (2007).

• Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, Schinkel AH. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 312: 144-152 (2005). *

• Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 42: 496-503 (2004).

• Payen L, Gao M, Westlake C, Theis A, Cole SP, Deeley RG. Functional interactions between nucleotide binding domains and LTC4 binding sites of multidrug resistance protein 1 (ABCC1). Mol. Pharmacol. 67: 1944-1953 (2005). *

• Pazos M, Siccardi D, Mumy KL, Bien JD, Louie S, Shi HN, Gronert K, Mrsny RJ, McCormick BA. Multidrug resistance-associated transporter 2 regulates mucosal inflammation by facilitating the synthesis of hepoxilin A3. J. Immunol. 181: 8044-8052 (2008). *

• Pel's IaR, Marusin AV, Spiridonova MG, Stepanov VA. Polymorphism of human MDR1 gene in the Siberian and central Asian populations. Mol. Biol. (Mosk.) 41: 982-988 (2007).

• Peng SF, Fu L, Tan DM. Heat-shock protein 27 linked to multi-drug resistance in human hepatic cancer cell lines. Zhonghua Gan Zang Bing Za Zhi 15: 362-365 (2007).

• Perdu J, Germain DP. Identification of novel polymorphisms in the pM5 and MRP1 (ABCC1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseudoxanthoma elasticum. Hum. Mutat. 17: 74-75 (2001). *

• Perrin L, Gatouillat G, Balasse E, Odot J, Nicolau C, Tosi PF, Madoulet C. Induction of autoantibodies to murine P-glycoprotein: consequences on drug sensitivity in MDR cancer cells and on the expression of MDR genes in organs. Biochem. Biophys. Res. Commun. 358: 325-330 (2007). *

• Petraccia L, Onori P, Sferra R, Lucchetta MC, Liberati G, Grassi M, Gaudio E. MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications. Clin. Ter. 154: 325-335 (2003).

• Petrick JS, Klaassen CD. Importance of hepatic induction of constitutive androstane receptor and other transcription factors that regulate xenobiotic metabolism and transport. Drug Metab. Dispos. 35: 1806-1815 (2007). *

• Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, Atanasova S, Toncheva D, Oellerich M, von Ahsen N. No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J. Cancer Res. Clin. Oncol. 134: 317-322 (2008). *

• Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin. Cancer Res. 11: 4487-4494 (2005). *

• Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19: 382-402 (2006). *

• Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466 (2004). *

• Pires MM, Hrycyna CA, Chmielewski J. Bivalent probes of the human multidrug transporter P-glycoprotein. Biochemistry 45: 11695-11702 (2006). *

• Pirnay JP, Bilocq F, Pot B, Cornelis P, Zizi M, Van Eldere J, Deschaght P, Vaneechoutte M, Jennes S, Pitt T, De Vos D. Pseudomonas aeruginosa population structure revisited. PLoS One 4: e7740 (2009). *

• Pizarro M, Balasubramaniyan N, Solis N, Solar A, Duarte I, Miquel JF, Suchy FJ, Trauner M, Accatino L, Ananthanarayanan M, Arrese M. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut 53: 1837-1843 (2004). *

• Planchamp C, Hadengue A, Stieger B, Bourquin J, Vonlaufen A, Frossard JL, Quadri R, Becker CD, Pastor CM. Function of both sinusoidal and canalicular transporters controls the concentration of organic anions within hepatocytes. Mol. Pharmacol. 71: 1089-1097 (2007). *

• Planchamp C, Montet X, Frossard JL, Quadri R, Stieger B, Meier PJ, Ivancevic MK, Vallee JP, Terrier F, Pastor CM. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest. Radiol. 40: 187-194 (2005).

• Plasschaert SL, Van Der Kolk DM, De Bont ES, Vellenga E, Kamps WA, De Vries EG. Breast cancer resistance protein (BCRP) in acute leukemia. Leuk. Lymphoma 45: 649-654 (2004).

• Ploski R, Flato B, Vinje O, Maksymowych W, Forre O, Thorsby E. Association to HLA-DRB1*08, HLA-DPB1*0301 and homozygosity for an HLA-linked proteasome gene in juvenile ankylosing spondylitis. Hum. Immunol. 44: 88-96 (1995).

• Pohl A, Lage H, Muller P, Pomorski T, Herrmann A. Transport of phosphatidylserine via MDR1 (multidrug resistance 1)P-glycoprotein in a human gastric carcinoma cell line. Biochem. J. 365: 259-268 (2002). *

• Polgar O, Bates SE. ABC transporters in the balance: is there a role in multidrug resistance? Biochem. Soc. Trans. 33: 241-245 (2005). *

• Poole BD, Schneider RI, Guthridge JM, Velte CA, Reichlin M, Harley JB, James JA. Early targets of nuclear RNP humoral autoimmunity in human systemic lupus erythematosus. Arthritis Rheum. 60: 848-859 (2009). *

• Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J. Hepatol. 43: 1045-1054 (2005). *

• Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, Kolb A, Friess H, Schuppan D. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J. Hepatol. 48: 453-464 (2008). *

• Potocnik U, Ferkolj I, Glavac D, Dean M. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 5: 530-539 (2004). *

• Poupon R, Ping C, Chretien Y, Corpechot C, Chazouilleres O, Simon T, Heath SC, Matsuda F, Poupon RE, Housset C, Barbu V. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J. Hepatol. 49: 1038-1045 (2008). *

• Prados J, Melguizo C, Fernandez JE, Carrillo E, Marchal JA, Boulaiz H, Martinez A, Rodriguez-Serrano F, Aranega A. Induction of drug resistance in embryonal rhabdomyosarcoma treated with conventional chemotherapy is associated with HLA class I increase. Neoplasma 53: 226-231 (2006). *

• Prashanth K, Badrinath S. Nosocomial infections due to Acinetobacter species: clinical findings, risk and prognostic factors. Indian J. Med. Microbiol. 24: 39-44 (2006).

• Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 21: 270-274 (2005). *

• Pulaski L, Szemraj J, Uchiumi T, Kuwano M, Bartosz G. Transcriptional upregulation of the human MRP2 gene expression by serine/threonine protein kinase inhibitors. J. Biol. Regul. Homeost. Agents 19: 113-119 (2005).

• Qadri I, Hu LJ, Iwahashi M, Al-Zuabi S, Quattrochi LC, Simon FR. Interaction of hepatocyte nuclear factors in transcriptional regulation of tissue specific hormonal expression of human multidrug resistance-associated protein 2 (abcc2). Toxicol. Appl. Pharmacol. 234: 281-292 (2009). *

• Qadri I, Iwahashi M, Kullak-Ublick GA, Simon FR. Hepatocyte nuclear factor (HNF) 1 and HNF4 mediate hepatic multidrug resistance protein 2 up-regulation during hepatitis C virus gene expression. Mol. Pharmacol. 70: 627-636 (2006). *

• Qi J, Liu N, Zhou Y, Tan Y, Cheng Y, Yang C, Zhu Z, Xiong D. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem. Biophys. Res. Commun. 349: 303-309 (2006). *

• Qi L, van Dam RM, Asselbergs FW, Hu FB. Gene-gene interactions between HNF4A and KCNJ11 in predicting type 2 diabetes in women. Diabet. Med. 24: 1187-1191 (2007). *

• Qia S, Wang H, Chen X. Reversal of HCC drug resistance by using hammerhead ribozymes against multidrug resistance 1 gene. J. Huazhong Univ. Sci. Technolog. Med. Sci. 25: 662-664 (2005).

• Qian W, Homma M, Itagaki F, Tachikawa H, Kawanishi Y, Mizukami K, Asada T, Inomata S, Honda K, Ohkohchi N, Kohda Y. MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol. Pharm. Bull. 29: 2446-2450 (2006). *

• Quemelo PR, Lourenco CM, Peres LC. Teratogenic effect of retinoic acid in Swiss mice. Acta Cir. Bras. 22: 451-456 (2007).

• Rachman H, Kaufmann SH. Exploring functional genomics for the development of novel intervention strategies against tuberculosis. Int. J. Med. Microbiol. 297: 559-567 (2007).

• Raggers RJ, van Helvoort A, Evers R, van Meer G. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J. Cell Sci. 112: 415-422 (1999). *

• Raggers RJ, Vogels I, van Meer G. Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem. J. 357: 859-865 (2001). *

• Rahi M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C, Laine K. Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta. Hum. Exp. Toxicol. 27: 65-71 (2008).

• Ramaen O, Sizun C, Pamlard O, Jacquet E, Lallemand JY. Attempts to characterise the NBD heterodimer of MRP1: transient complex formation involves G771 of the ABC signature sequence but does not enhance the intrinsic ATPase activity. Biochem. J. 391: 481-490 (2005). *

• Ramasamy K, Sisy Sam S, Chandrasekaran A. Allele and genotype frequency of MDR1 C3435T in Tamilian population. Drug Metab. Pharmacokinet. 21: 506-508 (2006). *

• Ramenskaia GV, Fainshtein SL, Sychev DA. The role of changes in the functional activity and the amount of P-glycoprotein in drug pharmacokinetics. Eksp. Klin. Farmakol. 70: 72-80 (2007).

• Rampersad R, Esserman D, McGinnis M, Lee D, Patel D, Tarrant T. S100A9 is not essential for disease expression in an acute (K/BxN) or chronic (CIA) model of inflammatory arthritis. Scand. J. Rheumatol. 38: 445-449 (2009).

• Rao A, Haywood J, Craddock AL, Belinsky MG, Kruh GD, Dawson PA. The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc. Natl. Acad. Sci. U.S.A. 105: 3891-3896 (2008). *

• Rapaka RS, Coates PM. Dietary supplements and related products: a brief summary. Life Sci. 78: 2026-2032 (2006). *

• Rassi DM, Junta CM, Fachin AL, Sandrin-Garcia P, Mello S, Marques MM, Fernandes AP, Foss-Freitas MC, Foss MC, Sakamoto-Hojo ET, Passos GA, Donadi EA. Metabolism genes are among the differentially expressed ones observed in lymphomononuclear cells of recently diagnosed type 1 diabetes mellitus patients. Ann. N. Y. Acad. Sci. 1079: 171-176 (2006). *

• Rassi DM, Junta CM, Fachin AL, Sandrin-Garcia P, Mello SS, Fernandes AP, Deghaide NN, Foss-Freitas MC, Foss MC, Sakamoto-Hojo ET, Passos GA, Donadi EA. Is HLA class II profile relevant for the study of large-scale differentially expressed genes in type 1 diabetes mellitus patients? Ann. N. Y. Acad. Sci. 1079: 305-309 (2006). *

• Rassi DM, Wastowski IJ, Simoes RT, Rodrigues S, Deghaide NN, Mendes-Junior CT, Simoes AL, Soares CP, Passos GA, Donadi EA. TNFa-e microsatellite, HLA-DRB1 and -DQB1 alleles and haplotypes in Brazilian patients presenting recently diagnosed type 1 diabetes mellitus. Ann. N. Y. Acad. Sci. 1079: 300-304 (2006). *

• Ratajewski M, Bartosz G, Pulaski L. Expression of the human ABCC6 gene is induced by retinoids through the retinoid X receptor. Biochem. Biophys. Res. Commun. 350: 1082-1087 (2006). *

• Rattmann I, Kleff V, Sorg UR, Bardenheuer W, Brueckner A, Hilger RA, Opalka B, Seeber S, Flasshove M, Moritz T. Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model. Blood 108: 2965-2971 (2006). *

• Rau S, Autschbach F, Riedel HD, Konig J, Kulaksiz H, Stiehl A, Riemann JF, Rost D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas. Eur. J. Clin. Invest. 38: 134-142 (2008). *

• Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther. 80: 468-476 (2006). *

• Rauch C, Pluen A. Multi drug resistance-dependent "vacuum cleaner" functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density. Eur. Biophys. J. 36: 121-131 (2007). *

• Rausa FM, Tan Y, Zhou H, Yoo KW, Stolz DB, Watkins SC, Franks RR, Unterman TG, Costa RH. Elevated levels of hepatocyte nuclear factor 3beta in mouse hepatocytes influence expression of genes involved in bile acid and glucose homeostasis. Mol. Cell. Biol. 20: 8264-8282 (2000). *

• Ravna AW, Sager G. Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4). Bioorg. Med. Chem. Lett. 18: 3481-3483 (2008). *

• Ravna AW, Sylte I, Sager G. Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5). Theor. Biol. Med. Model. 4: 33 (2007). *

• Reichen J. Gallstones - natural history and conservative management. Ther. Umsch. 60: 109-112 (2003).

• Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl. Acad. Sci. U.S.A. 100: 9244-9249 (2003). *

• Reijmerink NE, Bottema RW, Kerkhof M, Gerritsen J, Stelma FF, Thijs C, van Schayck CP, Smit HA, Brunekreef B, Koppelman GH, Postma DS. TLR-related pathway analysis: novel gene-gene interactions in the development of asthma and atopy. Allergy 65: 199-207 (2010). *

• Reljic R. IFN-gamma therapy of tuberculosis and related infections. J. Interferon Cytokine Res. 27: 353-364 (2007).

• Ren L, Xiao L, Hu J. MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells. J. Huazhong Univ. Sci. Technolog. Med. Sci. 27: 721-734 (2007).

• Ren XQ, Furukawa T, Haraguchi M, Sumizawa T, Aoki S, Kobayashi M, Akiyama S. Function of the ABC signature sequences in the human multidrug resistance protein 1. Mol. Pharmacol. 65: 1536-1542 (2004). *

• Ren XQ, Furukawa T, Nakajima Y, Takahasi H, Aoki S, Sumizawa T, Haraguchi M, Kobayashi M, Chijiiwa K, Akiyama SI. GSH inhibits trypsinisation of the C-terminal half of human MRP1. J. Biol. Chem. 280: 6231-6237 (2005). *

• Renes J, de Vries EE, Hooiveld GJ, Krikken I, Jansen PL, Muller M. Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. Biochem. J. 350: 555-561 (2000). *

• Renes J, de Vries EG, Jansen PL, Muller M. The (patho)physiological functions of the MRP family. Drug Resist. Updat. 3: 289-302 (2000).

• Renes J, de Vries EG, Nienhuis EF, Jansen PL, Muller M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. 126: 681-688 (1999). *

• Resta-Lenert S, Smitham J, Barrett KE. Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/- mice. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G153-G162 (2005). *

• Ribeiro-Silva A, Oliveira da Costa JP. Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study. Int. J. Biol. Markers 23: 154-160 (2008).

• Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L. P-glycoprotein in autoimmune diseases. Autoimmun. Rev. 3: 188-192 (2004).

• Richaud-Patin Y, Vega-Boada F, Vidaller A, Llorente L. Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients. Biomed. Pharmacother. 58: 320-324 (2004).

• Richert L, Tuschl G, Abadie C, Blanchard N, Pekthong D, Mantion G, Weber JC, Mueller SO. Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol. Appl. Pharmacol. 235: 86-96 (2009). *

• Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J. Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc. Natl. Acad. Sci. U.S.A. 97: 6001-6006 (2000). *

• Ringpfeil F, Nakano A, Uitto J, Pulkkinen L. Compound heterozygosity for a recurrent 16.5-kb Alu-mediated deletion mutation and single-base-pair substitutions in the ABCC6 gene results in pseudoxanthoma elasticum. Am. J. Hum. Genet. 68: 642-652 (2001). *

• Ringpfeil F, Pulkkinen L, Uitto J. Molecular genetics of pseudoxanthoma elasticum. Exp. Dermatol. 10: 221-228 (2001). *

• Rioja Zuazu J, Bandres Elizalde E, Rosell Costa D, Rincon Mayans A, Zudaire Bergera J, Gil Sanz MJ, Rioja Sanz LA, Garcia Foncillas J, Berian Polo JM. Steroid and xenobiotic receptor (SXR), multidrug resistance gene (MDR1) and GSTs, SULTs and CYP polymorphism expression in invasive bladder cancer, analysis of their expression and correlation with other prognostic factors. Actas Urol. Esp. 31: 1107-1116 (2007).

• Rippin SJ, Hagenbuch B, Meier PJ, Stieger B. Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. Hepatology 33: 776-782 (2001). *

• Ritchie MD, Bartlett J, Bush WS, Edwards TL, Motsinger AA, Torstenson ES. Exploring epistasis in candidate genes for rheumatoid arthritis. BMC Proc. 1 Suppl. 1: S70 (2007). *

• Ritter CA, Jedlitschky G, Meyer zu Schwabedissen H, Grube M, Kock K, Kroemer HK. Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab. Rev. 37: 253-278 (2005). *

• Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G640-G649 (2006). *

• Rius M, Hummel-Eisenbeiss J, Keppler D. ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4). J. Pharmacol. Exp. Ther. 324: 86-94 (2008). *

• Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38: 374-384 (2003). *

• Rius M, Thon WF, Keppler D, Nies AT. Prostanoid transport by multidrug resistance protein 4 (mrp4/abcc4) localized in tissues of the human urogenital tract. J. Urol. 174: 2409-2414 (2005).

• Robert J. Pharmacogenetics and pharmacogenomics of cancers. Pathol. Biol. (Paris) 52: 332-337 (2004).

• Robertson MD, Bickerton AS, Dennis AL, Vidal H, Jewell DP, Frayn KN. Enhanced metabolic cycling in subjects following colonic resection for ulcerative colitis. J. Clin. Endocrinol. Metab. 90: 2747-2754 (2005). *

• Rodrigues FF, Santos RE, Melo MB, Silva MA, Oliveira AL, Rozenowicz RL, Ulson LB, Aoki T. Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet. Mol. Res. 7: 177-183 (2008).

• Rodriguez Novoa S, Barreiro P, Rendon A, Barrios A, Corral A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. 42: 291-295 (2006). *

• Roelofsen H, Hooiveld GJ, Koning H, Havinga R, Jansen PL, Muller M. Glutathione S-conjugate transport in hepatocytes entering the cell cycle is preserved by a switch in expression from the apical MRP2 to the basolateral MRP1 transporting protein. J. Cell Sci. 112: 1395-1404 (1999). *

• Roelofsen H, Muller M, Jansen PL. Regulation of organic anion transport in the liver. Yale J. Biol. Med. 70: 435-445 (1997).

• Roelofsen H, Vos TA, Schippers IJ, Kuipers F, Koning H, Moshage H, Jansen PL, Muller M. Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 112: 511-521 (1997). *

• Roglans N, Vazquez-Carrera M, Alegret M, Novell F, Zambon D, Ros E, Laguna JC, Sanchez RM. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur. J. Clin. Pharmacol. 59: 855-861 (2004). *

• Roma MG, Milkiewicz P, Elias E, Coleman R. Control by signaling modulators of the sorting of canalicular transporters in rat hepatocyte couplets: role of the cytoskeleton. Hepatology 32: 1342-1356 (2000). *

• Roman RM, Wang Y, Lidofsky SD, Feranchak AP, Lomri N, Scharschmidt BF, Fitz JG. Hepatocellular ATP-binding cassette protein expression enhances ATP release and autocrine regulation of cell volume. J. Biol. Chem. 272: 21970-21976 (1997). *

• Romiti N, Tramonti G, Donati A, Chieli E. Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci. 76: 293-302 (2004). *

• Ronaldson PT, Ashraf T, Bendayan R. Regulation of multidrug resistance protein 1 (Mrp1) by tumor necrosis factor alpha (TNF-alpha) in cultured glial cells: involvement of nuclear factor-kappaB (NF-kappaB) and c-Jun N-terminal kinase (JNK) signaling pathways. Mol. Pharmacol. Jan 5 [Epub ahead of print] (2010). *

• Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J. Pathol. 200: 553-560 (2003). *

• Ros JE, Roskams TA, Geuken M, Havinga R, Splinter PL, Petersen BE, LaRusso NF, van der Kolk DM, Kuipers F, Faber KN, Muller M, Jansen PL. ATP binding cassette transporter gene expression in rat liver progenitor cells. Gut 52: 1060-1067 (2003). *

• Ros JE, Schuetz JD, Geuken M, Streetz K, Moshage H, Kuipers F, Manns MP, Jansen PL, Trautwein C, Muller M. Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology 33: 1425-1431 (2001). *

• Rosmorduc O, Hermelin B, Boelle PY, Poupon RE, Poupon R, Chazouilleres O. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 126: 1220-1222 (2004). *

• Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 120: 1459-1467 (2001). *

• Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J. Rare Dis. 2: 29 (2007). *

• Rost D, Kloeters-Plachky P, Stiehl A. Retrieval of the rat canalicular conjugate export pump Mrp2 is associated with a rearrangement of actin filaments and radixin in bile salt-induced cholestasis. Eur. J. Med. Res. 13: 314-318 (2008).

• Rost D, Kopplow K, Gehrke S, Mueller S, Friess H, Ittrich C, Mayer D, Stiehl A. Gender-specific expression of liver organic anion transporters in rat. Eur. J. Clin. Invest. 35: 635-643 (2005).

• Rost D, Kopplow K, Gehrke S, Stiehl A, Mayer D. Gender-specific expression of liver organic anion transporters. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 39. June 18-19 (2004). *

• Rothnie A, Callaghan R, Deeley RG, Cole SP. Role of GSH in estrone sulphate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1). J. Biol. Chem. 281: 13906-13914 (2006). *

• Roulet A, Puel O, Gesta S, Lepage JF, Drag M, Soll M, Alvinerie M, Pineau T. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur. J. Pharmacol. 460: 85-91 (2003). *

• Roy JN, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet. Genomics 16: 659-665 (2006).

• Ruan WJ, Lai MD, Zhou JG. Anticancer effects of Chinese herbal medicine, science or myth? J. Zhejiang Univ. Sci. B. 7: 1006-1014 (2006).

• Ruhl R, Sczech R, Landes N, Pfluger P, Kluth D, Schweigert FJ. Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor. Eur. J. Nutr. 43: 336-343 (2004). *

• Ruiz ML, M Villanueva SS, Luquita MG, Sanchez-Pozzi EJ, Crocenzi FA, Pellegrino JM, Ochoa JE, Vore M, Mottino AD, Catania VA. Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance-associated protein 2. Biochem. Pharmacol. 69: 531-539 (2005). *

• Ruiz ML, Villanueva SS, Luquita MG, Ikushiro S, Mottino AD, Catania VA. Beneficial effect of spironolactone administration on ethynylestradiol-induced cholestasis in the rat: involvement of up-regulation of multidrug resistance-associated protein 2. Drug Metab. Dispos. 35: 2060-2066 (2007). *

• Ruiz ML, Villanueva SS, Luquita MG, Pellegrino JM, Rigalli JP, Arias A, Pozzi EJ, Mottino AD, Catania VA. Induction of intestinal multidrug resistance-associated protein 2 (Mrp2) by spironolactone in rats. Eur. J. Pharmacol. 623: 103-106 (2009). *

• Ruiz ML, Villanueva SS, Luquita MG, Vore M, Mottino AD, Catania VA. Ethynylestradiol increases expression and activity of rat liver MRP3. Drug Metab. Dispos. 34: 1030-1034 (2006). *

• Rund D, Azar I, Shperling O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Adv. Exp. Med. Biol. 457: 71-75 (1999).

• Runge D, Kohler C, Kostrubsky VE, Jager D, Lehmann T, Runge DM, May U, Stolz DB, Strom SC, Fleig WE, Michalopoulos GK. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem. Biophys. Res. Commun. 273: 333-341 (2000). *

• Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 22: 209-214 (2006). *

• Rybarova S, Hodorova I, Hajdukova M, Schmidtova K, Mojzis J, Kajo K, Kviatkovska Z, Plank L, Benicky M, Mirossay A, Biros E, Bobrov N, Wagnerova M, Berc A, Mirossay L. Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters. Neoplasma 53: 128-135 (2006). *

• Sabbagh A, Darlu P. Data-mining methods as useful tools for predicting individual drug response: application to CYP2D6 data. Hum. Hered. 62: 119-134 (2006). *

• Saeki M, Kurose K, Tohkin M, Hasegawa R. Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem. Pharmacol. 76: 531-542 (2008). *

• Sahi J, Sinz MW, Campbell S, Mireles R, Zheng X, Rose KA, Raeissi S, Hashim MF, Ye Y, de Morais SM, Black C, Tugnait M, Keller LH. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem. Biol. Interact. 159: 156-168 (2006). *

• Saiman L. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr. Respir. Rev. 8: 249-255 (2007).

• Saini SP, Mu Y, Gong H, Toma D, Uppal H, Ren S, Li S, Poloyac SM, Xie W. Dual role of orphan nuclear receptor pregnane X receptor in bilirubin detoxification in mice. Hepatology 41: 497-505 (2005). *

• Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J. Hum. Genet. 47: 38-50 (2002).

• Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 25: 1391-1400 (2002). *

• Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4: 397-410 (2003).

• Sakamoto S, Kusuhara H, Horie K, Takahashi K, Baba T, Ishizaki J, Sugiyama Y. Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of S-8921 glucuronide, a pharmacologically active metabolite of S-8921. Drug Metab. Dispos. 36: 1553-1561 (2008). *

• Sakamoto S, Suzuki H, Kusuhara H, Sugiyama Y. Efflux mechanism of taurocholate across the rat intestinal basolateral membrane. Mol. Pharm. 3: 275-281 (2006). *

• Sambuelli AM, Negreira SM, Gil AH, Huernos SP, Goncalves S, Toro MA, Kogan Z, Cabanne A, Camarero S, Bai JC, Lazarowski AJ. Multidrug resistance gene (MDR-1) expression in the colonic mucosa of patients with refractory ulcerative colitis. Acta Gastroenterol. Latinoam. 36: 23-32 (2006).

• Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM, Matherly LH, Schuetz JD. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 4: E14 (2002). *

• Sanchez Hellín V, Gutierrez Rodero F. Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs. Enferm. Infecc. Microbiol. Clin. 26 Suppl. 6: 24-33 (2008).

• Sano K, Chijiiwa K, Kai M, Hidaka Y, Kanemaru M. Differential expression of organic anion transporters in rats subjected to 70% or 90% hepatectomy. Hepatogastroenterology 56: 176-180 (2009).

• Santamaria P. Genetic and therapeutic control of diabetogenic CD8+ T cells. Novartis Found. Symp. 292: 130-136 (2008).

• Sapmaz A, Ozen Karatayli SC, Dagli U, Kilic ZM, Toruner M, Celik Y, Ozkan M, Soykan I, Cetinkaya H, Ulker A, Ozden A, Bozdayi AM. Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease. Turk. J. Gastroenterol. 19: 168-173 (2008). *

• Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 86: 1179-1236 (2006). *

• Sartor LL, Bentjen SA, Trepanier L, Mealey KL. Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J. Vet. Intern. Med. 18: 117-118 (2004).

• Sato N, Nakayama T, Mizutani Y, Yuzawa M. Novel mutations of ABCC6 gene in Japanese patients with Angioid streaks. Biochem. Biophys. Res. Commun. 380: 548-553 (2009). *

• Satsu H, Hiura Y, Mochizuki K, Hamada M, Shimizu M. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J. Agric. Food Chem. 56: 5366-5373 (2008). *

• Savander M, Ropponen A, Avela K, Weerasekera N, Cormand B, Hirvioja ML, Riikonen S, Ylikorkala O, Lehesjoki AE, Williamson C, Aittomaki K. Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut 52: 1025-1029 (2003). *

• Savkur RS, Wu Y, Bramlett KS, Wang M, Yao S, Perkins D, Totten M, Searfoss G 3rd, Ryan TP, Su EW, Burris TP. Alternative splicing within the ligand binding domain of the human constitutive androstane receptor. Mol. Genet. Metab. 80: 216-226 (2003). *

• Sawada GA, Raub TJ, William Higgins J, Brennan NK, Moore TM, Tombline G, Detty MR. Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells. Bioorg. Med. Chem. 16: 9745-9756 (2008). *

• Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49: 1228-1235 (2009). *

• Schaefer U, Voloshanenko O, Willen D, Walczak H. TRAIL: a multifunctional cytokine. Front. Biosci. 12: 3813-3824 (2007).

• Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann. Oncol. 20: 175-181 (2009).

• Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, Oude Elferink RP, van der Valk P, Borst P, Scheper RJ. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. 82: 193-201 (2002).

• Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502 (1994).

• Schmidt C, Giese T, Hermann E, Zeuzem S, Meuer SC, Stallmach A. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm. Bowel Dis. 13: 65-70 (2007). *

• Schmidt C, Giese T, Ludwig B, Menges M, Schilling M, Meuer SC, Zeuzem S, Stallmach A. Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity. Int. J. Colorectal Dis. 21: 419-426 (2006). *

• Schmidt C, Hauser W, Giese T, Stallmach A. Irritable pouch syndrome is associated with depressiveness and can be differentiated from pouchitis by quantification of mucosal levels of proinflammatory gene transcripts. Inflamm. Bowel Dis. 13: 1502-1508 (2007). *

• Schmitt M, Kubitz R, Lizun S, Wettstein M, Haussinger D. Regulation of the dynamic localization of the rat Bsep gene-encoded bile salt export pump by anisoosmolarity. Hepatology 33: 509-518 (2001). *

• Schneider G, Paus TC, Kullak-Ublick GA, Meier PJ, Wienker TF, Lang T, van de Vondel P, Sauerbruch T, Reichel C. Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. Hepatology 45: 150-158 (2007). *

• Schuetz E, Strom S. Promiscuous regulator of xenobiotic removal. Nat. Med. 7: 536-537 (2001). *

• Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 93: 4001-4005 (1996). *

• Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem. 276: 39411-39418 (2001). *

• Schulz T, Schumacher U, Prehm P. Hyaluronan export by the ABC-transporter MRP5 and its modulation by intracellular cGMP. J. Biol. Chem. 282: 20999-21004 (2007). *

• Schulz V, Hendig D, Szliska C, Gotting C, Kleesiek K. Novel mutations in the ABCC6 gene of German patients with pseudoxanthoma elasticum. Hum. Biol. 77: 367-384 (2005).

• Schumm-Draeger PM. Iodine and thyroid autoimmunity. Z. Arztl. Fortbild. Qualitatssich. 98 Suppl. 5: 73-76 (2004).

• Schwab M. Pharmacogenetics in IBD therapy. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 29. May 7-8 (2004). *

• Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43: 285-307 (2003). *

• Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM, Eichelbaum M. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124: 26-33 (2003). *

• Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin. Pharmacol. Ther. 81: 669-678 (2007). *

• Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB. CFTR is a conductance regulator as well as a chloride channel. Physiol. Rev. 79: S145-S166 (1999). *

• Scoazec JY, Bringuier AF, Medina JF, Martinez-Anso E, Veissiere D, Feldmann G, Housset C. The plasma membrane polarity of human biliary epithelial cells: in situ immunohistochemical analysis and functional implications. J. Hepatol. 26: 543-553 (1997). *

• Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 22: 7496-7511 (2003). *

• Seelig A, Blatter XL, Wohnsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int. J. Clin. Pharmacol. Ther. 38: 111-121 (2000).

• Sekine S, Ito K, Horie T. Oxidative stress and Mrp2 internalization. Free Radic. Biol. Med. 40: 2166-2174 (2006).

• Sekine S, Ito K, Horie T. Canalicular Mrp2 localization is reversibly regulated by the intracellular redox status. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G1035-G1041 (2008). *

• Serrano MA, Macias RI, Briz O, Monte MJ, Blazquez AG, Williamson C, Kubitz R, Marin JJ. Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta. Placenta 28: 107-117 (2007).

• Serrano MA, Macias RI, Vallejo M, Briz O, Bravo A, Pascual MJ, St-Pierre MV, Stieger B, Meier PJ, Marin JJ. Effect of ursodeoxycholic acid on the impairment induced by maternal cholestasis in the rat placenta-maternal liver tandem excretory pathway. J. Pharmacol. Exp. Ther. 305: 515-524 (2003). *

• Servais A, Lechat P, Zahr N, Urien S, Aymard G, Jaudon MC, Deray G, Isnard Bagnis C. Tubular transporters OAT1 and MRP2 and clearance of adefovir. Nephrol. Ther. 1: 296-300 (2005).

• Shahwan A, Murphy K, Doherty C, Cavalleri GL, Muckian C, Dicker P, McCarthy M, Kinirons P, Goldstein D, Delanty N. The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res. 73: 192-198 (2007).

• Sharma R, Awasthi YC, Yang Y, Sharma A, Singhal SS, Awasthi S. Energy dependent transport of xenobiotics and its relevance to multidrug resistance. Curr. Cancer Drug Targets 3: 89-107 (2003).

• Sharma SK, Mohan A. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest 130: 261-272 (2006). *

• Sharom FJ. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem. Cell. Biol. 84: 979-992 (2006). *

• Shen CD, Zhang WL, Sun K, Wang YB, Zhen YS, Hui RT. Interaction of genetic risk factors confers higher risk for thrombotic stroke in male Chinese: a multicenter case-control study. Ann. Hum. Genet. 71: 620-629 (2007). *

• Sheps JA, Ling V. Preface: the concept and consequences of multidrug resistance. Pflugers Arch. 453: 545-553 (2007). *

• Sheps JA, Ralph S, Zhao Z, Baillie DL, Ling V. The ABC transporter gene family of Caenorhabditis elegans has implications for the evolutionary dynamics of multidrug resistance in eukaryotes. Genome Biol. 5: R15 (2004). *

• Shibayama Y, Takeda Y, Yamada K. Effect of methotrexate treatment on expression levels of organic anion transporter polypeptide 2, P-glycoprotein and bile salt export pump in rats. Biol. Pharm. Bull. 32: 493-496 (2009). *

• Shibayama Y, Ushinohama K, Ikeda R, Yoshikawa Y, Motoya T, Takeda Y, Yamada K. Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci. 97: 1260-1266 (2006). *

• Shinoda M, Tanaka Y, Kuno T, Matsufuji T, Matsufuji S, Murakami Y, Mizutani T. High levels of autoantibodies against drug-metabolizing enzymes in SLA/LP-positive AIH-1 sera. Autoimmunity 37: 473-480 (2004).

• Shirasaka Y, Onishi Y, Sakurai A, Nakagawa H, Ishikawa T, Yamashita S. Evaluation of human P-glycoprotein (MDR1/ABCB1) ATPase activity assay method by comparing with in vitro transport measurements: Michaelis-Menten kinetic analysis to estimate the affinity of P-glycoprotein to drugs. Biol. Pharm. Bull. 29: 2465-2471 (2006). *

• Shoda J, Kano M, Oda K, Kamiya J, Nimura Y, Suzuki H, Sugiyama Y, Miyazaki H, Todoroki T, Stengelin S, Kramer W, Matsuzaki Y, Tanaka N. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am. J. Gastroenterol. 96: 3368-3378 (2001). *

• Shoda J, Miura T, Utsunomiya H, Oda K, Yamamoto M, Kano M, Ikegami T, Tanaka N, Akita H, Ito K, Suzuki H, Sugiyama Y. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. Hepatology 39: 167-178 (2004). *

• Shoda J, Okada K, Inada Y, Kusama H, Utsunomiya H, Oda K, Yokoi T, Yoshizato K, Suzuki H. Bezafibrate induces multidrug-resistance P-glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol. Res. 37: 548-556 (2007). *

• Shoda J, Suzuki H, Suzuki H, Sugiyama Y, Hirouchi M, Utsunomiya H, Oda K, Kawamoto T, Matsuzaki Y, Tanaka N. Novel mutations identified in the human multidrug resistance-associated protein 2 (MRP2/ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. Hepatol. Res. 27: 323-326 (2003).

• Sidler Pfandler MA, Hochli M, Inderbitzin D, Meier PJ, Stieger B. Small hepatocytes in culture develop polarized transporter expression and differentiation. J. Cell. Sci. 117: 4077-4087 (2004). *

• Siemanowski B, Regueiro M. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 10: 178-184 (2007).

• Siewert E, Dietrich CG, Lammert F, Heinrich PC, Matern S, Gartung C, Geier A. Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem. Biophys. Res. Commun. 322: 232-238 (2004). *

• Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40 Suppl.: S13-S19 (1997). *

• Sills GJ, Brodie MJ. Response: lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 47: 450 (2006). *

• Silva CL, Bonato VL, dos Santos-Junior RR, Zarate-Blades CR, Sartori A. Recent advances in DNA vaccines for autoimmune diseases. Expert Rev. Vaccines 8: 239-252 (2009).

• Silva ML, Espírito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype-Magalhaes V, Caminha RC, de Andrade Maranhao-Filho P, Martins MA, de Menezes Martins R, Galler R, Freire MD, Marcovistz R, Homma A, Teuwen DE, Eloi-Santos SM, Andrade MC, et al. Clinical and immunological insights on severe adverse neurotropic/viscerotropic disease following 17D yellow fever vaccination. Clin. Vaccine Immunol. Nov 11 [Epub ahead of print] (2009). *

• Silva VM, Thibodeau MS, Chen C, Manautou JE. Transport deficient (TR(-)) hyperbilirubinemic rats are resistant to acetaminophen hepatotoxicity. Biochem. Pharmacol. 70: 1832-1839 (2005). *

• Silverman JA, Thorgeirsson SS. Regulation and function of the multidrug resistance genes in liver. Prog. Liver Dis. 13: 101-123 (1995).

• Simon FR, Iwahashi M, Hu LJ, Qadri I, Arias IM, Ortiz D, Dahl R, Sutherland E. Hormonal regulation of hepatic multidrug resistance-associated protein 2 (Abcc2) primarily involves the pattern of growth hormone secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G595-G608 (2006). *

• Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 26: 5674-5679 (2007). *

• Singh P, Paul K. Studies of interactions between uracil-based hybrid molecules and P-glycoprotein. Search for multidrug resistance modulators. Bioorg. Med. Chem. 14: 7183-7186 (2006). *

• Sinues B, Vicente J, Fanlo A, Mayayo-Sinues E, Gonzalez-Andrade F, Sanchez-Q D, Martinez-Jarreta B. CYP3A5*3, CYP3A4*1B and MDR1 C3435T genotype distributions in Ecuadorians. Dis. Markers 24: 325-331 (2008).

• Situ D, Haimeur A, Conseil G, Sparks KE, Zhang D, Deeley RG, Cole SP. Mutational analysis of ionizable residues proximal to the cytoplasmic Interface of membrane spanning domain 3 of the multidrug resistance protein, MRP1 (ABCC1). Glutamate1204 is important for both the expression and catalytic activity of the transporter. J. Biol. Chem. 279: 38871-38880 (2004). *

• Slitt AL, Allen K, Morrone J, Aleksunes LM, Chen C, Maher JM, Manautou JE, Cherrington NJ, Klaassen CD. Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. Biochim. Biophys. Acta 1768: 637-647 (2007). *

• Slitt AL, Cherrington N, Fisher C, Negishi M, Klaassen CD. Induction of genes for metabolism and transport by trans-stilbene oxide in livers of Sprague-Dawley and Wistar-Kyoto Rats. Drug Metab. Dispos. 34: 1190-1197 (2006). *

• Slitt AL, Cherrington NJ, Dieter MZ, Huang W, Aleksunes LM, Scheffer GL, Moore DD, Klaassen CD. Trans-stilbene oxide induces expression of genes involved in metabolism and disposition in mouse liver via CAR and Nrf2 transcription factors. Mol. Pharmacol. 69: 1554-1563 (2006). *

• Slitt AL, Cherrington NJ, Maher JM, Klaassen CD. Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. Drug Metab. Dispos. 31: 1176-1186 (2003). *

• Smeets PH, van Aubel RA, Wouterse AC, van den Heuvel JJ, Russel FG. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J. Am. Soc. Nephrol. 15: 2828-2835 (2004). *

• Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451-462 (1993).

• Smith AJ, de Vree JM, Ottenhoff R, Oude Elferink RP, Schinkel AH, Borst P. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (-/-) mice. Hepatology 28: 530-536 (1998). *

• Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, Varadi A, Sarkadi B, Borst P. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem. 275: 23530-23539 (2000). *

• Solazzo M, Fantappie O, Lasagna N, Sassoli C, Nosi D, Mazzanti R. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp. Cell Res. 312: 4070-4078 (2006). *

• Song IS, Lee YM, Chung SJ, Shim CK. Multiple alterations of canalicular membrane transport activities in rats with CCl(4)-induced hepatic injury. Drug Metab. Dispos. 31: 482-490 (2003). *

• Song X, Xie M, Zhang H, Li Y, Sachdeva K, Yan B. The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes. Drug Metab. Dispos. 32: 35-42 (2004). *

• Sonoda J, Evans RM. Biological function and mode of action of nuclear xenobiotic receptors. Pure Appl. Chem. 75: 1733-1742 (2003). *

• Sood R, Bhadauriya T, Rao M, Gautam R, Malhotra S, Barman TK, Upadhyay DJ, Rattan A. Antimycobacterial activities of oxazolidinones: a review. Infect. Disord. Drug Targets 6: 343-354 (2006).

• Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33: 783-791 (2001). *

• Soroka CJ, Mennone A, Hagey LR, Ballatori N, Boyer JL. Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis. Hepatology 51: 181-190 (2010). *

• Sparanese D, Lee CH. CRD-BP shields c-myc and MDR-1 RNA from endonucleolytic attack by a mammalian endoribonuclease. Nucleic Acids Res. 35: 1209-1221 (2007). *

• Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. 6: 71-84 (2003).

• Spiewak M, Malek LA, Kostrzewa G, Kisiel B, Serafin A, Filipiak KJ, Ploski R, Opolski G. Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndroms. Kardiol. Pol. 67: 827-834 (2009).

• Srinivas E, Murthy JN, Rao AR, Sastry GN. Recent advances in molecular modeling and medicinal chemistry aspects of phospho-glycoprotein. Curr. Drug Metab. 7: 205-217 (2006).

• St-Pierre MV, Stallmach T, Freimoser Grundschober A, Dufour JF, Serrano MA, Marin JJ, Sugiyama Y, Meier PJ. Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287: R1505-R1516 (2004). *

• Staley EM, Schoeb TR, Lorenz RG. Differential susceptibility of P-glycoprotein deficient mice to colitis induction by environmental insults. Inflamm. Bowel Dis. 15: 684-696 (2009).

• Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int. J. Colorectal Dis. 19: 308-315 (2003). *

• Stark M, Rothem L, Jansen G, Scheffer GL, Goldman ID, Assaraf YG. Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol. Pharmacol. 64: 220-227 (2003). *

• Staudinger JL, Madan A, Carol KM, Parkinson A. Regulation of drug transporter gene expression by nuclear receptors. Drug Metab. Dispos. 31: 523-527 (2003). *

• Stearns AT, Balakrishnan A, Rhoads DB, Ashley SW, Tavakkolizadeh A. Diurnal rhythmicity in the transcription of jejunal drug transporters. J. Pharmacol. Sci. 108: 144-148 (2008). *

• Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, Evans RM, Downes M. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl. Acad. Sci. U.S.A. 103: 11323-11328 (2006). *

• Stege A, Priebsch A, Nieth C, Lage H. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther. 11: 699-706 (2004).

• Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia 21: 1172-1176 (2007).

• Stephens RH, O'Neill CA, Bennett J, Humphrey M, Henry B, Rowland M, Warhurst G. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice. Br. J. Pharmacol. 135: 2038-3046 (2002). *

• Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118: 422-430 (2000). *

• Stomskaya TP, Rybalkina EY, Zabotina TN, Shishkin AA, Stavrovskaya AA. Influence of RARa gene on MDR1 expression and P-glycoprotein function in human leukemic cells. Cancer Cell Int. 5: 15 (2005). *

• Struk B, Cai L, Zach S, Ji W, Chung J, Lumsden A, Stumm M, Huber M, Schaen L, Kim CA, Goldsmith LA, Viljoen D, Figuera LE, Fuchs W, Munier F, Ramesar R, Hohl D, Richards R, Neldner KH, Lindpaintner K. Mutations of the gene encoding the transmembrane transporter protein ABC-C6 cause pseudoxanthoma elasticum. J. Mol. Med. 78: 282-286 (2000). *

• Sturm A, Cunningham P, Dean M. The ABC transporter gene family of Daphnia pulex. BMC Genomics 10: 170 (2009). *

• Su Y, Lee SH, Sinko PJ. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance. Eur. J. Pharm. Sci. 29: 102-110 (2006). *

• Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Sugimura H, Ishizaki T, Hishida A. MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese. Life Sci. 83: 301-304 (2008). *

• Sukhai M, Yong A, Kalitsky J, Piquette-Miller M. Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b genes. Mol. Cell. Biol. Res. Commun. 4: 248-256 (2000). *

• Sundaram SS, Sokol RJ. The multiple facets of ABCB4 (MDR3) deficiency. Curr. Treat. Options Gastroenterol. 10: 495-503 (2007).

• Sunder-Plassmann R, Rieger S, Endler G, Brunner M, Muller M, Mannhalter C. Simultaneous analysis of MDR1 C3435T, G2677T/A, and C1236T genotypes by multiplexed mutagenically separated PCR. Clin. Chem. Lab. Med. 43: 192-194 (2005). *

• Suresh N, Singh UB, Arora J, Pant H, Seth P, Sola C, Rastogi N, Samantaray JC, Pande JN. rpoB gene sequencing and spoligotyping of multidrug-resistant Mycobacterium tuberculosis isolates from India. Infect. Genet. Evol. 6: 474-483 (2006).

• Suzuki C, Sano N, Takikawa H. Effect of dexamethasone on biliary excretion of bile acids and organic anions in rats. Hepatol. Res. 25: 48-54 (2003). *

• Suzuki H. Analysis of xenobiotic detoxification system mediated by efflux transporters. Yakugaku Zasshi 119: 822-834 (1999).

• Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 66: 10120-10126 (2006). *

• Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 7: 584-590 (2001). *

• Szabo D, Richardson V, Ross D, Diliberto J, Kodavanti P, Birnbaum L. Effects of perinatal PBDE exposure on hepatic phase I, phase II, phase III and deiodinase 1 gene expression involved in thyroid hormone metabolism in male rat pups. Toxicol. Sci. 107: 27-39 (2009). *

• Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM. Predicting drug sensitivity and resistance; profiling ABC transporter genes in cancer cells. Cancer Cell 6: 129-137 (2004). *

• Szentpetery Z, Kern A, Liliom K, Sarkadi B, Varadi A, Bakos E. The role of the conserved glycines of ATP-binding cassette signature motifs of MRP1 in the communication between the substrate-binding site and the catalytic centers. J. Biol. Chem. 279: 41670-41678 (2004). *

• Szentpetery Z, Sarkadi B, Bakos E, Varadi A. Functional studies on the MRP1 multidrug transporter: characterization of ABC-signature mutant variants. Anticancer Res. 24: 449-455 (2004).

• Tabe Y. Molecular diagnosis of and molecular targeting therapy for leukemia. Rinsho Byori 57: 137-145 (2009).

• Tahara T, Arisawa T, Shibata T, Hirata I, Nakano H. Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J. Gastroenterol. Hepatol. 22: 1678-1682 (2007). *

• Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, Maruyama N, Kamano T, Kamiya Y, Nakagawa Y, Fujita H, Nagasaka M, Iwata M, Takahama K, Watanabe M, Hirata I, Arisawa T. Effect of MDR1 gene promoter methylation in patients with ulcerative colitis. Int. J. Mol. Med. 23: 521-527 (2009).

• Tai HL. Technology evaluation: Valspodar, Novartis AG. Curr. Opin. Mol. Ther. 2: 459-467 (2000).

• Takada T, Weiss M, Kretz O, Gross G, Sugiyama Y. Hepatic transport of PKI166 - an epidermal growth factor receptor kinase inhibitor of the pyrrolo-pyrimidine class - and its main metabolite ACU154. Drug Metab. Dispos. 32: 1272-1278 (2004). *

• Takahashi K, Hasegawa Y, Abe T, Yamamoto T, Nakashima K, Imaizumi K, Shimokata K. SLC11A1 (formerly NRAMP1) polymorphisms associated with multidrug-resistant tuberculosis. Tuberculosis (Edinb.) 88: 52-57 (2008).

• Takahashi M, Sakurai M, Enosawa S, Omasa T, Tsuruoka S, Matsumura T. Double-compartment cell culture apparatus: construction and biochemical evaluation for bioartificial liver support. Cell. Transplant. 15: 945-952 (2006).

• Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K, Ieiri I. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J. Pharmacol. Exp. Ther. 311: 1179-1187 (2004). *

• Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Leggas M, Ejendal KF, Hrycyna CA, Schuetz JD. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res. 67: 6965-6972 (2007). *

• Takeshita A, Inagaki K, Igarashi-Migitaka J, Ozawa Y, Koibuchi N. The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells. J. Endocrinol. 190: 897-902 (2006). *

• Takeuchi H, Greep NC, Hoon DS, Giuliano AE, Hansen NM, Umetani N, Singer FR. Hypermethylation of ABC transporter genes in primary hyperparathyroidism and its effect on sestamibi imaging. J. Clin. Endocrinol. Metab. 92: 1785-1790 (2007). *

• Takeyama Y, Uehara Y, Inomata S, Morihara D, Nishizawa S, Ueda S, Matsumoto T, Tanaka T, Anan A, Nishimura H, Irie M, Iwata K, Shakado S, Sohda T, Sakisaka S. Alternative transporter pathways in patients with untreated early-stage and late-stage primary biliary cirrhosis. Liver Int. 29: 406-414 (2009). *

• Takigawa N, Tanimoto M. Vinca alkaloid and MDR1. Gan To Kagaku Ryoho 35: 1086-1089 (2008).

• Takikawa H. Organic anion carriers. Nippon Rinsho 54: 646-651 (1996).

• Takikawa H. Hepatobiliary transport of bile acids and organic anions. J. Hepatobiliary Pancreat. Surg. 9: 443-447 (2002).

• Tanaka Y, Aleksunes LM, Cui YJ, Klaassen CD. ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2 dependent and independent signaling. Toxicol. Sci. 108: 247-257 (2009). *

• Tanaka Y, Chen C, Maher JM, Klaassen CD. Kupffer cell-mediated downregulation of hepatic transporter expression in rat hepatic ischemia-reperfusion. Transplantation 82: 258-266 (2006).

• Tanaka Y, Chen C, Maher JM, Klaassen CD. Ischemia-reperfusion of rat livers decreases liver and increases kidney multidrug resistance-associated protein 2 (Mrp2). Toxicol. Sci. 101: 171-178 (2008). *

• Tanaka Y, Kobayashi Y, Gabazza EC, Higuchi K, Kamisako T, Kuroda M, Takeuchi K, Iwasa M, Kaito M, Adachi Y. Increased renal expression of bilirubin glucuronide transporters in a rat model of obstructive jaundice. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G656-G662 (2002). *

• Tanaka Y, Tsujimura S. Multi-drug resistance in the treatments of autoimmune diseases. Nihon Rinsho Meneki Gakkai Kaishi 29: 319-324 (2006).

• Tanaka Y, Yoshikawa M, Kobayashi Y, Kuroda M, Kaito M, Shiroi A, Yamao J, Fukui H, Ishizaka S, Adachi Y. Expressions of hepatobiliary organic anion transporters and bilirubin-conjugating enzyme in differentiating embryonic stem cells. Biochem. Biophys. Res. Commun. 309: 324-330 (2003). *

• Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12: 437-450 (2002).

• Tang K, Wong LP, Lee EJ, Chong SS, Lee CG. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum. Mol. Genet. 13: 783-797 (2004). *

• Tang PM, Chan JY, Zhang DM, Au SW, Fong WP, Kong SK, Tsui SK, Waye MM, Mak TC, Fung KP. Pheophorbide a, an active component in Scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2. Cancer Biol. Ther. 6: 504-509 (2007). *

• Tang W, Yi C, Kalitsky J, Piquette-Miller M. Endotoxin downregulates hepatic expression of P-glycoprotein and MRP2 in 2-acetylaminofluorene-treated rats. Mol. Cell. Biol. Res. Commun. 4: 90-97 (2000).

• Taniguchi S, Mochida Y, Uchiumi T, Tahira T, Hayashi K, Takagi K, Shimada M, Maehara Y, Kuwano H, Kono S, Nakano H, Kuwano M, Wada M. Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol. Cancer Ther. 2: 1351-1359 (2003). *

• Tannert A, Pohl A, Pomorski T, Herrmann A. Protein-mediated transbilayer movement of lipids in eukaryotes and prokaryotes: the relevance of ABC transporters. Int. J. Antimicrob. Agents 22: 177-187 (2003). *

• Tatari F, Salek R, Mosaffa F, Khedri A, Behravan J. Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population. DNA Cell Biol. 28: 259-263 (2009).

• Tazuke Y, Kiristioglu I, Heidelberger KP, Eisenbraun MD, Teitelbaum DH. Hepatic P-glycoprotein changes with total parenteral nutrition administration. JPEN J. Parenter. Enteral Nutr. 28: 1-6 (2004). *

• ten Hove T, Drillenburg P, Wijnholds J, Te Velde AA, van Deventer SJ. Differential susceptibility of multidrug resistance protein-1 deficient mice to DSS and TNBS-induced colitis. Dig. Dis. Sci. 47: 2056-2063 (2002). *

• Teng S, Jekerle V, Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab. Dispos. 31: 1296-1299 (2003). *

• Teng S, Piquette-Miller M. Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br. J. Pharmacol. 151: 367-376 (2007). *

• Teng S, Piquette-Miller M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J. Pharmacol. Exp. Ther. 312: 841-848 (2005). *

• Teo JW, Thayalan P, Beer D, Yap AS, Nanjundappa M, Ngew X, Duraiswamy J, Liung S, Dartois V, Schreiber M, Hasan S, Cynamon M, Ryder NS, Yang X, Weidmann B, Bracken K, Dick T, Mukherjee K. Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob. Agents Chemother. 50: 3665-3673 (2006). *

• Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets 7: 893-909 (2006).

• Teodori E, Martelli C, Salerno M, Darghal N, Dei S, Garnier-Suillerot A, Gualtieri F, Manetti D, Scapecchi S, Romanelli MN. Isomeric N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors. J. Med. Chem. 50: 599-602 (2007). *

• Terra-Bustamante VC, Machado HR, Dos Santos Oliveira R, Serafini LN, Souza-Oliveira C, Escorsi-Rosset S, Yacubian EM, Naffah-Mazzacoratti MD, Scorza CA, Cavalheiro EA, Scorza FA, Sakamoto AC. Rasmussen encephalitis: long-term outcome after surgery. Childs Nerv. Syst. 25: 583-589 (2009).

• Thakur JK, Arthanari H, Yang F, Pan SJ, Fan X, Breger J, Frueh DP, Gulshan K, Li DK, Mylonakis E, Struhl K, Moye-Rowley WS, Cormack BP, Wagner G, Naar AM. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 452: 604-609 (2008). *

• Theodoulou FL. Plant ABC transporters. Biochim. Biophys. Acta 1465: 79-103 (2000). *

• Thompson R. Genetics of hereditary cholestatic and metabolic liver diseases. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 41 (2006). *

• Thornton SJ, Wong E, Lee SD, Wasan KM. Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice: implications for cholesterol metabolism. Lipids Health Dis. 7: 21 (2008). *

• Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, Brouwer KL. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob. Agents Chemother. 51: 3230-3234 (2007). *

• Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky M, Kruh G, Brouwer KL. Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab. Dispos. 36: 911-915 (2008). *

• Tian X, Zamek-Gliszczynski MJ, Zhang P, Brouwer KL. Modulation of multidrug resistance-associated protein 2 (mrp2) and mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Mol. Pharmacol. 66: 1004-1010 (2004). *

• Tietz P, Jefferson J, Pagano R, LaRusso NF. Membrane microdomains in hepatocytes: potential target areas for proteins involved in canalicular bile secretion. J. Lipid Res. 46: 1426-1432 (2005). *

• Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y, Adachi Y, Sakisaka S, Kuwano M. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 64: 739-746 (1999). *

• Tolson AH, Li H, Eddington ND, Wang H. Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug Metab. Dispos. 37: 1887-1894 (2009). *

• Tombline G, Bartholomew LA, Tyndall GA, Gimi K, Urbatsch IL, Senior AE. Properties of P-glycoprotein with mutations in the "catalytic carboxylate" glutamate residues. J. Biol. Chem. 279: 46518-46526 (2004). *

• Tombline G, Bartholomew LA, Urbatsch IL, Senior AE. Combined mutation of catalytic glutamate residues in the two nucleotide binding domains of P-glycoprotein generates a conformation that binds ATP and ADP tightly. J. Biol. Chem. 279: 31212-31220 (2004). *

• Tomer G, Ananthanarayanan M, Weymann A, Balasubramanian N, Suchy FJ. Differential developmental regulation of rat liver canalicular membrane transporters Bsep and Mrp2. Pediatr. Res. 53: 288-294 (2003). *

• Tomita M, Takizawa Y, Kishimoto H, Hayashi M. Assessment of ileal epithelial P-glycoprotein dysfunction induced by ischemia/reperfusion using in vivo animal model. Drug Metab. Pharmacokinet. 23: 356-363 (2008). *

• Torrence AE, Brabb T, Viney JL, Bielefeldt-Ohmann H, Treuting P, Seamons A, Drivdahl R, Zeng W, Maggio-Price L. Serum biomarkers in a mouse model of bacterial-induced inflammatory bowel disease. Inflamm. Bowel Dis. 14: 480-490 (2008). *

• Toti F, Schindler V, Riou JF, Lombard-Platet G, Fressinaud E, Meyer D, Uzan A, Le Pecq JB, Mandel JL, Freyssinet JM. Another link between phospholipid transmembrane migration and ABC transporter gene family, inferred from a rare inherited disorder of phosphatidylserine externalization. Biochem. Biophys. Res. Commun. 241: 548-552 (1997). *

• Toyoda Y, Hagiya Y, Adachi T, Hoshijima K, Kuo MT, Ishikawa T. MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica 38: 833-862 (2008). *

• Tradtrantip L, Piyachaturawat P, Soroka C, Harry K, Mennone A, Mahagita C, Ballatori N, Boyer JL. Phloracetophenone-induced choleresis in rats is mediated through Mrp2. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G66-G74 (2007). *

• Tran-Paterson R, Davin D, Krauss RD, Rado TA, Miller DM. Expression and regulation of the cystic fibrosis gene during rat liver regeneration. Am. J. Physiol. 263: C55-C60 (1992).

• Trauner M. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope? Hepatology 40: 260-263 (2004). *

• Trauner M. Molecular mechanisms of cholestasis. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 64-65 (2005). *

• Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, Suchy FJ, Keppler D, Boyer JL. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113: 255-264 (1997). *

• Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83: 633-671 (2003). *

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 20: 220-230 (2004). *

• Trauner M, Fickert P, Halilbasic E, Moustafa T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien. Med. Wochenschr. 158: 542-548 (2008). *

• Trauner M, Fickert P, Lammert F, Marschall HU. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 126: 1222-1223 (2004). *

• Trauner M, Fickert P, Moustafa T, Guelly C, Fuchsbichler A, Denk H, Wagner M, Zollner G. Side chain-shortened bile acids for the treatment of cholestasis: lessons from nor-ursodeoxycholic acid. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 77-78 (2006). *

• Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin. Liver Dis. 27: 77-98 (2007). *

• Trauner M, Fickert P, Wagner M, Zollner G. Adaptive hepatobiliary transporter regulation by ursodeoxycholic acid. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 48-49. June 18-19 (2004). *

• Trezise AE, Ratcliff R, Hawkins TE, Evans MJ, Freeman TC, Romano PR, Higgins CF, Colledge WH. Co-ordinate regulation of the cystic fibrosis and multidrug resistance genes in cystic fibrosis knockout mice. Hum. Mol. Genet. 6: 527-537 (1997). *

• Trezise AE, Romano PR, Gill DR, Hyde SC, Sepulveda FV, Buchwald M, Higgins CF. The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J. 11: 4291-4303 (1992). *

• Trombone AP, Ferreira Jr SB, Raimundo FM, de Moura KC, Avila-Campos MJ, Silva JS, Campanelli AP, De Franco M, Garlet GP. Experimental periodontitis in mice selected for maximal or minimal inflammatory reactions: increased inflammatory immune responsiveness drives increased alveolar bone loss without enhancing the control of periodontal infection. J. Periodontal Res. 44: 443-451 (2009).

• Troost J, Lindenmaier H, Haefeli WE, Weiss J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug resistant cells. Mol. Pharmacol. 66: 1332-1339 (2004). *

• Tsakovska I, Pajeva I. Phenothiazines and structurally related compounds as modulators of cancer multidrug resistance. Curr. Drug Targets 7: 1123-1134 (2006).

• Tsuboi K, Tazuma S, Nishioka T, Chayama K. Partial characterization of cytoprotective mechanisms of lecithin against bile salt-induced bile duct damage. J. Gastroenterol. 39: 955-960 (2004). *

• Tsuboi K, Tazuma S, Ochi H, Chayama K. Hydrophilic bile salts have a cytoprotective effect against cyclosporine A-induced cholestasis through enhanced canalicular membrane fluidity and transporter activity. Hepatol. Res. 25: 38-47 (2003). *

• Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78: 1182-1187 (2004).

• Tsuda-Tsukimoto M, Maeda T, Iwanaga T, Kume T, Tamai I. Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharm. Res. 23: 2646-2656 (2006). *

• Tsujimura S, Saito K, Kohno K, Tanaka Y. Fragmented hyaluronan induces transcriptional up-regulation of the multidrug resistance-1 gene in CD4+ T cells. J. Biol. Chem. 281: 38089-38097 (2006). *

• Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, Tanaka Y. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells 9: 1265-1273 (2004). *

• Tsujimura S, Saito K, Nakayamada S, Tanaka Y. Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus. Histol. Histopathol. 22: 465-468 (2007).

• Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U, Karadag O, Hayran M, Ertenli AI, Bozkurt A, Kiraz S. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J. Rheumatol. 34: 1540-1544 (2007). *

• Turella P, Filomeni G, Dupuis ML, Ciriolo MR, Molinari A, De Maria F, Tombesi M, Cianfriglia M, Federici G, Ricci G, Caccuri AM. A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein mediated resistance in tumor cells. NBDHEX triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells. J. Biol. Chem. 281: 23725-23732 (2006). *

• Turgut G, Bastemir M, Turgut S, Akin F, Kursunluoglu R, Kaptanoglu B. P-Glycoprotein polymorphism in hypo- and hyper-thyroidism patients. Mol. Biol. Rep. 35: 693-698 (2008). *

• Turgut G, Kurt E, Sengul C, Alatas G, Kursunluoglu R, Oral T, Turgut S, Herken H. Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Mol. Biol. Rep. 36: 495-499 (2009). *

• Turgut S, Turgut G, Atalay EO. Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey. Mol. Biol. Rep. 33: 295-300 (2006). *

• Turgut S, Yaren A, Kursunluoglu R, Turgut G. MDR1 C3435T polymorphism in patients with breast cancer. Arch. Med. Res. 38: 539-544 (2007).

• Turncliff RZ, Meier PJ, Brouwer KL. Effect of dexamethasone treatment on the expression and function of transport proteins in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 32: 834-839 (2004). *

• Turncliff RZ, Tian X, Brouwer KL. Effect of culture conditions on the expression and function of Bsep, Mrp2, and Mdr1a/b in sandwich-cultured rat hepatocytes. Biochem. Pharmacol. 71: 1520-1529 (2006). *

• Ueda K, Yoshida A, Amachi T. Recent progress in P-glycoprotein research. Anticancer Drug Des. 14: 115-121 (1999).

• Umehara KI, Iwai M, Adachi Y, Iwatsubo T, Usui T, Kamimura H. Hepatic uptake and excretion of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans. Drug Metab. Dispos. 36: 1030-1038 (2008). *

• Uno Y, Sakamoto Y, Yoshida K, Hasegawa T, Hasegawa Y, Koshino T, Inoue I. Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter. J. Hum. Genet. 48: 594-597 (2003). *

• Urbatsch IL, Gimi K, Wilke-Mounts S, Senior AE. Investigation of the role of glutamine-471 and glutamine-1114 in the two catalytic sites of P-glycoprotein. Biochemistry 39: 11921-11927 (2000). *

• Urbatsch IL, Julien M, Carrier I, Rousseau ME, Cayrol R, Gros P. Mutational analysis of conserved carboxylate residues in the nucleotide binding sites of P-glycoprotein. Biochemistry 39: 14138-14149 (2000). *

• Urcelay E, Mendoza JL, Martin MC, Mas A, Martinez A, Taxonera C, Fernandez-Arquero M, Diaz-Rubio M, Concha EG. MDR1 gene: susceptibility in Spanish Crohn's disease and ulcerative colitis patients. Inflamm. Bowel Dis. 12: 33-37 (2006). *

• Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47: 566-578 (2007). *

• Valente RC, Capella LS, Nascimento CR, Lopes AG, Capella MA. Modulation of multidrug resistance protein (MRP1/ABCC1) expression: a novel physiological role for ouabain. Cell Biol. Toxicol. 23: 421-427 (2007). *

• Valverde MA, Bond TD, Hardy SP, Taylor JC, Higgins CF, Altamirano J, Alvarez-Leefmans FJ. The multidrug resistance P-glycoprotein modulates cell regulatory volume decrease. EMBO J. 15: 4460-4468 (1996). *

• Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF. Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 355: 830-833 (1992). *

• van Aubel RA, Smeets PH, Van Den Heuvel JJ, Russel FG. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal Physiol. 288: F327-F333 (2005). *

• van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab. Dispos. 36: 604-613 (2008). *

• van de Ven R, Oerlemans R, van der Heijden JW, Scheffer GL, de Gruij TD, Jansen G, Scheper RJ. ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J. Leukoc. Biol. 86: 1075-1087 (2009). *

• van de Ven R, Scheffer GL, Reurs AW, Lindenberg JJ, Oerlemans R, Jansen G, Gillet JP, Glasgow JN, Pereboev A, Curiel DT, Scheper RJ, de Gruijl TD. A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. Blood 112: 2353-2359 (2008). *

• van de Ven R, Scheffer GL, Scheper RJ, de Gruijl TD. The ABC of dendritic cell development and function. Trends Immunol. 30: 421-429 (2009). *

• van de Wetering K, Feddema W, Helms JB, Brouwers JF, Borst P. Targeted netabolomics identifies glucuronides of dietary phytoestrogens as a major class of MRP3 substrates in vivo. Gastroenterology 137: 1725-1735 (2009). *

• van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, Vellenga E, Ossenkoppele GJ, Lowenberg B, Sonneveld P. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann. Hematol. 86: 329-337 (2007). *

• van der Deen M, de Vries EG, Timens W, Scheper RJ, Timmer-Bosscha H, Postma DS. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir. Res. 6: 59 (2005). *

• van der Deen M, Timens W, Timmer-Bosscha H, van der Strate BW, Scheper RJ, Postma DS, de Vries EG, Kerstjens HA. Reduced inflammatory response in cigarette smoke exposed Mrp1/Mdr1a/1b deficient mice. Respir. Res. 8: 49 (2007). *

• van Erpecum KJ. Biliary lipids, water and cholesterol gallstones. Biol. Cell. 97: 815-822 (2005). *

• van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87: 507-517 (1996). *

• Van Limbergen J, Russell RK, Nimmo ER, Ho GT, Arnott ID, Wilson DC, Satsangi J. Genetics of the innate immune response in inflammatory bowel disease. Inflamm. Bowel Dis. 13: 338-355 (2007). *

• Van Luyn MJ, Muller M, Renes J, Meijer C, Scheper RJ, Nienhuis EF, Mulder NH, Jansen PL, De Vries EG. Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1. Int. J. Cancer 76: 55-62 (1998). *

• van Nieuwerk CM, Groen AK, Ottenhoff R, van Wijland M, van den Bergh Weerman MA, Tytgat GN, Offerhaus JJ, Oude Elferink RP. The role of bile salt composition in liver pathology of mdr2 (-/-) mice: differences between males and females. J. Hepatol. 26: 138-145 (1997). *

• Van Nieuwkerk CM, Oude Elferink RP, Groen AK, Ottenhoff R, Tytgat GN, Dingemans KP, Van Den Bergh Weerman MA, Offerhaus GJ. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 111: 165-171 (1996). *

• van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 67: 4843-4850 (2007). *

• vanBerge-Henegouwen GP, Venneman NG, Portincasa P, Kosters A, van Erpecum KJ, Groen AK. Relevance of hereditary defects in lipid transport proteins for the pathogenesis of cholesterol gallstone disease. Scand. J. Gastroenterol. Suppl. 241: 60-69 (2004). *

• Vander Borght S, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, Verslype C, Nevens F, Roskams T. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 28: 1370-1380 (2008). *

• Vander Borght S, van Pelt J, van Malenstein H, Cassiman D, Renard M, Verslype C, Libbrecht L, Roskams TA. Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: a study in patients and in vitro. Hepatol. Res. 38: 1112-1121 (2008). *

• Velez DR, White BC, Motsinger AA, Bush WS, Ritchie MD, Williams SM, Moore JH. A balanced accuracy function for epistasis modeling in imbalanced datasets using multifactor dimensionality reduction. Genet. Epidemiol. 31: 306-315 (2007).

• Verkade HJ, Havinga R, Shields DJ, Wolters H, Bloks VW, Kuipers F, Vance DE, Agellon LB. The phosphatidylethanolamine N-methyltransferase pathway is quantitatively not essential for biliary phosphatidylcholine secretion. J. Lipid Res. 48: 2058-2064 (2007). *

• Vermeulen SH, Den Heijer M, Sham P, Knight J. Application of multi-locus analytical methods to identify interacting loci in case-control studies. Ann. Hum. Genet. 71: 689-700 (2007). *

• Vicente J, Sinues B, Fanlo A, Vasquez P, Medina JC, Martinez-Jarreta B. Polymorphism C3435T of the MDR1 gene in Central Americans and Spaniards. Mol. Biol. Rep. 35: 473-478 (2008). *

• Vierling JM. Primary sclerosing cholangitis: is autoimmunity involved in pathogenesis? Falk Symposium 142. GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), pp. 43-44. October 12-13 (2004). *

• Villanueva SS, Ruiz ML, Luquita MG, Sanchez Pozzi EJ, Catania VA, Mottino AD. Involvement of MRP2 in hepatic and intestinal disposition of dinitrophenyl-S-glutathione in partially hepatectomized rats. Toxicol. Sci. 84: 4-11 (2005). *

• Villanueva SS, Ruiz ML, Soroka CJ, Cai SY, Luquita MG, Torres AM, Sanchez Pozzi EJ, Pellegrino JM, Boyer JL, Catania VA, Mottino AD. Hepatic and extrahepatic synthesis and disposition of dinitrophenyl-S-glutathione in bile duct ligated rats. Drug Metab. Dispos. 34: 1301-1309 (2006). *

• Vincent M, Gallay J, Jamin N, Garrigos M, de Foresta B. The predicted transmembrane fragment 17 of the human multidrug resistance protein 1 (MRP1) behaves as an interfacial helix in membrane mimics. Biochim. Biophys. Acta 1768: 538-552 (2007). *

• Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Oude Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH. Carcinogen and anti-cancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J. Pharmacol. Exp. Ther. 318: 319-327 (2006). *

• Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13: 1042-1049 (2007). *

• Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297: 1568-1576 (2007). *

• von Wedel-Parlow M, Wolte P, Galla HJ. Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. J. Neurochem. 111: 111-118 (2009).

• Vore M, Gerk P. Activation of MRP2 transport by ursodeoxycholic acid (UDCA) and its amidates. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 60. June 18-19 (2004). *

• Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, Jansen PL, Muller M. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 28: 1637-1644 (1998). *

• Vos TA, Ros JE, Havinga R, Moshage H, Kuipers F, Jansen PL, Muller M. Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats. Hepatology 29: 1833-1839 (1999). *

• Voshol PJ, Havinga R, Wolters H, Ottenhoff R, Princen HM, Oude Elferink RP, Groen AK, Kuipers F. Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology 114: 1024-1034 (1998). *

• Voshol PJ, Koopen NR, de Vree JM, Havinga R, Princen HM, Oude Elferink RP, Groen AK, Kuipers F. Dietary cholesterol does not normalize low plasma cholesterol levels but induces hyperbilirubinemia and hypercholanemia in Mdr2 P-glycoprotein-deficient mice. J. Hepatol. 34: 202-209 (2001). *

• Wada M, Toh S, Taniguchi K, Nakamura T, Uchiumi T, Kohno K, Yoshida I, Kimura A, Sakisaka S, Adachi Y, Kuwano M. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum. Mol. Genet. 7: 203-207 (1998). *

• Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, Gonzalez FJ, Marschall HU, Denk H, Trauner M. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 125: 825-838 (2003). *

• Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42: 420-430 (2005). *

• Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Gujral J, Zatloukal K, Denk H, Jaeschke H, Trauner M. Hepatobiliary transporter expression in intercellular adhesion molecule 1 knockout and Fas receptor-deficient mice after common bile duct ligation is independent of the degree of inflammation and oxidative stress. Drug Metab. Dispos. 35: 1694-1699 (2007). *

• Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J. Hepatol. 51: 565-580 (2009). *

• Walsh C, Duffy G, O'Mahony R, Fanning S, Blair IS, McDowell DA. Antimicrobial resistance in Irish isolates of verocytotoxigenic Escherichia coli (E. coli)-VTEC. Int. J. Food Microbiol. 109: 173-178 (2006). *

• Walters JL, Buchholz AC, Martin Ginis KA. Evidence of dietary inadequacy in adults with chronic spinal cord injury. Spinal Cord 47: 318-322 (2009).

• Wang BL, Zhai HY, Chen BY, Zhai SP, Yang HY, Chen XP, Zhao WT, Meng L. Clinical relationship between MDR1 gene and gallbladder cancer. Hepatobiliary Pancreat Dis. Int. 3: 296-299 (2004). *

• Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics 15: 693-704 (2005).

• Wang H, Chen XP, Qiu FZ. Correlation of expression of multidrug resistance protein and messenger RNA with (99m)Tc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma. World J. Gastroenterol. 10: 1281-1285 (2004). *

• Wang H, Hao B, Zhou K, Chen X, Wu S, Zhou G, Zhu Y, He F. Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies. Ann. Hum. Genet. 68: 563-573 (2004). *

• Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 42: 1331-1357 (2003).

• Wang J, Chan JY, Fong CC, Tzang CH, Fung KP, Yang M. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines. Liver Int. 29: 1338-1347 (2009). *

• Wang J, Wicker LS, Santamaria P. IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity. Semin. Immunol. 21: 363-371 (2009). *

• Wang L, Chen L, Walker V, Jacob TJ. Antisense to MDR1 mRNA reduces P-glycoprotein expression, swelling-activated C1- current and volume regulation in bovine ciliary epithelial cells. J. Physiol. 511: 33-44 (1998). *

• Wang M, Wang M, Cheng G, Zhang Z, Fu G, Zhang Z. Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer. Mutat. Res. 661: 85-92 (2009).

• Wang R, Chen HL, Liu L, Sheps JA, Phillips MJ, Ling V. Compensatory role of P-glycoproteins in knockout mice lacking the bile salt export pump. Hepatology 50: 948-956 (2009). *

• Wang T, Ma X, Krausz KW, Idle JR, Gonzalez FJ. Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J. Pharmacol. Exp. Ther. 324: 674-684 (2008). *

• Wang W, Zhang XD, Guan DL, Lu YP, Ma LL, Hu XP, Zhang P, Wang Y, Chen X. Relationship between MDR1 polymorphism and blood concentration of cyclosporine A. Chin. Med. J. (Engl.) 118: 2097-2100 (2005).

• Wang Y, Wang C, Li J, Wang X, Zhu G, Chen X, Bi H, Huang M. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur. J. Clin. Pharmacol. 65: 239-247 (2009).

• Wang Z, Wang B, Tang K, Lee EJ, Chong SS, Lee CG. A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum. Mol. Genet. 14: 2075-2087 (2005). *

• Watanabe N, Takashimizu S, Kojima S, Kagawa T, Nishizaki Y, Mine T, Matsuzaki S. Clinical and pathological features of a prolonged type of acute intrahepatic cholestasis. Hepatol. Res. 37: 598-607 (2007). *

• Watanabe S, Yokoyama Y, Oda K, Kokuryo T, Shoda J, Okada K, Utsunomiya H, Nagino M. Choleretic effect of inchinkoto, a herbal medicine, on livers of patients with biliary obstruction due to bile duct carcinoma. Hepatol. Res. 39: 247-255 (2009). *

• Watkins RE, Noble SM, Redinbo MR. Structural insights into the promiscuity and function of the human pregnane X receptor. Curr. Opin. Drug Discov. Devel. 5: 150-158 (2002).

• Watts RN, Hawkins C, Ponka P, Richardson DR. Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proc. Natl. Acad. Sci. U.S.A. 103: 7670-7675 (2006). *

• Weersma RK, van Dullemen HM, van der Steege G, Nolte IM, Kleibeuker JH, Dijkstra G. Review article: inflammatory bowel disease and genetics. Aliment. Pharmacol. Ther. 26 Suppl. 2: 57-65 (2007). *

• Weihrauch D, Kanchanapoo J, Ao M, Prasad R, Piyachaturawat P, Rao MC. Weanling, but not adult, rabbit colon absorbs bile acids: flux is linked to expression of putative bile acid transporters. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G439-G450 (2006). *

• Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S, Agarwal V, Vernon A. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob. Agents Chemother. 51: 2861-2866 (2007). *

• Weismuller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis: aetiopathogenesis, autoimmunity, management and malignancy? J. Hepatol. 48: S38-S57 (2008). *

• Welch TJ, Fricke WF, McDermott PF, White DG, Rosso ML, Rasko DA, Mammel MK, Eppinger M, Rosovitz MJ, Wagner D, Rahalison L, Leclerc JE, Hinshaw JM, Lindler LE, Cebula TA, Carniel E, Ravel J. Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS ONE 2: e309 (2007). *

• Wesolowska O, Molnar J, Westman G, Samuelsson K, Kawase M, Ocsovszki I, Motohashi N, Michalak K. Benzo[a]phenoxazines: a new group of potent P-glycoprotein inhibitors. In Vivo 20: 109-113 (2006).

• Westerlund M, Belin AC, Olson L, Galter D. Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients. Cell Tissue Res. 334: 179-185 (2008). *

• Westlake CJ, Payen L, Gao M, Cole SP, Deeley RG. Identification and characterization of functionally important elements in the multidrug resistance protein 1 COOH-terminal region. J. Biol. Chem. 279: 53571-53583 (2004). *

• Wielosz E, Dryglewska M, Majdan M. Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis. Clin. Rheumatol. 28: 955-959 (2009). *

• Wilczynski JR, kufelnicka M, Smolarz B, Nowinska A, Kulig A, Szpakowski M. Is MDR 1 gene a key to successful chemotherapy? Ginekol. Pol. 77: 476-484 (2006).

• Wilk JN, Bilsborough J, Viney JL. The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease. Immunol. Res. 31: 151-160 (2005). *

• Williamson G, Aeberli I, Miguet L, Zhang Z, Sanchez MB, Crespy V, Barron D, Needs P, Kroon PA, Glavinas H, Krajcsi P, Grigorov M. Interaction of positional isomers of quercetin glucuronides with the transporter ABCC2 (CMOAT, MRP2). Drug Metab. Dispos. 35: 1262-1268 (2007). *

• Wimmer R, Hohenester S, Pusl T, Denk GU, Rust C, Beuers U. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKCalpha-/PKA-dependent mechanism in rat liver. Gut 57: 1448-1454 (2008).

• Wojtal KA, de Vries E, Hoekstra D, van Ijzendoorn SC. Efficient trafficking of MDR1/P-glycoprotein to apical canalicular plasma membranes in HepG2 cells requires PKA-RIIalpha anchoring and glucosylceramide. Mol. Biol. Cell 17: 3638-3650 (2006). *

• Wong H, Lehman-McKeeman LD, Grubb MF, Grossman SJ, Bhaskaran VM, Solon EG, Shen HS, Gerson RJ, Car BD, Zhao B, Gemzik B. Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. Toxicol. Sci. 84: 232-242 (2005). *

• Wong IL, Chow LM. The role of Leishmania enriettii multidrug resistance protein 1 (LeMDR1) in mediating drug resistance is iron-dependent. Mol. Biochem. Parasitol. 150: 278-287 (2006). *

• Wong LJ, Dimmock D, Geraghty MT, Quan R, Lichter-Konecki U, Wang J, Brundage EK, Scaglia F, Chinault AC. Utility of oligonucleotide array-based comparative genomic hybridization for detection of target gene deletions. Clin. Chem. 54: 1141-1148 (2008). *

• Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ. MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother. Pharmacol. 64: 183-188 (2009).

• Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr. Drug Metab. 5: 11-19 (2004). *

• Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J. Pharmacol. Exp. Ther. 310: 1199-1207 (2004). *

• Wortham M, Czerwinski M, He L, Parkinson A, Wan YJ. Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab. Dispos. 35: 1700-1710 (2007). *

• Woydziak ZR, Boiadjiev SE, Norona WS, McDonagh AF, Lightner DA. Synthesis and hepatic transport of strongly fluorescent cholephilic dipyrrinones. J. Org. Chem. 70: 8417-8423 (2005). *

• Wright AW, Dickinson RG. Abolition of valproate-derived choleresis in the Mrp2 transporter-deficient rat. J. Pharmacol. Exp. Ther. 310: 584-588 (2004). *

• Wu CP, Calcagno AM, Hladky SB, Ambudkar SV, Barrand MA. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 272: 4725-4740 (2005). *

• Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol. Dial. Transplant. 24: 3360-3366 (2009).

• Wu P, Oleschuk CJ, Mao Q, Keller BO, Deeley RG, Cole SP. Analysis of human multidrug resistance protein 1 (ABCC1) by matrix-assisted laser desorption ionization/time of flight mass spectrometry: towards identification of leukotriene C4 binding sites. Mol. Pharmacol. 68: 1455-1465 (2005). *

• Xia CQ, Milton MN, Gan LS. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr. Drug Metab. 8: 341-363 (2007).

• Xia CQ, Xiao G, Liu N, Pimprale S, Fox L, Patten CJ, Crespi CL, Miwa G, Gan LS. Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using ATPase activity assays. Mol. Pharm. 3: 78-86 (2006). *

• Xia X, Francis H, Glaser S, Alpini G, Lesage G. Bile acid interactions with cholangiocytes. World J. Gastroenterol. 12: 3553-3563 (2006). *

• Xie XY, Tan YJ, Zhu YL. Relation between mutant p53 and multidrug resistance in gastric cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban 35: 91-98 (2006).

• Xin HW, Schwab M, Klotz U. Transport studies with 5-aminosalicylate. Eur. J. Clin. Pharmacol. 62: 871-875 (2006). *

• Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28: 249-268 (2005).

• Xu D, Kang H, Fisher M, Juliano RL. Strategies for inhibition of MDR1 gene expression. Mol. Pharmacol. 66: 268-275 (2004). *

• Xu D, Lu Q, Hu X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett. 243: 274-280 (2006). *

• Xu D, Regner M, Smith D, Ruby J, Johnstone R, Mullbacher A. The multidrug resistance gene mdr1a influences resistance to ectromelia virus infection by mechanisms other than conventional immunity. Immunol. Cell Biol. 82: 462-470 (2004). *

• Yamada T, Arai T, Nagino M, Oda K, Shoda J, Suzuki H, Sugiyama Y, Nimura Y. Impaired expression of hepatic multidrug resistance protein 2 is associated with posthepatectomy hyperbilirubinemia in patients with biliary cancer. Langenbecks Arch. Surg. 390: 421-429 (2005). *

• Yamaguchi A, Tazuma S, Nishioka T, Ohishi W, Hyogo H, Nomura S, Chayama K. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig. Dis. Sci. 50: 1361-1371 (2005). *

• Yamamori M, Taniguchi M, Maeda S, Nakamura T, Okamura N, Kuwahara A, Iwaki K, Tamura T, Aoyama N, Markova S, Kasuga M, Okumura K, Sakaeda T. VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese. Int. J. Med. Sci. 5: 80-86 (2008). *

• Yamamoto-Furusho JK, Villeda-Ramírez MA, Fonseca-Camarillo G, Sanchez-Munoz F, Dominguez-Lopez A, Barreto-Zuniga R, Uribe M. High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. Inflamm. Bowel Dis. Aug 27 [Epub ahead of print] (2009). *

• Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, Chen SL, Rosa R, Cumiskey AM, Serreze DV, Gregory S, Rogers J, Lyons PA, Healy B, Smink LJ, Todd JA, Peterson LB, Wicker LS, Santamaria P. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 39: 329-337 (2007). *

• Yamasaki D, Nakamura T, Okamura N, Kokudai M, Inui N, Takeuchi K, Watanabe H, Hirai M, Okumura K, Sakaeda T. Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells. Eur. J. Pharm. Sci. 37: 126-132 (2009).

• Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab. Dispos. 34: 1247-1254 (2006). *

• Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo K, Sugimachi K. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74: 571-572 (2002).

• Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, Hochman JH, Prueksaritanont T, Lin JH. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 35: 737-753 (2005). *

• Yang XY, Xu DH. MDR1(ABCB1) gene polymorphisms associated with steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus. Pharmazie 62: 930-932 (2007).

• Yang Y, Liu Y, Dong Z, Xu J, Peng H, Liu Z, Zhang JT. Regulation of function by dimerization through the amino terminal membrane-spanning domain of human ABCC1/MRP1. J. Biol. Chem. 282: 8821-8830 (2007). *

• Yang Z, Wu D, Bui T, Ho RJ. A novel human multi-drug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J. Pharmacol. Exp. Ther. 327: 474-481 (2008). *

• Yasar U, Babaoglu MO, Bozkurt A. Disposition of a CYP2C9 phenotyping agent, iosartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1). Basic Clin. Pharmacol. Toxicol. 103: 176-179 (2008).

• Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry 30: 286-291 (2006).

• Yasuno K, Ando S, Misumi S, Makino S, Kulski JK, Muratake T, Kaneko N, Amagane H, Someya T, Inoko H, Suga H, Kanemoto K, Tamiya G. Synergistic association of mitochondrial uncoupling protein (UCP) genes with schizophrenia. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144B: 250-253 (2006).

• Yau JL, Noble J, Thomas S, Kerwin R, Morgan PE, Lightman S, Seckl JR, Pariante CM. The antidepressant desipramine requires the ABCB1 (Mdr1)-type p-glycoprotein to upregulate the glucocorticoid receptor in mice. Neuropsychopharmacology 32: 2520-2529 (2007).

• Ye S, Maceachran DP, Hamilton JW, O'Toole GA, Stanton BA. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif. Am. J. Physiol. Cell Physiol. 295: C807-C818 (2008). *

• Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. 76: 418-427 (2004). *

• Yin JY, Huang Q, Yang Y, Zhang JT, Zhong MZ, Zhou HH, Liu ZQ. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet. Genomics 19: 206-216 (2009).

• Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen. Liver Transpl. 11: 1064-1072 (2005). *

• Yoshikawa M, Ito A, Ishikawa T, Ikegami Y. Drug resistance mediated by ABC transporters. Gan To Kagaku Ryoho 31: 1-6 (2004).

• Yoshiyama T, Ogata H, Ito K, Aono A, Wada M. Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study. Kekkaku 82: 95-101 (2007).

• Yu C, Argyropoulos G, Zhang Y, Kastin AJ, Hsuchou H, Pan W. Neuroinflammation activates Mdr1b efflux transport through NFkappaB: promoter analysis in BBB endothelia. Cell. Physiol. Biochem. 22: 745-756 (2008). *

• Yu C, Kastin AJ, Tu H, Waters S, Pan W. TNF activates P-glycoprotein in cerebral microvascular endothelial cells. Cell. Physiol. Biochem. 20: 853-858 (2007). *

• Yu DS, Lin JC, Hsieh DS, Chang SY, Lee CF. Modulation of MDR-1 gene by MIF and GSTpi with drug resistance generation in hormone independent prostate cancer. Arch. Androl. 52: 283-291 (2006).

• Yu ST, Chen TM, Tseng SY, Chen YH. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem. Biophys. Res. Commun. 358: 79-84 (2007). *

• Yu XQ, Xue CC, Wang G, Zhou SF. Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Curr. Drug Metab. 8: 787-802 (2007).

• Yue W, Abe K, Brouwer KL. Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion. Mol. Pharm. 6: 134-143 (2009). *

• Yumoto R, Hamada S, Okada K, Kato Y, Ikehata M, Nagai J, Takano M. Effect of ursodeoxycholic acid treatment on the expression and function of multidrug resistance-associated protein 2 in rat intestine. J. Pharm. Sci. 98: 2822-2831 (2009). *

• Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm. 3: 55-61 (2006).

• Zaja R, Munic V, Klobucar RS, Ambriovic-Ristov A, Smital T. Cloning and molecular characterization of apical efflux transporters (ABCB1, ABCB11 and ABCC2) in rainbow trout (Oncorhynchus mykiss) hepatocytes. Aquat. Toxicol. 90: 322-332 (2008).

• Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa KI, Brouwer KL. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J. Pharmacol. Exp. Ther. 319: 459-467 (2006). *

• Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE, Webster LO, Bridges AS, Kalvass JC, Brouwer KL. Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab. Dispos. 33: 1158-1165 (2005). *

• Zamek-Gliszczynski MJ, Nezasa K, Tian X, Bridges AS, Lee K, Belinsky MG, Kruh GD, Brouwer KL. Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. J. Pharmacol. Exp. Ther. 319: 1485-1491 (2006). *

• Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, Brouwer KL. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol. Pharmacol. 70: 2127-2133 (2006). *

• Zapata Velandia AM, Ng SS, Brennan RF, Simonsen NR, Gastanaduy M, Zabaleta J, Lentz JJ, Craver RD, Correa H, Delgado A, Pitts AL, Himel JR, Udall JN Jr, Schmidt-Sommerfeld E, Brown RF, Athas GB, Keats BB, Mannick EE. Association of the T allele of an intronic single nucleotide polymorphism in the colony stimulating factor 1 receptor with Crohn's disease: a case-control study. J. Immune Based Ther. Vaccines 2: 6 (2004). *

• Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, Borst P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem. J. 371: 361-367 (2003). *

• Zelcer N, Saeki T, Bot I, Kuil A, Borst P. Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem. J. 369: 23-30 (2003). *

• Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J. Biol. Chem. 276: 46400-46407 (2001). *

• Zelcer N, van de Wetering K, de Waart R, Scheffer GL, Marschall HU, Wielinga PR, Kuil A, Kunne C, Smith A, van der Valk M, Wijnholds J, Oude Elferink RP, Borst P. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J. Hepatol. 44: 768-775 (2006). *

• Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 61: 7225-7232 (2001). *

• Zeng H, Liu G, Rea PA, Kruh GD. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 60: 4779-4784 (2000). *

• Zhai BJ, Shao ZY, Zhao CL, Hu K, Wu F. Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice. World J. Gastroenterol. 12: 6614-6619 (2006). *

• Zhang DW, Nunoya K, Vasa M, Gu HM, Theis A, Cole SP, Deeley RG. Transmembrane helix 11 of multidrug resistance protein 1 (MRP1/ABCC1): identification of polar amino acids important for substrate specificity and binding of ATP at nucleotide binding domain 1. Biochemistry 43: 9413-9425 (2004). *

• Zhang HX, Wang LS. Effect of genetic polymorphism on the activity of drug transporters and its clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban 33: 765-768 (2008).

• Zhang J, Alston MA, Huang H, Rabin RL. Human T cell cytokine responses are dependent on multidrug resistance protein-1. Int. Immunol. 18: 485-493 (2006). *

• Zhang J, Huang W, Qatanani M, Evans RM, Moore DD. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 279: 49517-49522 (2004). *

• Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab. Rev. 37: 611-703 (2005). *

• Zhang JT. Use of arrays to investigate the contribution of ATP-binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity. Cell Res. 17: 311-323 (2007). *

• Zhang L, Lin G, Kovacs B, Jani M, Krajcsi P, Zuo Z. Mechanistic study on the intestinal absorption and disposition of baicalein. Eur. J. Pharm. Sci. 31: 221-231 (2007). *

• Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 65: 1208-1216 (2004). *

• Zhang WX, Chen B, Zhang W, Chen N, Yu ZC, Cai WM. Effect of MDR1 gene polymorphism on progression of end-stage renal disease. Acta Pharmacol. Sin. 28: 579-583 (2007).

• Zhang Y, Jiang XH, Hu YQ, Li ZR, Su L, Wang ZG, Ma G. MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. Br. J. Clin. Pharmacol. 66: 247-254 (2008). *

• Zhang Y, Li W, Vore M. Translational regulation of rat multidrug resistance-associated protein 2 (Mrp2) expression is mediated by upstream open reading frames (uORFs) in the 5' untranslated region (UTR). Mol. Pharmacol. 71: 377-383 (2007). *

• Zhang YQ, Resta S, Jung BH, Barrett KE, Sarvetnick N. Up-regulation of activin signaling in experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. Jul 30 [Epub ahead of print] (2009). *

• Zhang YT, Yang LP, Shao H, Li KX, Sun CH, Shi LW. ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients. Br. J. Clin. Pharmacol. 66: 240-246 (2008). *

• Zhao Q, Chang XB. Mutation of the aromatic amino acid interacting with adenine moiety of ATP to a polar residue alters the properties of multidrug resistance protein 1. J. Biol. Chem. 279: 48505-48512 (2004). *

• Zhao Y, Migita K, Sun J, Katsuragi T. MRP transporters as membrane machinery in the bradykinin-inducible export of ATP. Naunyn. Schmiedebergs Arch. Pharmacol. Feb 5 [Epub ahead of print] (2010). *

• Zhao Y, Zhai D, He H, Liu J, Li T, Chen X, Ji H. Matrine improves 17alpha-ethinyl estradiol-induced acute cholestasis in rats. Hepatol. Res. 39: 1144-1149 (2009). *

• Zhou C, Tabb MM, Sadatrafiei A, Grun F, Blumberg B. Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab. Dispos. 32: 1075-1082 (2004). *

• Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab. Rev. 36: 57-104 (2004). *

• Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832 (2008). *

• Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, Duan W. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab. 9: 738-784 (2008).

• Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 15: 1981-2039 (2008).

• Zhou Y, Gottesman MM, Pastan I. Domain exchangeability between the multidrug transporter (MDR1) and phosphatidylcholine flippase (MDR2). Mol. Pharmacol. 56: 997-1004 (1999). *

• Zhou Z, Wang L, Song Z, Saari JT, McClain CJ, Kang YJ. Zinc supplementation prevents alcoholic liver injury in mice through attenuation of oxidative stress. Am. J. Pathol. 166: 1681-1690 (2005). *

• Zhu B, Liu GT, Zhao YM, Wu RS, Strada SJ. Chemosensitizing multiple drug resistance of human carcinoma by bicyclol involves attenuated P-glycoprotein, GST-P and Bcl-2. Cancer Biol. Ther. 5: 536-543 (2006).

• Zhu H, Cai C, Chen J. Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1. FEBS Lett. 576: 369-374 (2004). *

• Ziegler G, Prinz V, Albrecht MW, Harhausen D, Khojasteh U, Nacken W, Endres M, Dirnagl U, Nietfeld W, Trendelenburg G. Mrp-8 and-14 mediate CNS injury in focal cerebral ischemia. Biochim. Biophys. Acta 1792: 1198-1204 (2009). *

• Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, Williams BG, Dye C. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194: 479-485 (2006). *

• Zimmermann C. Expression of drug transporters in intestine and blood. Ph.D. Thesis, Philosophisch-Naturwissenschaftlichen Fakultat der Universitat Basel (2005). *

• Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, Drewe J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated proteins 1 to 5 mRNA expression along the human intestinal tract. Drug Metab. Dispos. 33: 219-224 (2005). *

• Zimniak P. Dubin-Johnson and Rotor syndromes: molecular basis and pathogenesis. Semin. Liver Dis. 13: 248-260 (1993).

• Zinchuk V, Zinchuk O, Akimaru K, Moriya F, Okada T. Ethanol consumption alters expression and colocalization of bile salt export pump and multidrug resistance protein 2 in the rat. Histochem. Cell Biol. 127: 503-512 (2007). *

• Zinchuk V, Zinchuk O, Okada T. Experimental LPS-induced cholestasis alters subcellular distribution and affects colocalization of Mrp2 and Bsep proteins: a quantitative colocalization study. Microsc. Res. Tech. 67: 65-70 (2005). *

• Zinchuk VS, Okada T, Akimaru K, Seguchi H. Asynchronous expression and colocalization of Bsep and Mrp2 during development of rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G540-G548 (2002). *

• Ziol M, Barbu V, Rosmorduc O, Frassati-Biaggi A, Barget N, Hermelin B, Scheffer GL, Bennouna S, Trinchet JC, Beaugrand M, Ganne-Carrie N. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 135: 131-141 (2008). *

• Zolk O, Jacobi J, Pahl A, Fromm MF, Schmieder RE. MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet. Genomics 17: 137-144 (2007).

• Zollner G, Fickert P, Fuchsbichler A, Silbert D, Wagner M, Arbeiter S, Gonzalez FJ, Marschall HU, Zatloukal K, Denk H, Trauner M. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J. Hepatol. 39: 480-488 (2003). *

• Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol. 38: 717-727 (2003). *

• Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, Zatloukal K, Trauner M. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33: 633-646 (2001). *

• Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 25: 367-379 (2005). *

• Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, Trauner M. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int. 27: 920-929 (2007). *

• Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, Fuchsbichler A, Halilbasic E, Denk H, Marschall HU, Trauner M. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter alpha/beta in the adaptive response to bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G923-G932 (2006). *

• Zrieki A, Farinotti R, Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. 25: 1991-2001 (2008). *

• Zubor P, Lasabova Z, Hatok J, Stanclova A, Danko J. A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women. Oncol. Rep. 18: 211-217 (2007). *

Number of references = 1651

www psc-literature.org